

097438 09/743885

Practitioner's Docket No. U 013212-4

JC06 Rec'd PCT/PTO 16 JAN 2001

Optional Customer No. Bar Code



00140

PATENT TRADEMARK OFFICE

CHAPTER II

TRANSMITTAL LETTER  
TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

INTERNATIONAL APPLICATION NO. CLAIMED	INTERNATIONAL FILING DATE	PRIORITY DATE
PCT/NL99/00453	15 JULY 1999	16 JULY 1998 14 DECEMBER 1998

TITLE OF INVENTION

PROCESS TO COLLECT METABOLITES FROM MODIFIED NECTAR BY INSECTS

APPLICANT(S)

1. JANTINA CREEMERS
2. GERRIT CORNELIS ANGENENT
3. MARTIN MARIA KATER

Box PCT

Assistant Commissioner for Patents

Washington D.C. 20231

ATTENTION: EO/US

## CERTIFICATION UNDER 37 C.F.R. 1.10\*

(Express Mail label number is *mandatory*.)(Express Mail certification is *optional*.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date January 16, 2001, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EL 728210604 US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(type or print name of person mailing paper)

Signature of person mailing paper

## WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

## \*WARNING:

Each paper or fee filed by "Express Mail" *must* have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b)  
 "Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will *not* be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442

**NOTE:** *The completion of those filing requirements that can be made at a time later than 30 months from the priority date results from the Commissioner exercising his judgment under the authority granted under 35 USC 371(d). The filing receipt will show the actual date of receipt of the last item completing the entry into the national phase. See 37 C.F.R. §1.491 which states: "An international application enters the national state when the applicant has filed the documents and fees required by 35 USC 371(c) within the periods set forth in § 1.494 and § 1.495."*

**WARNING:** *Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. §1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. §1.8).*

**NOTE:** *Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).*

1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:

- a. ☒ This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
- b. ☒ The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2. Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
[ ]*	TOTAL CLAIMS	30 - 20 =	10	x \$ 18.00 =	\$180.00 (NOT PAID AT THIS TIME)
	INDEPENDENT CLAIMS	7 - 3 =	4	x \$ 80.00 =	320.00 (NOT PAID AT THIS TIME)
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00				
BASIC FEE**	<p>[ ] U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY            Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO:            [ ] and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(2) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 CFR 1.492(a)(4)) ..... \$100.00            [ ] and the above requirements are not met (37 CFR 1.492(a)(1)) ..... \$690.00</p> <p>[X] U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY            Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO:            [ ] has been paid (37 CFR 1.492(a)(2)) ..... \$710.00            [ ] has not been paid (37 CFR 1.492(a)(3)) ..... \$1,000.00            [X] where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5)) ..... \$860.00</p>				
	Total of above Calculations				=860.00
SMALL ENTITY	Reduction by ½ for filing by small entity, if applicable. Affidavit must be filed. (note 37 CFR 1.9, 1.27, 1.28)				
	Subtotal				\$60.00
	Total National Fee				\$860.00
	Fee for recording the enclosed assignment document \$40.00 (37 CFR 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".				
TOTAL	Total Fees enclosed				\$860.00

\*See attached Preliminary Amendment Reducing the Number of Claims.

- i. ☒ [X] A check in the amount of \$60.00 to cover the above fees is enclosed.  
ii. ☐ [ ] Please charge Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.  
A duplicate copy of this sheet is enclosed.

**\*\*WARNING:** "To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date. \*\*\* (2) the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended " 37 C F R § 1.495(b)

**WARNING:** If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office 37 C F R § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40

3. ☒ [X] A copy of the International application as filed (35 U.S.C. 371(c)(2)):

**NOTE:** Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below

- a. ☐ [ ] is transmitted herewith.  
b. ☐ [ ] is not required, as the application was filed with the United States Receiving Office.  
c. ☒ [X] has been transmitted  
i. ☒ [X] by the International Bureau.  
Date of mailing of the application (from form PCT/IB/308): \_\_\_\_\_.  
ii. ☐ [ ] by applicant on \_\_\_\_\_.  
Date

4. ☒ [X] A translation of the International application into the English language (35 U.S.C. 371(c)(2)):

- a. ☒ [X] is transmitted herewith.  
b. ☐ [ ] is not required as the application was filed in English.  
c. ☐ [ ] was previously transmitted by applicant on \_\_\_\_\_.  
Date  
d. ☐ [ ] will follow.

5. ☒ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3)):

*NOTE: The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36.*

- a. ☐ are transmitted herewith.  
b. ☐ have been transmitted.  
i. ☐ by the International Bureau.  
Date of mailing of the amendment (from form PCT/IB/308): \_\_\_\_\_  
ii. ☐ by applicant on \_\_\_\_\_.  
Date  
c. ☒ have not been transmitted as  
i. ☒ applicant chose not to make amendments under PCT Article 19.  
Date of mailing of Search Report (from form PCT/ISA/210): MAY 11, 1999.  
ii. ☐ the time limit for the submission of amendments has not yet expired.  
The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.
6. ☒ A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. 371(c)(3)):  
a. ☐ is transmitted herewith.  
b. ☐ is not required as the amendments were made in the English language.  
c. ☒ has not been transmitted for reasons indicated at point 5(c) above.
7. ☒ A copy of the international examination report (PCT/IPEA/409)  
☒ is transmitted herewith.  
☐ is not required as the application was filed with the United States Receiving Office.
8. ☒ Annex(es) to the international preliminary examination report  
a. ☒ is/are transmitted herewith.  
b. ☐ is/are not required as the application was filed with the United States Receiving Office.
9. ☒ A translation of the annexes to the international preliminary examination report  
a. ☒ is transmitted herewith.  
b. ☐ is not required as the annexes are in the English language.

10. ☒ An oath or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 U.S.C. 115
- a. ☐ was previously submitted by applicant on \_\_\_\_\_  
Date
- b. ☐ is submitted herewith, and such oath or declaration
- i. ☐ is attached to the application.
- ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70.
- c. ☒ will follow.

Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):
- a. ☒ is transmitted herewith.
- b. ☐ has been transmitted by the International Bureau.  
Date of mailing (from form PCT/IB/308): \_\_\_\_\_.
- c. ☐ is not required, as the application was searched by the United States International Searching Authority.
- d. ☐ will be transmitted promptly upon request.
- e. ☐ has been submitted by applicant on \_\_\_\_\_  
Date
12. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98:
- a. ☐ is transmitted herewith.  
Also transmitted herewith is/are:  
☐ Form PTO-1449 (PTO/SB/08A and 08B).  
☐ Copies of citations listed.
- b. ☒ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
- c. ☐ was previously submitted by applicant on \_\_\_\_\_  
Date
13. ☐ An assignment document is transmitted herewith for recording.

A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

14. ☒ Additional documents:
- a. ☐ Copy of request (PCT/RO/101)
  - b. ☒ International Publication No. WO /04176
    - i. ☒ Specification, claims and drawing
    - ii. ☐ Front page only
  - c. ☐ Preliminary amendment (37 C.F.R. § 1.121)
  - d. ☐ Other
- \_\_\_\_\_
- \_\_\_\_\_
- \_\_\_\_\_
15. ☒ The above checked items are being transmitted
- a. ☒ before 30 months from any claimed priority date.
  - b. ☐ after 30 months.
16. ☐ Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on \_\_\_\_\_, namely:
- \_\_\_\_\_
- \_\_\_\_\_
- \_\_\_\_\_

#### AUTHORIZATION TO CHARGE ADDITIONAL FEES

**WARNING:** *Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.*

**NOTE:** *"A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).*

**NOTE:** *"Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).*

☒ The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 12-0425.

☒ 37 C.F.R. 1.492(a)(1), (2), (3), and (4) (filing fees)

**WARNING:** *Because failure to pay the national fee within 30 months without extension (37 C.F.R. § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.*

☐ 37 C.F.R. 1.492(b), (c) and (d) (presentation of extra claims)

**NOTE:** *Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must*

528 Rec'd PCT/PTO 16 JAN 2001

only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

- [X] 37 C.F.R. 1.17 (application processing fees)  
[X] 37 C.F.R. 1.17(a)(1)-(5)(extension fees pursuant to § 1.136(a).  
[X] 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

*NOTE Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance 37 C.F.R. § 1.311(b)*

*NOTE 37 C.F.R. 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b) (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.*

- [ ] 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).



---

SIGNATURE OF PRACTITIONER

Reg. No.: 25,858

---

WILLIAM R. EVANS

(type or print name of practitioner)

Tel. No.: (212)708-1930

---

LADAS & PARRY

P.O. Address

Customer No.: 00140

---

26 WEST 61<sup>ST</sup> STREET

NEW YORK, NEW YORK. 10023



**PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Jantina CREEMERS, et al

Serial No.: 09/743,885

Group No.:

Filed: January 16, 2001

Examiner:

For: PROCESS TO COLLECT METABOLITES FROM MODIFIED NECTAR BY INSECTS

Attorney Docket No.: U-013212-4

**Assistant Commissioner Patents and Trademarks  
Washington, DC 20231**

**PRELIMINARY AMENDMENT**

Sir:

Please amend the above application as follows:

**IN THE SPECIFICATION:**

Please amend the paragraph beginning on page 19, line 21 as follows:

**CERTIFICATE OF MAILING (37 CFR 1.8a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, DC 20231

CLIFFORD J. MASS

Type or print name of person mailing paper)

Date: October 22, 2001

(Signature of person mailing paper)

The nucleotide sequence of this 3' cDNA clone was determined by the dideoxynucleotide chain termination method (ABI PRISM™ Ready Reaction DyeDeoxy™ Terminator Cycle Sequencing Kit, P/N 402078, Perkin Elmer) and is shown in Figure 2. The DNA fragment has a length of 460 nucleotides. The missing 5' part of the cDNA was isolated using the Marathon™ cDNA Amplification Kit of Clontech (catalog K1802-1) and following the procedure as described in the manual. Briefly, Poly A+ RNA was isolated from nectaries of *Petunia hybrida* flowers. After double stranded cDNA synthesis, adapters were ligated and a 5' RACE reaction was carried out using the adapter primer AP1 supplied in the kit and a gene-specific primer prat 122. The nucleotide sequence of prat 122 is: 5'-gtgggaaggctatgctacaagc-3' (SEQ ID NO:8) (Figure 2). The PCR product was diluted 10x and 1 µl was used in a second 5' RACE reaction with the nested adapter primer supplied by the kit (AP2) and the nested gene-specific primer prat 119 (Figure 2). The nucleotide sequence of prat 119 is: 5'-ccttctccatggactgcaatgcg-3' (SEQ ID NO:9). After gel electrophoreses a fragment of ±850 bp was obtained that hybridised with clone DD18a. The fragment, now called RC8, was extracted from the gel, purified and cloned into a PMOSBlue T-vector as described above. The sequence is shown in Figure 3. The combined (overlapping) sequences of clones DD18a and RC8 are shown in Figure 4, comprising the full length cDNA of a gene called *NEC1* hereafter. The *NEC1* clone has a length of 1205 nucleotides and encodes for a polypeptide of 265 amino acid residues. Based on the deduced amino acid sequence, high homology was found with a cDNA that is associated with *Rhizobium*-induced nodule development in the legume *Medicago trunculata* (MtN3, gene bank number: gn1/PID/e274341). The percentages of identity and similarity are 47% and 72% respectively. Analysis of the predicted protein, using the CAOS/CAMM programme (Protein analysis 1991, Genetics Computer Group inc., Wisconsin USA), shows that the putative protein structure resembles membrane proteins, having six evenly spaced hydrophobic loops that traverse the cell

membrane. In addition, a signal sequence is predicted at the N-terminus, while the C-terminus is highly hydrophilic. Highest homology with MtN3 is found in the N-terminal signal sequence, the first two membrane-spanning loops and the last two membrane-spanning loops. The C-terminal hydrophilic part shows the lowest homology (28% identity, 30% similarity). The function of *NECI* has not yet been determined.

Please amend the paragraph beginning on page 22, line 17 as follows:

The RNA expression of *NECI* was determined by standard Northern blot hybridisation experiments. A DNA fragment comprising the complete sequence of the Differential Display clone DD18 (Figure 2) was used as a probe. Using 10 µg of total RNA from various petunia tissues, strong expression of *NECI* was detectable in nectaries and weak expression in anthers. No expression was detectable in other floral organs, in leaves or in roots (Figure 5A). The expression in the ovary and nectaries was determined by in situ hybridisation using a DIG labelled antisense RNA probe corresponding to the nucleotides 79 to 1036 of *NECI* cDNA, comprising the coding region and part of the 3' untranslated region. A clone containing this sequence was obtained by PCR on adapter-ligated cDNA, using two gene-specific primers prat 122 and prat 129 (Figure 4). The nucleotide sequence of prat 122 is: 5' -gtgggaaggctatgctacaagc-3' (SEQ ID NO:8), comprising the nucleotides 1015 to 1036 of the *NECI* cDNA. The nucleotide sequence of prat 129 is: 5' - gggatccatggcgcaattacgtgctgatg-3' (SEQ ID NO:10), comprising the nucleotides 79 to 100 of the *NECI* cDNA. The gene-specific region of the primers is underlined. The primer contains an extra BamHI and NcoI site at the 5' end. A PCR fragment of 958 nucleotides was obtained and cloned into a PMOSBlue vector. The fragment was subcloned in a vector containing the T7 promoter and in vitro antisense RNA transcripts were made using T7

RNA polymerase. A standard protocol for in situ hybridisation was used as described by Canäs et al., 1994. Strong hybridizing signals were observed in the outer cell layers of the nectaries (Figure 6A)

Please amend the paragraph beginning on page 23, line 16 as follows:

The promoter fragment of *NEC1* was cloned using the genome walker protocol (PT3042-1) and kit as provided by Clontech Laboratories. Briefly, genomic DNA from *Petunia hybrida* was digested with 5 different blunt cutting restriction enzymes. Genome Walker adapters were ligated and PCR reactions were carried out on each Genome Walker “library” with a gene specific, reversed primer prat 148 and the adapter primer from the kit (AP1). The nucleotide sequence of prat 148 is: 5' - ccaagaaggccaaatatgaaagac-3' (SEQ ID NO:11) comprising the nucleotides 105 to 128 of the *NEC1* cDNA (Figure 4). PCR products were subjected to a second round of PCR, using the nested adapter primer AP2 and the nested gene specific, reversed primer prat 149. The nucleotide sequence of prat 149 is: 5' -aagtcacgcacgtaattgcgcc-3' (SEQ ID NO:12), comprising the nucleotides 81 to 104 of the *NEC1* cDNA. From the second PCR a 2 kb fragment was isolated from the *StuI* library, which was cloned in the PMOSBlue T-vector, yielding the construct pMA5-10. Figure 7 (SEQ ID NO:7) shows the DNA sequence of the *NEC1* promoter in the construct pMA5-10, including the translation start of *NEC1* cDNA.

Please amend the paragraph beginning on page 24, line 4 as follows:

A PCR reaction was performed on pMA5-10 (example 5), using the forward vector primer U19 of pMOSBlue and the gene-specific primer prat 169. The nucleotide sequence of prat

169 is:

5' -cgctgcagcgccatggttttttagtgaagccccc-3' (SEQ ID NO:13). The gene-specific region is underlined. The primer contains an NcoI and BgIII restriction site at the 3' end. The PCR product was digested with KpnI and NcoI and ligated into a pBluescript-derived vector (pMO4) that contains the NTM19 promoter (Custers et al., 1997), the reporter gene *GUS* and the nos terminator. The KpnI/NcoI NTM19 promoter fragment was replaced, resulting in a *NEC1*-promoter/*GUS* translational fusion. The resulting plasmid pNEP1 was digested with SmaI to release the *NEC1* promoter/*GUS*/nos fragment and this fragment was ligated into a derivative of the binary plasmid pBIN (Bevan, 1984) yielding the binary plasmid pBNEP1 (Figure 8). pBNEP1 was introduced into *Agrobacterium tumefaciens* strain LBA4404 or C58pMP90 by electroporation. Plasmid DNA from the *Agrobacterium* transformants was isolated and the structure of the binary vector was verified by restriction analysis and PCR.

Please amend the paragraph beginning on page 26, line 22 as follows:

Honey samples were loaded on an SDS PAGE gel and after electrophoreses the gel was blotted on a PVDF membrane. After staining the CVH29 and CVH50 bands were cut out from the blot and N-terminal sequencing was performed on both proteins. The N-terminal sequence of CVH50 is: SVLDFCVADPSLPDGPAGYSCSTEPSTVTSQDF (SEQ ID NO:14). The N-terminal sequence of CVH29 is: SVLDFCVADPSLPDGPAGYSCKEPAKVTVDDFVFHGLGTA (SEQ ID NO:15). A gene bank homology search (BLAST) showed high amino acid sequence homology (63%) with germin-like proteins isolated from *Arabidopsis* (Figure 12).

Please amend the paragraph beginning on page 27, line 4 as follows:

Because the germin-like protein CVH29 is excreted in heather nectar it was expected that part of the cDNA encodes a signal sequence. Based on the N-terminal amino acid sequence, degenerated primers were designed. The sequence of the forward primer prat 176 is: 5' - gaytttytgycngcngaycc-3' (SEQ ID NO:16) (y= c or t, n= c, t, a or g). The sequence of the reversed primer prat 177 is: ccertgraanacraartcrtc (SEQ ID NO:17) (r= g or a). A PCR reaction performed on genomic DNA of heather yielded a 99 bp DNA fragment. The fragment was sequenced and two reversed, gene-specific 5' primers were designed to clone the 5' cDNA by Marathon cDNA racing using the kit and protocol of Clontech laboratories (protocol PT1115-1, Clontech Palo Alto USA). The sequence of gene-specific primer prat 207 that was used is: 5' - ggtgacttttagaggcctcttcg-3' (SEQ ID NO:18), the sequence of gene-specific nested primer prat 206 is:

5'-gctccttcgaggagtagcctgc-3' (SEQ ID NO:19) (Figure 13). RNA was isolated from open flowers of heather and mRNA was prepared using the Pharmacia quickprep micro mRNA kit. After cDNA synthesis and adapter ligation a PCR reaction was performed, using the adapter primer AP1 and the gene-specific primer prat 207. The PCR product was used for a second PCR, using adapter primer AP2 and the nested gene-specific primer prat 206. A single fragment of around 300 nucleotides was obtained and cloned in a PMOSBlue T-vector. Four clones were sequenced. Figure 14 shows that three clones were identical and one clone had two different nucleotides in the untranslated 5' region. A putative signal sequence of 17 amino acids was identified between the ATG start codon and the first codon of the mature protein CVH29 that was identical in all four clones. The nucleotide sequence of the putative signal sequence (SEQ ID NO:6) is:

5' -atgtttcttccaattctctcaccatttcctctctctctctctctcccatget-3' .

Please amend the paragraph beginning on page 28, line 5 as follows:

To clone the *NEC1* promoter into a pMOSBlue vector a PCR reaction was carried out on pMA5-10 (example 5) using the forward primer prat 247 and the reversed primer prat 248 (Fig. 7). Prat 247 contains an extra PstI restriction site. The *NdeI* restriction site of prat 248 coincides with the ATG translation start of *NEC1*. The nucleotide sequence of prat 247 is: 5' -ggctgcaggagtggtctttgatagaatg-3' (SEQ ID NO:20), the nucleotide sequence of prat 248 is: 5' -cgccatatgttttttatggaagcccc-3' (SEQ ID NO:21). Gene-specific regions are underlined. A 1,8 kb promoter fragment was obtained and cloned into a pMOSBlue vector, yielding the plasmid pNECP.

Please amend the paragraph beginning on page 28, line 17 as follows:

A DNA molecule encoding the signal sequence CVSP as depicted in SEQ ID NO:6 was produced by synthesis and subsequent annealing of two oligo molecules prat 245 and prat 246. The sequence of prat 245 is: 5' tatgttcttccaattctttcactatttct-cttctttctcttctctcatgcttctgttcttgatttc' 3 (SEQ ID NO:22), the sequence of prat 246 is: 5' gatccgaatcaagaacagaagcatgagaagaagagaaaagaa-gagaatatgtgaaaagaattggaaggaaca' 3 (SEQ ID NO:23). The region encoding the signal sequence CVSP is underlined. To ensure correct cleavage of the signal peptide, the linkers were extended with the coding region for the first five amino acids of the mature germin-like protein (Fig. 13). The codon usage of the signal peptide

sequence was optimised for Arabidopsis. By addition of a BamHI restriction site at the 3' end, 2 extra amino acids were linked in frame to the mature protein. The resulting DNA molecule is shown in Figure 15. The fragment was ligated into a NdeI/BamHI cut PMOSBlue vector, yielding the plasmid pCVSP.

Please amend the paragraph beginning on page 29, line 4 as follows:

A 250 bp long fragment containing the NOS terminator sequence (NOST) was obtained by PCR, using the forward primer prat 251 and the reversed primer prat 252 on DNA of pRAP 33, which is a pUC 19 derived plasmid. Prat 251 adds a SacI and XhoI site, prat 252 adds a SmaI and EcoRI site. The sequence of prat 251 is: 5'-gggagctcgagtcggtcaaacatttggcaataaag-3' (SEQ ID NO:24). The sequence of prat 252 is: 5'-cgaattccgggatctagtaacatagatgacac-3' (SEQ ID NO:25). The NOST-specific regions are underlined. The PCR product was cloned into pCR-Script™ Amp SK(+) Cloning Kit (Catalog 21188-21190, Stratagene Al Jolla USA), yielding the plasmid pCR-NOST. pCR-NOST was digested with SacI and EcoRI and the resulting fragment was cloned into the pUC 19 (ClonTech), derived plasmid pUCAP yielding the plasmid pCVNOS.

Please amend the paragraph beginning on page 29, line 19 as follows:

The plasmid pGUSN358 was purchased from Clontech (catalog 6030-1) containing the reporter gene GUS in pUC 119, modified to destroy the N-linked glycosylation site within the 1.814 Kb GUS coding sequence. A PCR reaction was carried out with gene-specific primers prat 249 and prat 250, yielding a fragment that contains the GUS gene coding region and a BamHI



restriction site at the 5' end and a SacI restriction site at the 3' end. The sequence of prat 249 is: 5' -ccggatccatgtttacgtcctgtagaacc-3' (SEQ ID NO:26). The sequence of prat 250 is: 5' -gggagctcccaccgaggtgtag-3' (SEQ ID NO:27). The GUS specific regions are underlined. Subsequently, the PCR fragment was digested with BamHI and SacI and ligated into the BamHI/SacI cut plasmid pCVNOS, yielding the plasmid pCV2. A schematic representation of pCV2 is given in Figure 17.

Please amend the paragraph beginning on page 34, line 5 as follows:

PCR primers were designed that hybridise with the cDNA of an invertase gene cloned from *Solanum tuberosum*. The 5' primer 5' - AAGGACTTTAGAGAGACCCGACCACTGCTGG-3' (SEQ ID NO:28) and the 3' primer 5' - AAATGTCTTTGATGCATAATATTTCCCATATC-3' (SEQ ID NO:29) were used for a PCR reaction on genomic DNA of petunia to yield a fragment of around 420 bp. The fragment was sequenced and cloned into a pMOSBlue vector to used as a probe to screen a petunia nectary-specific cDNA library. Hybridizing phage plaques were purified and cDNAs were retrieved by in vivo excision as described in example 2. The expression of the cDNA s was determined by Northern blotting as described in example 3 and the sequence of a nectary-specific invertase was determined as described in example 2. The invertase gene was amplified using a 5' primer that hybridises with sequences just upstream of the ATG translation start site and a 3' primer that hybridises with sequences just downstream of the translation stop site. Extra restriction enzyme recognition sites were generated to allow cloning of the cDNA in sense (overexpression) or antisense direction into the binary vector pCPO31 as described in example 18. The chimerical

gene constructs are transferred via *Agrobacterium* GV3101 to petunia variety W115, using the transformation method as described in example 7. Transgenic petunia plants were selected that exhibit modified sugar composition in nectar.

Please delete the Sequence Listing appearing on page 39, line 1 - page 47, line 1 in entirety and rewrite as shown attached.

**IN THE CLAIMS:**

Please amend the following claims.

3. (Amended) An isolated DNA sequence according to claim 1, obtained from a plant of *Petunia hybrida*, the sequence consisting essentially of the sequence given in SEQ ID N0:7, or a functional fragment thereof having promoter activity.
5. (Amended) An isolated DNA sequence according to claim 4 having.
  - a) a nucleotide sequence given in SEQ ID N0:4, or
  - b) a nucleotide sequence that hybridises with the nucleotide sequence of (a) or with a fragment of (a) under the following hybridisation conditions: pre-hybridisation for 1h at about 65 °C in a solution of Church and Gilbert, comprising 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS, followed by hybridisation in the same solution for 18h at about 65 °C, followed by washing three times in 0.1 x SSC, 0.1% SDS at about 65 °C for 30 min., or
  - c) a nucleotide sequence that has at least 85% homology to the nucleotide sequence of a).

9. (Amended) An isolated DNA sequence according to claim 8, having:
  - a) a nucleotide sequence given in SEQ ID N0:6 obtained from a plant of *Calluna vulgaris*, or
  - b) a nucleotide sequence that hybridises with the nucleotide sequence given in a), under the following hybridisation conditions: pre-hybridisation for 1h at about 65 °C in a solution of Church and Gilbert, comprising 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS, followed by hybridisation in the same solution for 18h at about 65 °C, followed by washing three times in 0.1 x SSC, 0.1% SDS at about 65 °C for 30 min.,  
or
  - c) a nucleotide sequence that has at least 95% homology to the nucleotide sequence of a).
10. (Amended) A recombinant double-stranded DNA molecule comprising an expression cassette comprising the following constituents:
  - i) a promoter functional in plants,
  - ii) DNA sequence coding for a protein as defined in claim 4 which is fused to the promoter sequence in sense or antisense orientation, and optionally

- iii) a signal sequence functional in plants for the transcription determination and polyadenylation of an RNA molecule.

13. (Amended) A recombinant double-stranded DNA molecule according to claim 11 wherein the promoter is an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence encodes a protein comprising the amino acid sequence given in SEQ ID NO:1, or a protein that has at least 60% homology to the amino acid sequence given in SEQ ID NO:1.

14. (Amended) A recombinant double-stranded DNA molecule according to claim 12 wherein the DNA sequence encoding a signal peptide is an isolated DNA sequence comprising the coding region for a signal peptide, wherein the information contained in the DNA sequence permits, upon translational fusion with a DNA sequence encoding a protein that is expressed in nectaries, targeting of the protein to nectar.

15. (Amended) A process for producing a transgenic plant exhibiting excretion of a recombinant protein in its nectar, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim 12, wherein the recombinant protein is excreted in nectar,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

16. (Amended) A process for producing a transgenic plant exhibiting a modified nectar composition, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim 11, wherein the recombinant protein interferes with metabolic pathways in the nectaries,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

17. (Amended) A process for producing a transgenic plant exhibiting a modified nectar secretion, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim 11, wherein the recombinant protein interferes with sink strength of nectaries,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

18. (Amended) A process for producing a transgenic plant exhibiting a modified nectary development, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim 11, wherein the recombinant protein interferes with the development of nectaries,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

19. (Amended) A process for producing honey from modified nectar of transgenic plants, comprising:

- i) producing a transgenic plant by introducing in a plant cell a recombinant double-stranded DNA molecule as defined in claim 11, regenerating plants from the transgenic cell, and selecting modified plants exhibiting the excretion of nectar with a modified composition,
- ii) allowing insects to collect nectar from the transgenic plants and to process the nectar into honey.

20. (Amended) A process for producing a recombinant gene product from honey, comprising:

- ii) producing a transgenic plant by introducing in a plant cell a recombinant- double-stranded DNA molecule as defined in claim

12, regenerating plants from the transgenic cell, and selecting modified plants exhibiting excretion of the recombinant gene product in nectar,

- ii) allowing insects to collect nectar from the transgenic plants and to process the nectar into honey, and
- iii) isolating and purifying the gene product from the honey.

2.2. (Amended) Micro organisms containing DNA sequences according to claim 1.

23. (Amended) Micro organisms containing recombinant DNA molecules according to claim 10.

24. (Amended) A plant cell or plant cell culture transformed with one or more DNA sequences according to claim 1.

25. (Amended) A plant cell or plant cell culture transformed with recombinant DNA molecules according to claim 10.

26. (Amended) A plant consisting essentially of the plant cells of claim 24.


27. (Amended) A transgenic plant obtained by the process of claim 15.

**REMARKS**

The above amendatory action to the specification is taken to comply with the Sequence Listing requirements of 37 CFR 1.821 - 1.825 and, in particular, to assure that each sequence described in the specification has been assigned an appropriate identifier. Applicants submit herewith a computer readable form copy of the Sequence Listing and the required statements that the paper and computer readable form copies of the Sequence Listing are the same and contain no new matter.

The above amendatory action to the claims is taken to avoid claim fees that would otherwise accrue due to the presence of multiply dependent and to eliminate doubly dependent claims.

Respectfully submitted,



CLIFFORD J. MASS  
LADAS & PARRY  
26 WEST 61ST STREET  
NEW YORK, NY 10023  
REG. NO.30,086 (212)708-1890

MARKED-UP COPY

U-013212-4

09/743,885

**IN THE SPECIFICATION:**

Please amend the paragraph beginning on page 19, line 21 as follows:

The nucleotide sequence of this 3' cDNA clone was determined by the dideoxynucleotide chain termination method (ABI PRISM™ Ready Reaction DyeDeoxy™ Terminator Cycle Sequencing Kit, P/N 402078, Perkin Elmer) and is shown in Figure 2. The DNA fragment has a length of 460 nucleotides. The missing 5' part of the cDNA was isolated using the Marathon™ cDNA Amplification Kit of Clontech (catalog K1802-1) and following the procedure as described in the manual. Briefly, Poly A+ RNA was isolated from nectaries of *Petunia hybrida* flowers. After double stranded cDNA synthesis, adapters were ligated and a 5' RACE reaction was carried out using the adapter primer AP1 supplied in the kit and a gene-specific primer prat 122. The nucleotide sequence of prat 122 is: 5' -gtgggaaggctatgctacaagc-3' (SEQ ID NO:8) (Figure 2). The PCR product was diluted 10x and 1 µl was used in a second 5' RACE reaction with the nested adapter primer supplied by the kit (AP2) and the nested gene-specific primer prat 119 (Figure 2). The nucleotide sequence of prat 119 is: 5' -cetttcctcatggactgcaatgcg-3' (SEQ ID NO:9). After gel electrophoresis a fragment of ±850 bp was obtained that hybridised with clone DD18a. The fragment, now called RC8, was extracted from the gel, purified and cloned into a PMOSBlue T-vector as described above. The sequence is shown in Figure 3. The combined (overlapping) sequences of clones DD18a and RC8 are shown in Figure 4, comprising the full length cDNA of a gene called *NECI* hereafter. The *NECI* clone has a length of 1205 nucleotides and encodes for a polypeptide of 265 amino acid residues. Based on the deduced amino acid



sequence, high homology was found with a cDNA that is associated with *Rhizobium*-induced nodule development in the legume *Medicago trunculata* (MtN3, gene bank number: gn1/PID/e274341). The percentages of identity and similarity are 47% and 72% respectively. Analysis of the predicted protein, using the CAOS/CAMM programme (Protein analysis 1991, Genetics Computer Group inc., Wisconsin USA), shows that the putative protein structure resembles membrane proteins, having six evenly spaced hydrophobic loops that traverse the cell membrane. In addition, a signal sequence is predicted at the N-terminus, while the C-terminus is highly hydrophilic. Highest homology with MtN3 is found in the N-terminal signal sequence, the first two membrane-spanning loops and the last two membrane-spanning loops. The C-terminal hydrophilic part shows the lowest homology (28% identity, 30% similarity). The function of *NECI* has not yet been determined.

Please amend the paragraph beginning on page 22, line 17 as follows:

The RNA expression of *NECI* was determined by standard Northern blot hybridisation experiments. A DNA fragment comprising the complete sequence of the Differential Display clone DD18 (Figure 2) was used as a probe. Using 10 µg of total RNA from various petunia tissues, strong expression of *NECI* was detectable in nectaries and weak expression in anthers. No expression was detectable in other floral organs, in leaves or in roots (Figure 5A). The expression in the ovary and nectaries was determined by in situ hybridisation using a DIG labelled antisense RNA probe corresponding to the nucleotides 79 to 1036 of *NECI* cDNA, comprising the coding region and part of the 3' untranslated region. A clone containing this sequence was obtained by PCR on adapter-ligated cDNA, using two gene-specific primers prat 122 and prat 129 (Figure 4). The nucleotide sequence of prat 122 is: 5'-gtgggaaggctatgctacaagc-

3' ([SEQ ID NO:8](#)), comprising the nucleotides 1015 to 1036 of the *NEC1* cDNA. The nucleotide sequence of prat 129 is: 5' - gggatccatgcgcaattacgtgctgatg-3' ([SEQ ID NO:10](#)), comprising the nucleotides 79 to 100 of the *NEC1* cDNA. The gene-specific region of the primers is underlined. The primer contains an extra BamHI and NcoI site at the 5' end. A PCR fragment of 958 nucleotides was obtained and cloned into a PMOSBlue vector. The fragment was subcloned in a vector containing the T7 promoter and in vitro antisense RNA transcripts were made using T7 RNA polymerase. A standard protocol for in situ hybridisation was used as described by Canäs et al., 1994. Strong hybridizing signals were observed in the outer cell layers of the nectaries (Figure 6A)

Please amend the paragraph beginning on page 23, line 16 as follows:

The promoter fragment of *NEC1* was cloned using the genome walker protocol (PT3042-1) and kit as provided by Clontech Laboratories. Briefly, genomic DNA from *Petunia hybrida* was digested with 5 different blunt cutting restriction enzymes. Genome Walker adapters were ligated and PCR reactions were carried out on each Genome Walker "library" with a gene specific, reversed primer prat 148 and the adapter primer from the kit (AP1). The nucleotide sequence of prat 148 is: 5' - ccaagaaggccaaatatgaaagac-3' ([SEQ ID NO:11](#)) comprising the nucleotides 105 to 128 of the *NEC1* cDNA (Figure 4). PCR products were subjected to a second round of PCR, using the nested adapter primer AP2 and the nested gene specific, reversed primer prat 149. The nucleotide sequence of prat 149 is: 5' - aagtcacgcacgtaattgcgc-3' ([SEQ ID NO:12](#)), comprising the nucleotides 81 to 104 of the *NEC1* cDNA. From the second PCR a 2 kb fragment was isolated from the *StuI* library, which was cloned in the PMOSBlue T-vector, yielding the

construct pMA5-10. Figure 7 (SEQ ID NO:7) shows the DNA sequence of the *NEC1* promoter in the construct pMA5-10, including the translation start of *NEC1* cDNA.

Please amend the paragraph beginning on page 24, line 4 as follows:

A PCR reaction was performed on pMA5-10 (Example 5), using the forward vector primer U19 of pMOSBlue and the gene-specific primer prat 169. The nucleotide sequence of prat 169 is:

5' -cgctgcagcgccatggttttttagtgaagccccc-3' (SEQ ID NO:13). The gene-specific region is underlined. The primer contains an NcoI and BglII restriction site at the 3' end. The PCR product was digested with KpnI and NcoI and ligated into a pBluescript-derived vector (pMO4) that contains the NTM19 promoter (Custers et al., 1997), the reporter gene *GUS* and the nos terminator. The KpnI/NcoI NTM19 promoter fragment was replaced, resulting in a *NEC1*-promoter/*GUS* translational fusion. The resulting plasmid pNEP1 was digested with SmaI to release the *NEC1* promoter/*GUS*/nos fragment and this fragment was ligated into a derivative of the binary plasmid pBIN (Bevan, 1984) yielding the binary plasmid pBNEP1 (Figure 8). pBNEP1 was introduced into *Agrobacterium tumefaciens* strain LBA4404 or C58pMP90 by electroporation. Plasmid DNA from the *Agrobacterium* transformants was isolated and the structure of the binary vector was verified by restriction analysis and PCR.

Please amend the paragraph beginning on page 26, line 22 as follows:

Honey samples were loaded on an SDS PAGE gel and after electrophoreses the gel was blotted on a PVDF membrane. After staining the CVH29 and CVH50 bands were cut out from

the blot and N-terminal sequencing was performed on both proteins. The N-terminal sequence of CVH50 is: SVLDFCVADPSLPDGPAGYSCSTEPSTVTSQDF (SEQ ID NO:14). The N-terminal sequence of CVH29 is: SVLDFCVADPS-LPDGPAGYSCKEPAKVTVDVDFVHGLGTA (SEQ ID NO:15). A gene bank homology search (BLAST) showed high amino acid sequence homology (63%) with germin-like proteins isolated from Arabidopsis (Figure 12).

Please amend the paragraph beginning on page 27, line 4 as follows:

Because the germin-like protein CVH29 is excreted in heather nectar it was expected that part of the cDNA encodes a signal sequence. Based on the N-terminal amino acid sequence, degenerated primers were designed. The sequence of the forward primer prat 176 is: 5' - gaytitytgytngcngaycc-3' (SEQ ID NO:16) (y= c or t, n= c, t, a or g). The sequence of the reversed primer prat 177 is: ccertgraanacraartertc (SEQ ID NO:17) (r= g or a). A PCR reaction performed on genomic DNA of heather yielded a 99 bp DNA fragment. The fragment was sequenced and two reversed, gene-specific 5' primers were designed to clone the 5' cDNA by Marathon cDNA racing using the kit and protocol of Clontech laboratories (protocol PT1115-1, Clontech Palo Alto USA). The sequence of gene-specific primer prat 207 that was used is: 5' - ggtgactttagagggtcctctgc-3' (SEQ ID NO:18), the sequence of gene-specific nested primer prat 206 is:

5'-gctccttcgaggagtagcctgc-3' (SEQ ID NO:19) (Figure 13). RNA was isolated from open flowers of heather and mRNA was prepared using the Pharmacia quickprep micro mRNA kit. After cDNA synthesis and adapter ligation a PCR reaction was performed, using the adapter primer

API and the gene-specific primer prat 207. The PCR product was used for a second PCR, using adapter primer AP2 and the nested gene-specific primer prat 206. A single fragment of around 300 nucleotides was obtained and cloned in a PMOSBlue T-vector. Four clones were sequenced. Figure 14 shows that three clones were identical and one clone had two different nucleotides in the untranslated 5' region. A putative signal sequence of 17 amino acids was identified between the ATG start codon and the first codon of the mature protein CVH29 that was identical in all four clones. The nucleotide sequence of the putative signal sequence (SEQ ID NO:6) is:

5' -atgttttccaattctcttcaccattccctcctctctctctctcccatgct-3' .

Please amend the paragraph beginning on page 28, line 5 as follows:

To clone the *NEC1* promoter into a PMOSBlue vector a PCR reaction was carried out on pMA5-10 (example 5) using the forward primer prat 247 and the reversed primer prat 248 (Fig. 7). Prat 247 contains an extra PstI restriction site. The *NdeI* restriction site of prat 248 coincides with the ATG translation start of *NEC1*. The nucleotide sequence of prat 247 is: 5' - ggctgcaggagtgtctttgatagaatg-3' (SEQ ID NO:20), the nucleotide sequence of prat 248 is: 5' - cgccatatgtttttatggaagcccc-3' (SEQ ID NO:21). Gene-specific regions are underlined. A 1,8 kb promoter fragment was obtained and cloned into a pMOSBlue vector, yielding the plasmid pNECP.

Please amend the paragraph beginning on page 28, line 17 as follows:

A DNA molecule encoding the signal sequence CVSP as depicted in SEQ ID NO:6 was produced by synthesis and subsequent annealing of two oligo molecules prat 245 and prat 246. The sequence of prat 245 is: 5' tatgttccttccaattcttttcaactattct-cttcttttctcttctcatgcttctgttcttgattc' 3' (SEQ ID NO:22), the sequence of prat 246 is: 5' gatccgaaatcaagaacagagcatgagagaagaagaaaaagaa-gagaatatgtgaaaaaattggaaggaaaca' 3' (SEQ ID NO:23). The region encoding the signal sequence CVSP is underlined. To ensure correct cleavage of the signal peptide, the linkers were extended with the coding region for the first five amino acids of the mature germin-like protein (Fig. 13). The codon usage of the signal peptide sequence was optimised for Arabidopsis. By addition of a BamHI restriction site at the 3' end, 2 extra amino acids were linked in frame to the mature protein. The resulting DNA molecule is shown in Figure 15. The fragment was ligated into a NdeI/BamHI cut PMOSBlue vector, yielding the plasmid pCVSP.

Please amend the paragraph beginning on page 29, line 4 as follows:

A 250 bp long fragment containing the NOS terminator sequence (NOST) was obtained by PCR, using the forward primer prat 251 and the reversed primer prat 252 on DNA of pRAP 33, which is a pUC 19 derived plasmid. Prat 251 adds a SacI and XhoI site, prat 252 adds a SmaI and EcoRI site. The sequence of prat 251 is: 5'-gggagctcgagtcgttcaaacatttggcacaataag-3' (SEQ ID NO:24). The sequence of prat 252 is: 5'-cgaattccgggatctagtaacatagatgacac-3' (SEQ ID NO:25). The NOST-specific regions are underlined. The PCR product was cloned into pCR-Script™ Amp SK(+) Cloning Kit (Catalog 21188-21190, Stratagene Al Jolla USA), yielding the plasmid pCR-

NOST. PCR-NOST was digested with SacI and EcoRI and the resulting fragment was cloned into the pUC 19 (ClonTech), derived plasmid pUCAP yielding the plasmid pCVNOS.

Please amend the paragraph beginning on page 29, line 19 as follows:

The plasmid pGUSN358 was purchased from Clontech (catalog 6030-1) containing the reporter gene GUS in pUC 119, modified to destroy the N-linked glycosylation site within the 1.814 Kb GUS coding sequence. A PCR reaction was carried out with gene-specific primers prat 249 and prat 250, yielding a fragment that contains the GUS gene coding region and a BamHI restriction site at the 5' end and a SacI restriction site at the 3' end. The sequence of prat 249 is: 5' -ccggatccatgttacgtcctctagaaacc-3' (SEQ ID NO:26). The sequence of prat 250 is: 5' -gggagctccaccaggagctgtag-3' (SEQ ID NO:27). The GUS specific regions are underlined. Subsequently, the PCR fragment was digested with BamHI and SacI and ligated into the BamHI/SacI cut plasmid pCVNOS, yielding the plasmid pCV2. A schematic representation of pCV2 is given in Figure 17.

Please amend the paragraph beginning on page 34, line 5 as follows:

PCR primers were designed that hybridise with the cDNA of an invertase gene cloned from *Solanum tuberosum*. The 5' primer 5' - AAGGACTTTAGAGAGACCCGACCACTGCTGG-3' (SEQ ID NO:28) and the 3' primer 5' - AAATGCTCTTTGATGCATAATATTTCCATAATC-3' (SEQ ID NO:29) were used for a PCR reaction on genomic DNA of petunia to yield a fragment of around 420 bp. The fragment was

sequenced and cloned into a pMOSBlue vector to used as a probe to screen a petunia nectary-specific cDNA library. Hybridizing phage plaques were purified and cDNAs were retrieved by in vivo excision as described in example 2. The expression of the cDNA s was determined by Northern blotting as described in example 3 and the sequence of a nectary-specific invertase was determined as described in example 2. The invertase gene was amplified using a 5' primer that hybridises with sequences just upstream of the ATG translation start site and a 3' primer that hybridises with sequences just downstream of the translation stop site. Extra restriction enzyme recognition sites were generated to allow cloning of the cDNA in sense (overexpression) or antisense direction into the binary vector pCPO31 as described in example 18. The chimerical gene constructs are transferred via Agrobacterium GV3101 to petunia variety W115, using the transformation method as described in example 7. Transgenic petunia plants were selected that exhibit modified sugar composition in nectar.



**IN THE CLAIMS:**

3 (Amended) An isolated DNA sequence according to claim 1 [or 2], obtained from a plant of *Petunia hybrida*, the sequence consisting essentially of the sequence given in SEQ ID N0:7, or a functional fragment thereof having promoter activity.

5. (Amended) An isolated DNA sequence according to claim 4 having:

- a) a nucleotide sequence given in SEQ ID N0:4, or
- b) a nucleotide sequence that hybridises with the nucleotide sequence of (a) or with a fragment of (a) under the following hybridisation conditions: pre-hybridisation for 1h at about 65 °C in a solution of Church and Gilbert, comprising 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS, followed by hybridisation in the same solution for 18h at about 65 °C, followed by washing three times in 0.1 x SSC, 0.1% SDS at about 65 °C for 30 min. [as defined in claim 2], or
- c) a nucleotide sequence that has at least 85% homology to the nucleotide sequence of a).

9. (Amended) An isolated DNA sequence according to claim 8, having:

- a) a nucleotide sequence given in SEQ ID N0:6 obtained from a plant of *Calluna vulgaris*, or
- b) a nucleotide sequence that hybridises with the nucleotide sequence given in a), under the following hybridisation conditions: pre-hybridisation for 1h at about 65 °C in a solution of Church and Gilbert, comprising 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS, followed by hybridisation in the same solution for 18h at about 65 °C, followed by washing three times in 0.1 x SSC, 0.1% SDS at about 65 °C for 30 min. [as defined in claim 2], or
- c) a nucleotide sequence that has at least 95% homology to the nucleotide sequence of a).

10. (Amended) A recombinant double-stranded DNA molecule comprising an expression cassette comprising the following constituents:

- i) a promoter functional in plants,
- ii) DNA sequence coding for a protein as defined in claim 4 [any of claims 4 to 7] which is fused to the promoter sequence in sense or antisense orientation, and optionally
- iii) a signal sequence functional in plants for the transcription determination and polyadenylation of an RNA molecule.

13. (Amended) A recombinant double-stranded DNA molecule according to claim 11 [or 12] wherein the promoter is an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence encodes a protein comprising the amino acid sequence given in SEQ ID NO:1, or a protein that has at least 60% homology to the amino acid sequence given in SEQ ID NO:1, [as defined in any of claims 1-3].

14 (Amended) A recombinant double-stranded DNA molecule according to claim 12 [or 13] wherein the DNA sequence encoding a signal peptide is an isolated DNA sequence comprising the coding region for a signal peptide, wherein the information contained in the DNA sequence permits, upon translational fusion with a DNA sequence encoding a protein that is expressed in nectaries, targeting of the protein to nectar. [as defined in claim 8 or 9].

15. (Amended) A process for producing a transgenic plant exhibiting excretion of a recombinant protein in its nectar, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim 12 [any of claims 12 to 14], wherein the recombinant protein is excreted in nectar,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

16. (Amended) A process for producing a transgenic plant exhibiting a modified nectar composition, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim [any of claims] 11 [to 14], wherein the recombinant protein interferes with metabolic pathways in the nectaries,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

17. (Amended) A process for producing a transgenic plant exhibiting a modified nectar secretion, comprising:

- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim [any of claims] 11 [to 14], wherein the recombinant protein interferes with sink strength of nectaries,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

18. (Amended) A process for producing a transgenic plant exhibiting a modified nectary development, comprising:

- ii) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claim [claims] 11 [or 14], wherein the recombinant protein interferes with the development of nectaries,
- ii) regenerating plants from the transgenic cell, and
- iii) selecting transgenic plants.

19. (Amended) A process for producing honey from modified nectar of transgenic plants, comprising:

- i) producing a transgenic plant by introducing in a plant cell a recombinant double-stranded DNA molecule as defined in claim [any of claims] 11 [to 14], regenerating plants from the transgenic cell, and selecting modified plants exhibiting the excretion of nectar with a modified composition,
- ii) allowing insects[, preferably bees,] to collect nectar from the transgenic plants and to process the nectar into honey.

20. (Amended) A process for producing a recombinant gene product from honey, comprising:

- i) producing a transgenic plant by introducing in a plant cell a recombinant- double-stranded DNA molecule as defined in claim [any of claims] 12 [to 14], regenerating plants from the transgenic cell, and selecting modified plants exhibiting excretion of the recombinant gene product in nectar,
- ii) allowing insects[, preferably bees,] to collect nectar from the transgenic plants and to process the nectar into honey, and
- iii) isolating and purifying the gene product from the honey.

5

22. (Amended) Micro organisms containing DNA sequences according to claim [one or more of claims] 1 [to 9].

23. (Amended) Micro organisms containing recombinant DNA molecules according to claim [any of claims] 10 [to 14].

24. (Amended) A plant cell or plant cell culture transformed with one or more DNA sequences according to claim [claims] 1 [to 9].

25. (Amended) A plant cell or plant cell culture transformed with recombinant DNA molecules according to claim [any of] 10 [to 14].

26. (Amended) A plant consisting essentially of the plant cells of claim [claims] 24 [or 25].

27. (Amended) A transgenic plant obtained by the process of claim [any of claims] 15 [to 18].



10 Rec'd PCT/PTO 01 APR 2002 #9

**PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Jantina CREEMERS, et al

Serial No.: 09/743,885

Group No.:

Filed: January 16, 2001

Examiner:

For: PROCESS TO COLLECT METABOLITES FROM MODIFIED NECTAR BY INSECTS

Attorney Docket No.: U-013212-4

**Assistant Commissioner Patents and Trademarks  
Washington, DC 20231**

**SECOND PRELIMINARY AMENDMENT**

Sir:

In response to the Official Communication of March 12, 2002 and further to the Preliminary Amendment dated October 22, 2001, please further amend the application as follows  
please amend the above application as follows:

**IN THE SPECIFICATION:**

Please delete the Sequence Listing appearing on page 39, line 1 - page 47, line 1 in entirety and rewrite as shown attached.

---


**CERTIFICATE OF MAILING (37 CFR 1.8a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, DC 20231

CLIFFORD J. MASS

Type or print name of person mailing paper)

Date: March 28, 2002

  
(Signature of person mailing paper)



## SEQUENCE LISTING

1349 CREEMERS, Jantina  
 ANGENENT, Gerrit  
 KATER, Martin

<120> Process to collect metabolites from modified nectar by insects

<130> U-13212-4

<140> 09/743885

<141> 2001-01-16

<160> 29

<170> PatentIn Ver. 2.1

<210> 1

<211> 265

<212> PRT

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland

<220>

<223> NEC1 amino acid sequence

<400> 1

Met	Ala	Gln	Leu	Arg	Ala	Asp	Asp	Leu	Ser	Phe	Ile	Phe	Gly	Leu	Leu
1				5				10					15		
Gly	Asn	Ile	Val	Ser	Phe	Met	Val	Phe	Leu	Ala	Pro	Val	Pro	Thr	Phe
	20						25					30			
Tyr	Lys	Ile	Tyr	Lys	Arg	Lys	Ser	Ser	Glu	Gly	Tyr	Gln	Ala	Ile	Pro
	35						40					45			
Tyr	Met	Val	Ala	Leu	Phe	Ser	Ala	Gly	Leu	Leu	Leu	Tyr	Tyr	Ala	Tyr
	50					55					60				
Leu	Arg	Lys	Asn	Ala	Tyr	Leu	Ile	Val	Ser	Ile	Asn	Gly	Phe	Gly	Cys
65			70						75					80	
Ala	Ile	Glu	Leu	Thr	Tyr	Ile	Ser	Leu	Phe	Leu	Phe	Tyr	Ala	Pro	Arg
			85					90						95	
Lys	Ser	Lys	Ile	Phe	Thr	Gly	Trp	Leu	Met	Leu	Leu	Glu	Leu	Gly	Ala
			100					105					110		
Leu	Gly	Met	Val	Met	Pro	Ile	Thr	Tyr	Leu	Leu	Ala	Glu	Gly	Ser	His
		115					120						125		

Arg Val Met Ile Val Gly Trp Ile Cys Ala Ala Ile Asn Val Ala Val  
130 135 140

Phe Ala Ala Pro Leu Ser Ile Met Arg Gln Val Ile Lys Thr Lys Ser  
145 150 155 160

Val Glu Phe Met Pro Phe Thr Leu Ser Leu Phe Leu Thr Leu Cys Ala  
165 170 175

Thr Met Trp Phe Phe Tyr Gly Phe Phe Lys Lys Asp Phe Tyr Ile Ala  
180 185 190

Phe Pro Asn Ile Leu Gly Phe Leu Phe Gly Ile Val Gln Met Leu Leu  
195 200 205

Tyr Phe Val Tyr Lys Asp Ser Lys Arg Ile Asp Asp Glu Lys Ser Asp  
210 215 220

Pro Val Arg Glu Ala Thr Lys Ser Lys Glu Gly Val Glu Ile Ile Ile  
225 230 235 240

Asn Ile Glu Asp Asp Asn Ser Asp Asn Ala Leu Gln Ser Met Glu Lys  
245 250 255

Asp Phe Ser Arg Leu Arg Thr Ser Lys  
260 265

<210> 2

<211> 221

<212> PRT

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland, secretory cell

<220>

<223> FBP15 amino acid sequence

<400> 2

Met Gly Arg Gly Lys Ile Glu Ile Lys Arg Ile Glu Asn Thr Thr Asn  
1 5 10 15

Arg Gln Val Thr Phe Cys Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala  
20 25 30

Tyr Glu Leu Ser Val Leu Cys Asp Ala Glu Val Ala Leu Ile Val Phe  
35 40 45

Ser Ser Arg Gly Arg Leu Tyr Glu Tyr Ala Asn Asn Ser Val Lys Ala  
50 55 60



Thr Ile Asp Arg Tyr Lys Lys Ala Ser Ser Asp Ser Ser Asn Thr Gly  
65 70 75 80

Ser Thr Ser Glu Ala Asn Thr Gln Phe Tyr Gln Gln Glu Ala Ala Lys  
85 90 95

Leu Arg Val Gln Ile Gly Asn Leu Gln Asn Ser Asn Arg Asn Met Leu  
100 105 110

Gly Glu Ser Leu Ser Ser Leu Thr Ala Lys Asp Leu Lys Gly Leu Glu  
115 120 125

Thr Lys Leu Glu Lys Gly Ile Ser Arg Ile Arg Ser Lys Lys Asn Glu  
130 135 140

Leu Leu Phe Ala Glu Ile Glu Tyr Met Arg Lys Arg Glu Ile Asp Leu  
145 150 155 160

His Asn Asn Asn Gln Met Leu Arg Ala Lys Ile Ala Glu Ser Glu Arg  
165 170 175

Asn Val Asn Met Met Gly Gly Glu Phe Glu Leu Met Gln Ser His Pro  
180 185 190

Tyr Asp Pro Arg Asp Phe Phe Gln Val Asn Gly Leu Gln His Asn His  
195 200 205

Gln Tyr Pro Arg Gln Asp Asn Met Ala Leu Gln Leu Val  
210 215 220

<210> 3

<211> 18

<212> PRT

<213> Calluna vulgaris

<220>

<223> tissue type: flower

<220>

<223> Calluna vulgaris signal peptide

<400> 3

Met Phe Leu Pro Ile Leu Phe Thr Ile Ser Leu Leu Phe Ser Ser Ser  
1 5 10 15

His Ala

<210> 4

<211> 1205

<212> DNA

<213> Petunia x hybrida

<220>  
<223> strain: W115

<220>  
<223> tissue type: nectar gland

<220>  
<223> NEC1

<400> 4  
tcgagcggcc gcccgggcag gtattcaaca agagtattca ccacttgaac tcaaaagggg 60  
cttcactaaa aaaaaatcat ggcgcaatta cgtgctgatg acttgtcttt catatttggc 120  
cttcttggtg atattgtatc attcatgggc ttcttagcac ccgtgccaac attttacaaa 180  
atatataaaa ggaatcatc agaaggatat caagcaatac catatatggt agcactgttc 240  
agcgccggac tattgctata ttatgcttat ctcaggaaga atgcctatct tctcgtcagc 300  
attaatggct ttggatgtgc cattgaatta acatatatct ctctgtttct cttttacggc 360  
cccagaaagt ctaagatttt cacagggtgg ctgatgctct tagaattggg agccctagga 420  
atggtgatgc caattactta ttattagca gaaggctcac atagagtgat gatagtggga 480  
tggatttggt cagctatcaa tgttgctgtc ttgtgctgtc ctttaagcat catgagggcaa 540  
gtaataaaaa caaagagtggt agagttcatg cccctcactt tatcttttgtt cctcactctc 600  
tgtgccacta tgtggttttt ctatgggttt tcaagaagg acttttacct tgcgtttcca 660  
aatatactgg gctttctatt cggaatcggt caaatgctat tatattttgt ttacaaggat 720  
tcaaaagaaa tagatgatga aaaatctgat cctgttcgag aagctacaaa atcaaaagaa 780  
ggtgtagaaa tcattatcaa cattgaagat gataattctg ataacgcatt gcagtcctatg 840  
gagaaggatt ttccagact gcggacatca aaataagcaa gaagatgatc aaaaaatgac 900  
aaagctaagg agtttgaagt aaggcaagga acttgacact gaatactcaa gctaattagc 960  
aagacttttag cagctttgaa tatttagtgt ttgtgaggtg tatccttata attagcttgt 1020  
agcatagcct tcccactaat aattctgctt agcgaatctt atatatggga aatacttaca 1080  
ctagtatgca tcttctatat acatgttttg cacttgacta tacatagaaa aattaacaag 1140  
catttctcac ctcaatttgt cacttactta taagttagctg aataataata tgcaattttc 1200  
acccc 1205

<210> 5  
<211> 1157  
<212> DNA  
<213> Petunia x hybrida

<220>  
<223> strain: W115  
<220>  
<223> tissue type: nectar gland

<220>  
<223> cDNA library of nectaries from Petunia hybrida flowers

<220>  
<223> FBP15

<400> 5  
tctgaataca agctgtgtgt gtagagagat ttcataaaga cagcaaacat cccttctttt 60  
tgttctggtt taaaagttcc cttcttcaac cagctctttt cctcatcagg gtaagttgca 120  
aataaaagggg atgttccaga atcaagaaga gaagatgtca gactcgccct agaggaagat 180  
gggaagagga aagattgaga ttaagaggat tgaaaataca acaaatcgct aagtcacttt 240

```

ctgtaagaga agaaatgggt tgcctaaaaa agcttatgaa cttctgttc tttgtgatgc 300
tgaagtgtct ctcatcggtt tctcaagcgc tggccgcctc tatgaatatg ctaacaacag 360
tgtgaaggca acaattgata gatataagaa agcatcctca gatctctcca acactggatc 420
tactcttgaa gctaacactc agttttatca acaagaagct gccaaactcc gaggttcagat 480
tggtaactta cagaactcaa acaggaacat gctaggcgag tctctaagtt ctctgactgc 540
aaaagatctg aaaggcctgg agaccaaat tgagaaagga attagtagaa ttagggtcca 600
aaagaatgaa ctctctgttg ctgagattga gtatatgcga aaaagggaaa ttgatttgca 660
caacaacaat cagatgcttc gggcaagat agctgagagt gaaagaaatg tgaacatgat 720
gggaggagaa tttgagctga tgcacatcca tccgtacgat ccaagagact tcttccaagt 780
gaacggctta cagcataatc atcaatatcc acgccaaagc aactggctc ttcaattagt 840
ataagtttat aataaaatgc atggtttgaa gcactctgat tgtgggtgat ttggattatg 900
tataagggag tgcaggccat ttgccaatca ttgaaaggta ctcaaacagg aagttgaaga 960
agttcatcat ctctctcatc tatatgtctt aacaaaaagtc ttagcttatg gactctaaaa 1020
caagacttta atttaacata taaatataat tgtgtaatgc tgtgttatgt tatggtatgt 1080
atccaaaac atttaatacc tatcttttcc ttcaaatatg gtctcctttg atacaaacta 1140
ctaacatatt ttcttat 1157

```

```

<210> 6
<211> 54
<212> DNA
<213> Calluna vulgaris

```

```

<220>
<221> sig_peptide
<222> (1) .. (54)

```

```

<400> 6
atgtttcttc caattctctt caccatttcc ctctctttct cctcctccca tgct 54

```

```

<210> 7
<211> 2141
<212> DNA
<213> Petunia x hybrida

```

```

<220>
<223> strain: W115

```

```

<220>
<223> NEC1 promoter

```

```

<400> 7
cctaggagaa atcaagccta ctcttaagat ggatgactca ctgccccga tggtaagggtg 60
aaggatctgt tgattagagt tgggaagttc atgttctctg ctgattttat tattctagac 120
tatgaaggag accaagaagc tccaataatt ttgggaagag cattcttaat cacatcgatg 180
gcaattattg acatggaact tggggagatg actgtgagag cgcatggaga aaaggttact 240
ttcaagggtt ataataaaaa ggatcatatg gctaagtttg aagagtgttc tttgatagaa 300
tgtgtcagac gagaacatga aagtaaacgc aaagaggtgt ttgagcggaa tgtagaacaa 360
agtgaccacg gcacaataat tgacaagttg aaggaaaaat cactaaagg aaggaagaag 420
acaaaagttc gtctgaacaa gaggagacgt aaatgtctga agtgagctta aagggtgtgt 480
cgtactacga cgttaactaa ggcgcttgct gggaggcaac cctagctttg tatgtaaatg 540
taaaagtaaa aaatatatat atagaaaaag gaaaatacaa aaagagtctg gccgcgacgt 600
taaatcaagc gcttggttga aggcaaccca atttttattg ttttagttgt ttacttatt 660
tagtattacg tagtttcttg ttgttttttg agggctcggg actttcggaa ggtgagggtg 720
ttcaaggcca tcgcggtgtg tattgcagcg aggttaagtgt aagagttgag ttggaagcgt 780

```

```

ttggccaagt gttgcaccgt gagaggcttt caacctgttg cgacacgtga aaaattaaga 840
gccagatctg ctacattagc actgaagcat cgcttggcca atagcttgga atggaagcaa 900
gaattcaaac caaaatcaga aacgccacaa gagatgtgtc gcacactgca aagctttgtg 960
caaaactagt aacgcagaaa tagaaatgct acagcccatt cgctgcttgg ctlatggcag 1020
gcagcaaaaa ttcagcagca aaacagaaac gctgcgagaa acgcgtgcga tacgccatag 1080
ctttgtgtca aacagaacgt ccagaaattg aaaagctata agccgtgctc gcttggtcca 1140
tggcgtgcag actagaaaag ctctagcaga tgcgtgcgt attgtatagc ttgggtgtgaa 1200
acagaaagtt cgaaacttgg aaaacgataa cccagcgtcg cctcttcaac cgcgtccagg 1260
taagtccaag attcttacgg gtgacccat taacccattg atcggctgat tataaacaa 1320
aaaaacatcac ctccaactat cacatgattt cataagtttg acctaggata ttttatatat 1380
atatatatat atatacacac acacaccatt tccagcgtac ttacctcatt tttattcaaa 1440
ccatttttct gcttcaaaag tttaaattat taatatgata agtcatccat agtcaaacaa 1500
gattttctat actattttgt ccttgtaat tttaaaaaaa aaatgagcga tggtaagata 1560
aacattgttt gcaagtgtac aatttttagta tatgcaaac aacgcttctt ctccaacta 1620
tcacctaaaa ctacatcatt tatggcgggc ggactagacg tagccaaaata taaaaacgca 1680
atggccattc agttcatgtc atttttatat ccttcatcca ataattatc tcaaaattga 1740
tgtacagttt gttctctgat gtgcacttta ctatacgtaa tacggaattt acattataat 1800
taaagagaac tgttccacta aattttaatg atttaattaa ttaactcgg ttacttgtat 1860
tattattatt gctgtatttg ttgtcattt gaatttgga ccgcagattt ttgtatgcaa 1920
ttaaccctca tatatctttt ggccaaataa agaaaaagtc tgcataattc ttgccaaaaa 1980
ttatcatcac ttaccggaat tcttgtttt tgtttctctg ttgtgttctt ccactataaa 2040
taacatttgc agtgagtaaa gtttcttcag gtctcttttg tagattcaac aagagtattc 2100
agcacttgaa ctcaaaaggg gcttccactaa aaaaaatcat g 2141

```

```

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer prat
122

```

```

<400> 8
gtgggaaggc tatgctacaa gc 22

```

```

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer prat
119

```

```

<400> 9
ccttctccat ggactgcaat gcg 23

```

```

<210> 10
<211> 29
<212> DNA
<213> Artificial Sequence

```

<220>  
 <223> Description of Artificial Sequence: primer prat  
 129  
  
 <400> 10  
 gggatccatg gcgcaattac gtgctgatg 29  
  
 <210> 11  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer prat  
 148  
  
 <400> 11  
 ccaagaaggc caaatatgaa agac 24  
  
 <210> 12  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer prat  
 149  
  
 <400> 12  
 aagtcacag cacgtaattg cgcc 24  
  
 <210> 13  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer prat  
 169  
  
 <400> 13  
 cgctgcagcg ccattggtttt ttttagtgaa gcccc 35  
  
 <210> 14  
 <211> 32  
 <212> PRT  
 <213> Calluna vulgaris  
  
 <220>  
 <223> CVH 50 N-terminal sequence  
  
 <400> 14

Ser Val Leu Asp Phe Cys Val Ala Asp Pro Ser Leu Pro Asp Gly Pro  
 1 5 10 15

Ala Gly Tyr Ser Cys Thr Glu Pro Ser Thr Val Thr Ser Gln Asp Phe  
 20 25 30

<210> 15

<211> 40

<212> PRT

<213> Calluna vulgaris

<220>

<223> CVH 29 N-terminal sequence

<400> 15

Ser Val Leu Asp Phe Cys Val Ala Asp Pro Ser Leu Pro Asp Gly Pro  
 1 5 10 15

Ala Gly Tyr Ser Cys Lys Glu Pro Ala Lys Val Thr Val Asp Asp Phe  
 20 25 30

Val Phe His Gly Leu Gly Thr Ala  
 35 40

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
 176

<400> 16

gayttytggy tngengaycc 20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
 177

<400> 17

ccrtgraana craartcrtc 20

<210> 18  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 207

<400> 18  
 ggtgacttta gagggctect tgc

23

<210> 19  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 206

<400> 19  
 gctccttgca ggagtagcct gc

22

<210> 20  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 247

<400> 20  
 ggctgcagga gtgttctttg atagaatg

28

<210> 21  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 248

<400> 21  
 cgccatatgt ttttttatgg aagcccc

27

<210> 22  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

```

<220>
<223> Description of Artificial Sequence: primer prat
      245

<400> 22
tatgttcctt ccaattcttt tcactatttc tcttcttttc tcttcttttc atgcttctgt 60
tcttgatttc                                     70

<210> 23
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer prat
      246

<400> 23
gatccgaaat caagaacaga agcatgagaa gaagagaaaa gaagagaaat agtgaagaaga 60
attggaagga aca                                     73

<210> 24
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer prat
      251

<400> 24
gggagctcga gtggttcaaa catttggcaa taaag                                     35

<210> 25
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer prat
      252

<400> 25
cgaattcccg ggatctagta acatagatga cac                                     33

<210> 26
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer prat

```



249

<400> 26  
 ccggatccat gttacgtcct gtagaaacc 29

<210> 27  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 250

<400> 27  
 gggagctccc accgagctg tag 23

<210> 28  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 28  
 aaggacttta gagagaccg accactgctg g 31

<210> 29  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence


<220>  
 <223> Description of Artificial Sequence: primer

<400> 29  
 aaatgtcttt gatgcataat atttcccata atc 33

**REMARKS**

In response to the Official Communication of March 12, 2002, Applicants request the above amendatory action to the specification to comply with the Sequence Listing requirements of 37 CFR 1.821 - 1.825. Applicants resubmit herewith a computer readable form copy of the Sequence Listing and the required statements that the paper and computer readable form copies of the Sequence Listing are the same and contain no new matter.

Respectfully submitted,



CLIFFORD J. MASS  
LADAS & PARRY  
26 WEST 61ST STREET  
NEW YORK, NY 10023  
REG. NO.30,086 (212)708-1890

09/743885

WO 00/04176

PCT/NL99/00453

Process to collect metabolites from modified nectar by insects.

**Field of the invention**

The present invention relates to isolated, purified DNA sequences which can act as promoters in eukaryotic cells. More specifically, the present invention is related to such DNA sequences which act as promoters to express genes in nectaries of plants. The present invention also relates to chimerical gene constructs comprising a structural or a synthetic gene under the control of a promoter that effects expression of said genes in nectaries. This invention also relates to a process for producing metabolites in honey by allowing insects, preferably bees, to collect and process nectar from plants that excrete said metabolites in nectar or other exudates. Further, this invention relates to plant cells, plants or derivatives therefrom, that express the said chimerical gene.

**Background of the invention**

Nectaries are nectar secreting organs or tissues that can be located inside (floral) or outside (extrafloral) the flower. The main component of nectar is sugar, the variation between nectars of flowers from different species mainly being the concentration and ratio of glucose, fructose and sucrose (Baker and Baker, 1982). In addition, depending on the plant species, varying amounts of polysaccharides, lipids, organic acids, volatiles, minerals, phosphates, alkaloids, amino acids and proteins have been detected

(Baker and Baker, 1982). Being a specialised sink organ, the nectaries are supplied with sucrose by phloem unloading (Davis et al., 1985, Hagitzer and Fahn, 1992).

- 5 The mechanisms of sugar accumulation and nectar secretion have been described for several plant species (Fahn et al., 1979). Sugar transport to the nectaries is achieved by active transport mechanisms and/or osmotic and chemical gradients. In the nectaries of many plants sucrose is  
10 converted to glucose and fructose, resulting in a hexose dominant nectar. Part of the hexoses are converted to starch, which is hydrolysed prior to anthesis and nectar secretion. Cell to cell transport of nectar in the nectary parenchyma tissue is mainly symplastic, as demonstrated by  
15 the presence of many plasmodesmata between these cells (Fahn et al., 1979). Nectar is secreted from secretory cells via the cell membrane (eccrine secretion) or via the Golgi and endoplasmatic reticulum vesicles (granulocrine secretion). Research on the molecular regulation of nectary  
20 development and nectary biochemistry has not been reported.

- The main function of floral nectar is to reward pollinating insects. Insects collect nectar to meet their short-term energy requirements. Colony-living honeybees process large  
25 quantities of nectar into honey, which is stored in honeycombs of the beehive and is used as food supply during the winter period. Within the bee colony different classes of worker bees cooperate in the honey production process. Foraging bees collect pollen and nectar from the flowers  
30 and bring it to the hive. On returning to the hive they give most of it up to household bees. Pollen is used as a protein source, especially to feed the brood. Adult nurse and worker bees use little protein, their capacity to digest proteins being very low (Crailsheim et al., 1993).  
35 Honey processing takes place by repeated swallowing and bringing up of the nectar from the honey stomach. In the first process 15% of the water content is lost. This semi-

processed nectar is temporarily stored in a honeycomb cell and taken out later for further processing. The final process includes filtering the honey to discard small particles like pollen grains. Sugar metabolising enzymes (invertase, amylase) are added and the honey is concentrated to an average water content of 20%. Most nectars and honeys only contain traces of protein (<0.2%). However, *Calluna vulgaris* (heather) honey can contain up to 1.8% protein, giving it thixotropic properties (Butler, 1962).

It is known that bees add enzymes like invertase to nectar during the honey processing. Therefore, the probability that proteases are also added is very low. Protein digestion does not take place in the honey stomach but in the intestine of the honeybee. However, the ability of adult worker bees to digest proteins is very low, their main requirement being energy which they obtain from nectar. Until now, it was not established which proteins are present in heather honey and whether these originate from floral heather nectar or are added to honey by honeybees.

In the present invention it was established that heather honey contains two unique proteins that originate from floral nectar of heather. Based on these results a production system for proteins in nectar and honey was established.

It is an object of the present invention to show that recombinant proteins can be secreted in nectar of transgenic plants, that this nectar is collected by honeybees and that the bees process this nectar into honey that contains the unaltered protein in a concentrated form.

#### Definitions

**Honey:** A substance that contains approximately 80% sugar and varying amounts of other components and that is produced by insects, preferably bees, that collect and process

nectar from floral or extrafloral nectaries, from honeydew, other plant exudates or artificial sugar solutions.

**MADS box gene**: a gene coding for a transcription factor  
5 having a region of 56 amino acids which is homologous to a similar region in the Arabidopsis AGAMOUS protein and Antirrhinum DEFICIENS protein. This region is called the 'MADS box'. At least 50% of the amino acids in this region should be identical to the amino acid composition in the  
10 MADS boxes of AGAMOUS and/or DEFICIENS.

**Nectary**: secretory organ or secretory tissue of plants, located in the flowers (floral nectaries) or outside the flower (extrafloral nectaries) that excrete nectar.  
15

**Nectar**: sugar containing fluid that is secreted by nectaries. Nectar can also contain substances like minerals, amino acids, proteins, organic acids, volatiles, alkaloids etc.  
20

**Recombinant protein**: the gene product of a recombinant DNA molecule.

**Recombinant DNA molecule**: A DNA molecule in which sequences  
25 which are not naturally contiguous have been placed next to each other by in vitro manipulations.

**Promoter**: The DNA region, usually upstream to the coding sequence of a gene, which binds RNA polymerase and directs  
30 the enzyme to the correct transcriptional start site.

#### **Summary of the invention**

The production of recombinant proteins for pharmaceutical  
35 purposes is a growing market. Until now, mainly bacterial and yeast systems have been used for bulk production of proteins. Recently animal production systems have also been

- developed. With the availability of efficient transformation techniques for plants, procedures to use plants for the production of proteins are now in progress. In plants, the recombinant proteins are targeted to sink organs like tubers and seeds. A serious draw-back of these production methods is that the recombinant protein can only be obtained after extended, and therefore expensive, purification steps.
- 10 The present invention provides a method to produce metabolites, preferably recombinant proteins in honey, which is manufactured by insects, preferably honeybees, that collect floral nectar of transgenic plants. Harvesting of honey is very simple and purification of the protein is very
- 15 straight forward and requires no advanced purification steps. To give an estimation of the protein yield in a crop like rapeseed, we suggest an average protein production of 2% in honey, as has been found in honey of heather. If one hectare of rapeseed yields 100-500 kilo honey in one
- 20 season, a yield of 2 to 10 kilo protein can be obtained. In addition, the present invention provides a method to collect metabolites from honey that is derived from non-transgenic plants that secrete these metabolites in nectar. An example are secondary metabolites like acetylcholine, a
- 25 diterpine compound, that is excreted in nectar of *Rhododendron arboreum* and *Rhododendron barbatum* and of *Piptanthus nepalensis* (Martini et al., 1990).
- This invention provides a gene from petunia, *NEC1*, that is
- 30 highly expressed in the nectaries of petunia and weakly expressed in the stamens. It also provides another gene from petunia, *FBP15*, that encodes a MADS box protein and which is specifically expressed in the nectaries of petunia. Further, it provides the isolated DNA sequences of the
- 35 promoters of the *NEC1* and the *FBP15* genes. Furthermore, this invention provides an isolated DNA sequence expressed in nectaries encoding a signal peptide that is translation-

ally fused to a germin-like protein (Lane et al., 1993, Dumas et al., 1995), having the function to target the mature germin-like protein to nectar of heather (*Calluna vulgaris*). This invention gives proof that protein-containing sugar solution is collected by honeybees to produce honey that has a higher protein content than the sugar solution itself, the protein having undergone no qualitative alterations. This invention also proves that a recombinant protein can be produced in nectar of transgenic plants and that this protein is present in honey produced by honeybees that collected this nectar.

Accordingly, this invention provides an isolated DNA sequence which encodes a protein indicated NEC1 and having the amino acid sequence given in SEQ ID NO:1 of the sequence listing hereafter or homologs of NEC1. A homolog of NEC1 is predominantly expressed in nectaries and/or has at least 60% homology with the amino acid sequence given in SEQ ID NO:1. Further this invention provides an isolated DNA sequence which encodes a protein indicated FBP15 and having the amino acid sequence given in SEQ ID NO:2 of the sequence listing hereafter or a homolog of FBP15. A homolog of FBP15 is specifically expressed in nectaries and belonging to the MADS box family. Furthermore, a homolog is also a gene sequence that has at least 80% homology within the MADS box region and a 60% overall homology with the amino acid sequence given in SEQ ID NO:2. Further this invention provides the characterisation and the isolation of a DNA sequence which encodes a signal peptide indicated "CVSP" (*Calluna vulgaris* signal peptide), wherein the information contained in the DNA sequence permits, upon translational fusion with a DNA sequence encoding a protein that is expressed in nectaries, targeting of the protein to nectar.

The DNA sequences of the invention can also be characterised in that they comprise the NEC1 gene and the FBP15 gene having the nucleotide sequences given in SEQ ID NO:4 and



SEQ ID NO:5 respectively, or a functionally homologous gene or an essentially identical nucleotide sequence or part thereof or derivatives thereof which are derived from said sequences by insertion, deletion or substitution of one or more nucleotides, said derived nucleotide sequences being obtainable by hybridisation with the nucleotide sequences given in SEQ ID NO:4 and 5 respectively.

Furthermore, the DNA sequences of the invention can also be characterised in that they comprise signal sequence CVSP having the nucleotide sequence given in SEQ ID NO:6, or an essentially identical nucleotide sequence or part thereof or derivatives thereof which are derived from said sequences by insertion, deletion or substitution of one or more nucleotides.

Further, this invention provides an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence encodes a protein comprising the amino acid sequence given in SEQ ID NO:1, or a homologous protein.

Furthermore, this invention provides an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence encodes a protein comprising the amino acid sequence given in SEQ ID NO:2, or a homologous protein.

In a further aspect, the invention provides a protein encoded by any of the above defined DNA sequences. Further, the invention provides processes of producing transgenic plants exhibiting excretion of recombinant proteins in nectar, the expression of the chimerical genes and the targeting of the recombinant proteins being under the control of promoter sequences and a signal sequence as described in this invention. Still further, the invention provides processes of producing transgenic plants that produce recombinant proteins in nectar, the expression of

- 8 -

the chimerical genes being under the control of promoter regions upstream of other genes that are expressed in nectaries. Still further, the invention provides processes of producing transgenic plants that produce recombinant proteins in nectar, the expression of these proteins being under the control of any signal peptide that affects targeting of a protein in nectar.

Also, the invention provides recombinant double stranded DNA molecules comprising expression cassettes to be used in the above process. Further, the invention provides transgenic bacteria, transgenic plants producing recombinant proteins in nectar, and also plant cells, tissue culture, plant parts or progeny plants derived from said transgenic plants. Finally, the invention provides a process to produce recombinant gene products in honey, produced by bees that collect nectar from transgenic plants and process this nectar into honey.

#### Brief description of the figures:

**Figure 1** shows a polyacrylamide gel with PCR products after Differential Display mRNA amplification. PCR reactions were performed with the oligo-dT primer T12MG in combination with 5 different random primers Ap11-AP15 on cDNA samples of pistils without nectaries (two independent samples), nectaries (two independent samples), leaves and a mixture of sepals (s), petals (p) and stamens (a). Bold arrow depicts the cloned fragment DD18.

**Figure 2** is the DNA sequence of the Differential Display RT-PCR clone DD18a. The primers prat 122 and prat 119 that were used for 5' RACE PCR reactions are underlined.

**Figure 3** is the DNA sequence of clone RC8, obtained by RACE PCR with gene specific primers prat 122 and prat 119 (Fig. 2) in combination with adapter primers. Primer prat 129 (underlined) is used in the next step together with primer prat 122 to amplify the coding region of the *NEC1* cDNA.

**Figure 4** is the full length sequence of *NEC1* cDNA. The translation start (ATG) and translation stop (TAA) are depicted bold.

10

**Figure 5** shows the expression of *NEC1* (A) and *FBP15* (B) in wild type petunia plants (line W115) as determined by Northern blot analysis. Blot A contains total RNA, while blot B is enriched for mRNA. The tissues are indicated as: 1= leaf, 2= sepal, 3= petal, 4= stamen, 5= pistil, 6= nectary. For blot A the HindIII/EcoRI fragment of pDD18a was used as a probe. For blot B the full length cDNA of *FBP15* was used as a probe.

**Figure 6** Expression of *NEC1* by in situ localisation of *NEC1* transcripts (A) and activity of the *NEC1* promoter in the nectaries (B) and the stamen (C) as shown by GUS expression driven by the *NEC1* promoter. The GUS assay used for the stamens was incubated overnight without modifications to prevent diffusion (example 8). The GUS assay for the nectaries was incubated for 5 hrs, using an assay mixture to prevent diffusion (example 8). For in situ localisation longitudinal sections of flowers of *Petunia hybrida* were hybridised with digoxigenin-labeled antisense *NEC1* RNA

30

**Figure 7** is the DNA sequence from the promoter region upstream of a sequence encoding the *NEC1* protein. Underlined is the translation start of *NEC1* cDNA.

**Figure 8** depicts a schematic presentation of the T-DNA region between the borders of the binary vector pBNEP1, containing the *NEC1* promoter (Figure 7), the *GUS* reporter

gene and the nos terminator in pBINPLUS. This vector was used to generate transgenic plants to study the expression of the *NEC1* promoter.

- 5 **Figure 9** shows the SDS-PAGE separation of proteins that are present in commercial honey samples from different flowers. M= marker, lane 1: wattle bark, lane 2: flower mixture, lane 3: heather, lane 4: clover, lane 5: rapeseed.
- 10 **Figure 10** shows the SDS-PAGE separation of proteins that are present in commercial honey samples of rapeseed (RH2x, RH10x) and heather (HH2x, HH10x) and of nectar samples of rapeseed (RN2x, RN10x) and heather (HN2x, HN10x). M= molecular weight marker. Two (2x) or ten (10x) fold dilutions were used.
- 15

- Figure 11** shows the SDS-PAGE separation of proteins present in dilutions of the sugar/BSA feeding solution (A) and of honey from bees that had collected the sugar/BSA solution (B). The dilutions of the sugar/BSA and honey/BSA solution was the same for both gels: 1= 15x, 2= 30x, 3= 60x, 4= 75x, 5= 75x, 6= 90x, 7= 105x, 8= 120x, 9= 135x. M= marker
- 20

- Figure 12** shows the sequence homology of the N-terminal protein sequence of CVH29, a unique protein present in heather honey and nectar, with a germin-like protein GER1 from a gene bank homology search (BLAST).
- 25

- Figure 13** shows the deduced DNA sequence of the N-terminal protein sequence of CVH29. The degenerated primers prat 176 and prat 177 are underlined (A). The DNA sequence of the PCR product obtained with prat 176 and prat 177 performed on genomic DNA of heather is shown in B. The gene-specific primers prat 207 and prat 206 used to perform 5'RACE PCR reactions on cDNA from heather flowers are underlined.
- 30
- 35

- 11 -

Figure 14 shows the DNA sequence of four independent clones obtained by 5'RACE PCR with prat 207 and prat 206 on cDNA of heather flowers. The ATG translation start of the putative signal sequence is boxed. The end of the putative signal sequence and the start of the mature protein are indicated by arrows.

Figure 15 is the sequence of the synthetically produced DNA molecule encoding the signal sequence CVSP (boxed) with linkers.

Figure 16 is the schematic representation of the plasmid pCV1. Not all restriction sites are indicated.

Figure 17 is the schematic representation of the plasmid pCV2. Not all restriction sites are indicated.

Figure 18 is the schematic representation of the plasmid pCV3. Not all restriction sites are indicated.

Figure 19 is the DNA sequence of the full length cDNA of FBP15. The translation start (ATG) and translation stop (TAA) are boxed. The MAD-box and K-box region are underlined.

#### Detailed description of the invention

This invention provides processes of producing transgenic plants that produce recombinant proteins in nectaries and nectar that is collected by foraging honeybees. This invention gives evidence that honeybees process protein containing nectar into honey that contains the unaltered protein in a concentrated form. Subsequently, the desired protein can be purified from the honey.

- 12 -

- To express recombinant proteins in nectaries of transgenic plants, a translational fusion of an isolated DNA sequence from a promoter region upstream of a sequence encoding a protein that is expressed in nectaries with a sequence encoding the recombinant protein has to be carried out. Preferably, the isolated DNA sequence from a promoter region is upstream of a sequence that is specifically or highly expressed in nectaries.
- 10 The invention relates to a DNA sequence isolated from *Petunia hybrida* that encodes a protein indicated NEC1 or a homologous protein or part thereof. A homologous protein has at least 65% homology with the amino acid sequence given in SEQ ID NO:1. The cDNA sequence of the *NEC1* gene is given in Fig. 4 and in SEQ ID NO:4. The deduced amino acid sequence of the *NEC1* gene is given in SEQ ID NO:1. The *NEC1* gene shows strong expression in the nectaries and in a very localised region of the anther filaments of *Petunia hybrida*. The deduced amino acid sequence of *NEC1* predicts a membrane bound protein. The precise function of the gene has not been elucidated yet, but considering the phenotype of transgenic plants that ectopically express *NEC1* in the leaves, a role in sugar metabolism of *NEC1* is apparent.
- 25 The present invention also relates to homologous DNA sequences that can be isolated from other organisms, preferably plants, using standard methods and the already known DNA sequence of the *NEC1* gene. More precisely, it is also possible to use DNA sequences which have a high degree of homology to the DNA sequence of the *NEC1* gene, but which are not completely identical, in the process according to the invention. The use of sequences having homologies between 85 and 100 % is to be preferred. DNA sequences can also be used which result from the sequence shown in SEQ ID NO:4 by insertion, deletion or substitution of one or more nucleotides. This includes naturally occurring variations or variations introduced through targeted mutagenesis or

recombination. The DNA sequence shown in SEQ ID NO:4 can also be produced by using DNA synthesis techniques.

The invention also relates to a DNA sequence isolated from *Petunia hybrida* that encodes a MADS box protein indicated  
5 FBP15 or a homologous protein or part thereof. The cDNA sequence of FBP15 is given in SEQ ID NO:5. FBP15 shows exclusively expression in the nectaries of *Petunia hybrida*. The function of FBP15 is unknown.

10 The present invention also relates to homologous DNA sequences that can be isolated from other organisms, preferably plants, using standard methods and the already known DNA sequence of FBP15. More precisely, it is also possible to use DNA sequences which have a high degree of  
15 homology to the DNA sequence of FBP15, but which are not completely identical, in the process according to the invention. The use of sequences having homologies between 85 and 100 % is to be preferred. DNA sequences can also be used which result from the sequence shown in SEQ ID NO:5 by  
20 insertion, deletion or substitution of one or more nucleotides. This includes naturally occurring variations or variations introduced through targeted mutagenesis or recombination. The DNA sequence shown in SEQ ID NO:5 can also be produced by using current DNA synthesis techniques.

25 Further, this invention provides an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed  
30 sequence encodes a protein comprising the amino acid sequence given in SEQ ID NO:1, or a homologous protein that is expressed in nectaries. Furthermore, this invention provides an isolated DNA sequence from the promoter region upstream of an isolated DNA sequence from the promoter  
35 region upstream of a nectary-specific expressed sequence, which nectary specific sequence encodes a protein compri-

sing the amino acid sequence given in SEQ ID NO:2, or a homologous protein that is expressed in nectaries.

More specifically this invention provides an isolated DNA  
5 sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence has:

- a) a nucleotide sequence given in SEQ ID NO:4, or
- b) a nucleotide sequence obtainable by hybridisation with  
10 the nucleotide sequence of (a) or with a fragment of (a).

In a more specific embodiment this invention provides an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, obtained from a  
15 plant of *Petunia hybrida*, the sequence consisting essentially of the sequence given in SEQ ID NO:7, or a functional fragment thereof having promoter activity.

In a further aspect, the invention provides an isolated DNA  
20 sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence has:

- a) a nucleotide sequence given in SEQ ID NO:5, or
- b) a nucleotide sequence obtainable by hybridisation with  
25 the nucleotide sequence of (a) or with a fragment of (a).

In a more specific embodiment this invention provides an isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, obtained from a  
30 plant of *Petunia hybrida*, the sequence consisting essentially of the sequence given in SEQ ID NO:8, or a functional fragment thereof having promoter activity.

Further, this invention provides an isolated DNA sequence  
35 comprising the coding region for a signal peptide, wherein the information contained in the DNA sequence permits, upon translational fusion with a DNA sequence encoding a protein



that is expressed in nectaries, targeting of the protein to nectar. More specifically, the DNA sequence comprises the nucleotide sequence given in SEQ ID NO:6 obtained from a plant of *Calluna vulgaris*, or a nucleotide sequence obtainable by hybridisation with the nucleotide sequence given in SEQ ID NO:6. The use of sequences having homologies between 95 and 100 % is to be preferred. DNA sequences can also be used which result from the sequence shown in SEQ ID NO:6 by insertion, deletion or substitution of one or more nucleotides. This includes naturally occurring variations or variations introduced through targeted mutagenesis or recombination. The DNA sequence shown in SEQ ID NO:6 can also be produced by using DNA synthesis techniques. The signal peptide CVSP was isolated from nectar of *Calluna vulgaris* flowers and from honey processed by honeybees that collected the nectar. The function of CVSP in heather nectaries is to target the germin-like protein to nectar. The DNA sequence CVSP can also be used to target other proteins to nectar in plant species.

A subject of the present invention is the use of DNA sequences for producing recombinant proteins in nectar of plants, wherein the protein is produced in nectaries and targeted to nectar, and wherein expression in nectaries is achieved by using a DNA sequence consisting of the promoter region upstream of a DNA sequence that is expressed in nectaries, and wherein secretion in nectar is achieved by using a DNA sequence that encodes a signal sequence that targets the recombinant protein to nectar. In a further aspect the present invention relates to processes wherein a recombinant protein is expressed in other plant tissues than the nectaries and wherein the biochemical composition of nectar is changed as a consequence of the recombinant gene expression. The present invention also relates to processes wherein a recombinant protein is expressed in nectaries of a transgenic plant, wherein the biochemical composition of nectar or the nectar secretion is changed as

a consequence of this protein expression. In particular, it relates to processes where the recombinant protein is an enzyme that interferes with the sugar metabolism in nectaries.

- 5 The production of a recombinant protein in nectaries and nectar is achieved by integrating into the genome of the plants a recombinant double-stranded DNA molecule comprising an expression cassette having the following constituents and expressing it:
- 10 i) a promoter functional in nectaries of plants,
  - ii) a DNA sequence encoding a protein which is fused to the promoter,
  - 15 iii) a DNA sequence encoding a signal peptide that targets the recombinant protein to nectar, which is translationally fused to the DNA sequence encoding the recombinant protein, and optionally
  - iv) a signal sequence functional in plants for the transcription termination and polyadenylation of
  - 20 an RNA molecule.

Such DNA molecules are also subject of the invention. The present invention provides an example of such a DNA molecule that contains the described expression cassettes in the form of plasmid pCV3 (Fig. 18), which comprises the promoter region of the *NEC1* gene from petunia, the signal sequence CVSP from heather, the coding region of the reporter gene *GUS* and the NOS terminator. In principle, any promoter that is active in the nectaries of plants can be used as promoter. The promoter is to ensure that the chosen gene is expressed in nectaries. Also, in principle, any signal sequence that targets the expressed protein to nectar can be used as a signal sequence. The signal sequence is to ensure that the protein is excreted in nectar.

25 Furthermore, any sequence that encodes a recombinant protein in nectaries can be used in the present invention. Preferably, the subject of this invention relates to DNA

30

35

sequences that encode proteins to be used for pharmaceutical purposes. It is also possible to use the invention to produce proteins for other purposes, e.g. enzymes for biotests or antioxidants for food additives. Furthermore,

5 it is possible to use the invention to produce metabolites in nectar that attract predators of pest insects or that kill or repel pest insects. In another aspect it is possible to use the invention to produce metabolites in nectar that modify the attractiveness of the plant for pollinating

10 insects or improve the health of pollinating insects. It is also possible to use DNA sequences that encode proteins that modify the nectar composition or the sink strength of nectaries. This means that the recombinant protein interferes with metabolic pathways in the nectaries, resulting in changed levels of compounds that are

15 already present in nectar, or the formation of new compounds in nectar. In addition, the present invention also relates to expression cassettes that contain the above mentioned DNA sequences, except for a signal sequence. The recombinant protein

20 is then only expressed in the nectaries, but not targeted to the nectar. Consequently, the expression of the recombinant protein in the nectaries can still affect nectar composition.

25 In a further aspect, the present invention also relates to expression cassettes that contain DNA sequences coding for a protein that is expressed in other tissues than the nectaries. The expression of the recombinant protein affects changes in the biochemical composition of nectar or

30 in nectar secretion. Finally, the present invention also relates to non-transgenic plants that produce metabolites in nectar that can be harvested and purified from honey that is produced by honeybees that collect this nectar. Examples for these

35 metabolites are alkaloids, terpenes, amino acids, proteins, pigments and volatiles.

A preferred embodiment of the process discussed above provides that the expression cassette is transformed to a plant species that produces nectar. Preferably, the recombinant protein is produced in nectar of plants that are visited by honeybees that collect the nectar. Honeybees collect floral as well as extrafloral nectar. The present invention relates to plants that produce recombinant proteins in floral or extrafloral nectar. In addition, the present invention also relates to plants that produce recombinant proteins in other plant organs, said plant organs producing an exudate that is collected by insects, preferably bees, and processed into honey. A particularly preferred embodiment of the present invention are plants that can be grown under controlled conditions. Controlled conditions are greenhouses or field facilities where transgenic plants can be grown according to the safety rules that are required. Preferably, the controlled conditions are such that bee colonies that perform normal foraging behaviour can be maintained in the same compartment during the flowering period. Preferred plants originate from the *Brassicaceae* family, in particular *Brassica napus*.

#### Examples

##### Example 1:

##### Cloning of *NEC1*

The *NEC1* cDNA was isolated using the mRNA Differential Display system (Genhunter Corporation, Brookline USA). The isolation of total RNA from nectaries, sepals, petals, stamens and pistils from open flowers and from young leaves of *Petunia hybrida* was done according to Verwoerd et al. (1989). Two independent RNA isolations were performed on nectaries as well as on pistils. A DNase treatment was carried out on each RNA sample, using the RNA MessageClean™ Kit (Genhunter Corporation Brookline USA, cat. No. M601). A

- 19 -

reverse transcription reaction was carried out on 0.1  $\mu$ g RNA of each sample, using the oligo-dT primer T12MG from the Genhunter Kit. Following the protocol, PCR reactions were carried out using the arbitrary primers AP11-AP15 in combination with primer T12MG from the Kit. The PCR products were loaded on a sequencing gel and after electrophoresis the gel was blotted on 3M paper, dried and exposed to X-ray film (Figure 1). Two adjacent nectary-specific bands were cut out from the blot and the DNA was purified according to the manual. Reamplification of the fragment was carried out using the oligo-dT primer T12MG and the arbitrary primer AP15. After electrophoresis, the PCR product was extracted from the agarose gel by freezing the isolated fragment in liquid nitrogen, followed by centrifugation. DNA was precipitated by adding 1/10 volume 1% HAc, 0.1M  $MgCl_2$  and 2.5 volume of 96% ethanol to the supernatant. The pellet was dissolved in 10  $\mu$ l TE buffer. The fragment, now called DD18a, was cloned into a PMOSBlue T-vector (RPN 1719, Amersham Little Chalfont UK) giving the vector pDD18a.

The nucleotide sequence of this 3' cDNA clone was determined by the dideoxynucleotide chain termination method (ABI PRISM™ Ready Reaction DyeDeoxy™ Terminator Cycle Sequencing Kit, P/N 402078, Perkin Elmer) and is shown in Figure 2. The DNA fragment has a length of 460 nucleotides. The missing 5' part of the cDNA was isolated using the Marathon™ cDNA Amplification Kit of Clontech (catalog K1802-1) and following the procedure as described in the manual. Briefly, Poly A+ RNA was isolated from nectaries of *Petunia hybrida* flowers. After double stranded cDNA synthesis, adapters were ligated and a 5'RACE reaction was carried out using the adapter primer AP1 supplied in the kit and a gene-specific primer prat 122. The nucleotide sequence of prat 122 is: 5'-gtgggaaggctatgctacaagc-3' (Figure 2). The PCR product was diluted 10x and 1  $\mu$ l was used in a second 5' RACE reaction with the nested adapter primer supplied by the kit (AP2) and the nested gene-specific primer prat 119

(Figure 2). The nucleotide sequence of prat 119 is: 5'-ccttctccatggactgcaatgcg-'3. After gel electrophoreses a fragment of  $\pm 850$  bp was obtained that hybridised with clone DD18a. The fragment, now called RC8, was extracted from the gel, purified and cloned into a PMOSBlue T-vector as described above. The sequence is shown in Figure 3. The combined (overlapping) sequences of clones DD18a and RC8 are shown in Figure 4, comprising the full length cDNA of a gene called *NEC1* hereafter. The *NEC1* clone has a length of 1205 nucleotides and encodes for a polypeptide of 265 amino acid residues. Based on the deduced amino acid sequence, high homology was found with a cDNA that is associated with *Rhizobium*-induced nodule development in the legume *Medicago trunculata* (MtN3, gene bank number: gnl/PID/e274341). The percentages of identity and similarity are 47% and 72% respectively. Analysis of the predicted protein, using the CAOS/CAMM programme (Protein analysis 1991, Genetics Computer Group inc., Wisconsin USA), shows that the putative protein structure resembles membrane proteins, having six evenly spaced hydrophobic loops that traverse the cell membrane. In addition, a signal sequence is predicted at the N-terminus, while the C-terminus is highly hydrophilic. Highest homology with MtN3 is found in the N-terminal signal sequence, the first two membrane-spanning loops and the last two membrane-spanning loops. The C-terminal hydrophilic part shows the lowest homology (28% identity, 30% similarity). The function of *NEC1* has not yet been determined.

**Example 2:**  
Cloning of *FBP15*

Petunia MADS box cDNA clones were isolated from a cDNA library made from nectaries of *Petunia hybrida* flowers. The cDNA library was constructed using the lambda ZAP cloning vector (Stratagene, La Jolla USA, catalog nr. 200400-

200402). The library was screened under low stringency hybridisation conditions with a mixed probe comprising the MADS box regions of Floral binding protein gene *FBP2*, *FBP6* and *pmADS3* (Angenent et al., 1993, 1994, Tsuchimoto 1993).

5 The hybridizing phage plaques were purified using standard techniques. Using the in vivo excision method, *E.coli* clones which contain a double-stranded Bluescript SK-plasmid with the cDNA insertion between the *EcoRI* and *XhoI* cleavage site of the polylinker were generated. Cross-

10 hybridisation of the purified clones revealed 3 independent clones that did not cross hybridise with previously isolated *FBP* cDNA's and which were designated *FBP15*, *FBP16* and *FBP17*. The nucleotide sequence of *FBP15* was determined by the dideoxynucleotide-mediated chain termination method and

15 is depicted in SEQ ID NO:5. The *FBP15* cDNA clone has a length of 1157 nucleotides and encodes a peptide of 222 amino acid residues. All characteristics of a MADS box protein are present in *FBP15*: a N-terminal located MADS box region which shows a high degree of similarity with other

20 MADS box proteins, and a K-box in the middle of the protein with an alpha helical structure. *FBP15* is most similar to the tobacco MADS box protein *NAG1*, which is an *Agamou* homolog and expressed in whorl 3 and 4 (Huang et al., 1996, Mizukami et al., 1996).

25

### Example 3:

#### Expression of *FBP15*

Expression of *FBP15* was determined by standard Northern blot hybridisation experiments. A DNA fragment comprising

30 the complete cDNA of *FBP15* was used as a probe. High stringency hybridisation and washing conditions were used. Using 10  $\mu$ g of total RNA from various petunia tissues, expression of *FBP15* was only detectable in nectaries. Using

35 10  $\mu$ g of mRNA from various tissues, prepared by using the kit and protocol of the Quickprep Micro mRNA Purification

- 22 -

Kit (Pharmacia Biotech), expression of *FBP15* was only detectable in nectaries as shown in Figure 5B. The expression in the ovary and nectaries was determined by in situ hybridisation using a DIG labelled antisense RNA probe corresponding to the full length cDNA of *FBP15*. In vitro antisense RNA transcripts were made using T7 RNA polymerase. A standard protocol for in situ hybridisation was used as described by Canās et al., 1994. A hybridizing signal was observed evenly strong in all cells of the nectary tissue.

**Example 4:****Expression of *NEC1***

The RNA expression of *NEC1* was determined by standard Northern blot hybridisation experiments. A DNA fragment comprising the complete sequence of the Differential Display clone DD18 (Figure 2) was used as a probe. Using 10 µg of total RNA from various petunia tissues, strong expression of *NEC1* was detectable in nectaries and weak expression in anthers. No expression was detectable in other floral organs, in leaves or in roots (Figure 5A). The expression in the ovary and nectaries was determined by in situ hybridisation using a DIG labelled antisense RNA probe corresponding to the nucleotides 79 to 1036 of *NEC1* cDNA, comprising the coding region and part of the 3' untranslated region. A clone containing this sequence was obtained by PCR on adapter-ligated cDNA, using two gene-specific primers prat 122 and prat 129 (Figure 4). The nucleotide sequence of prat 122 is: 5'-gtgggaaggctatgctacagc-3', comprising the nucleotides 1015 to 1036 of the *NEC1* cDNA. The nucleotide sequence of prat 129 is: 5'-gggatccatggcgcaattacgtgctgatg-3', comprising the nucleotides 79 to 100 of the *NEC1* cDNA. The gene-specific region of the primers is underlined. The primer contains an extra



BamHI and NcoI site at the 5' end. A PCR fragment of 958 nucleotides was obtained and cloned into a PMOSBlue vector. The fragment was subcloned in a vector containing the T7 promoter and in vitro antisense RNA transcripts were made  
 5 using T7 RNA polymerase. A standard protocol for in situ hybridisation was used as described by Canās et al., 1994. Strong hybridizing signals were observed in the outer cell layers of the nectaries (Figure 6A)

10

#### Example 5:

Isolation of *NEC1* promoter fragment

15 The promoter fragment of *NEC1* was cloned using the genome walker protocol (PT3042-1) and kit as provided by Clontech Laboratories. Briefly, genomic DNA from *Petunia hybrida* was digested with 5 different blunt cutting restriction enzymes. GenomeWalker adapters were ligated and PCR reactions  
 20 were carried out on each GenomeWalker "library" with a gene specific, reversed primer prat 148 and the adapter primer from the kit (AP1). The nucleotide sequence of prat 148 is: 5'-ccaagaaggccaatatgaaagac-3' comprising the nucleotides 105 to 128 of the *NEC1* cDNA (Figure 4). PCR products were  
 25 subjected to a second round of PCR, using the nested adapter primer AP2 and the nested gene specific, reversed primer prat 149. The nucleotide sequence of prat 149 is: 5'-aagtcacgacgacgtaattgcgcc-3', comprising the nucleotides 81 to 104 of the *NEC1* cDNA. From the second PCR a 2 kb  
 30 fragment was isolated from the *StuI* library, which was cloned in the PMOSBlue T-vector, yielding the construct pMA5-10. Figure 7 (SEQ ID NO:7) shows the DNA sequence of the *NEC1* promoter in the construct pMA5-10, including the translation start of *NEC1* cDNA.

35

- 24 -

**Example 6:**Construction of *NEC1* promoter-GUS

A PCR reaction was performed on pMA5-10 (example 5), using the forward vector primer U19 of pMOSBlue and the gene-specific primer prat 169. The nucleotide sequence of prat 169 is:

5'-cgctgcagcgccatggttttttttaagtgaagcccc-3'. The gene-specific region is underlined. The primer contains an NcoI and BglII restriction site at the 3' end. The PCR product was digested with KpnI and NcoI and ligated into a pBluescript-derived vector (pMO4) that contains the NTM19 promoter (Custers et al., 1997), the reporter gene *GUS* and the nos terminator. The KpnI/NcoI NTM19 promoter fragment was replaced, resulting in a *NEC1*-promoter/*GUS* translational fusion. The resulting plasmid pNEP1 was digested with SmaI to release the *NEC1* promoter/*GUS*/nos fragment and this fragment was ligated into a derivative of the binary plasmid pBIN (Bevan, 1984) yielding the binary plasmid pBNEP1 (Figure 8). pBNEP1 was introduced into *Agrobacterium tumefaciens* strain LBA4404 or C58pMP90 by electroporation. Plasmid DNA from the *Agrobacterium* transformants was isolated and the structure of the binary vector was verified by restriction analysis and PCR.

**Example 7:**Generation of transgenic *Petunia* plants

*Agrobacterium* strain LBA4404 transformants were used to transform *Petunia hybrida* using leaf discs as described by Horsch et al. (1985). After shoot and root induction on kanamycin selection media, plants were transferred to soil in the greenhouse.

**Example 8:****Histochemical GUS assay**

Different plant parts of Kanamycin-resistant plants transformed with the pBNEP1 construct were analysed for the distribution of  $\beta$ -glucuronidase activity (GUS) using the method described by (Jefferson et al., 1987). In transgenic plants with high expression levels diffusion of reaction products to other tissues was observed. To avoid this spreading a modified GUS assay was used. Briefly, tissues were pre-treated with 90% cold acetone at -20°C for 1 h, then rinsed three times 20' with 100 mM phosphate buffer containing 1 mM potassium ferricyanide. After this treatment the standard GUS assay was performed with the modification that ferricyanide was excluded from the reaction mixture.

**Example 9:****Results histochemical GUS assay**

In very young flowers (<1,4 cm) no blue staining was observed, in flowers of 2-4 cm weak blue staining of the nectaries was observed. In flowers of (4-6 cm) strong blue staining was observed in the nectaries (figure 6B) and in a very restricted region of the upper part of the anther filaments (Figure 6C). GUS expression was highest in the outer cell layers of the nectary parenchyma. In cross sections of the anther filaments GUS expression was observed in all cells except in the xylem of the inner vascular bundle.

**Example 10:****Protein analysis of heather honey and nectar**

Samples of pure heather honey, together with samples of rapeseed, clover, wattle bark and lavender honey were diluted, dialysed and loaded on a 12% SDS page gel (Laemmli,

1970). All honey samples showed several identical high molecular weight protein bands. Heather honey contained 2 unique protein bands of 29 and 50 kDa (Figure 9). The proteins were named CVH29 and CVH50 (CVH stands for *Calluna vulgaris* honey). To determine the origin of the proteins, nectar and honey samples of rapeseed and heather were prepared and loaded on a 12% SDS page gel. The high molecular weight protein bands of around 70 kDa that are present in all honey samples were not observed in rapeseed or heather nectar (Figure 10). These proteins are added by honeybees during honey processing. Proteins CVH29 and CVH50 are present in heather honey and heather nectar, but not in nectar of rapeseed. Therefore, it was concluded that CVH29 and CVH50 are secreted in nectar of heather and can be recovered from honey derived from this nectar. The protein concentration in the heather honey we tested was around 0.5%.

#### Example 11:

N-terminal sequence analysis of CVH29 and CVH50

Honey samples were loaded on an SDS PAGE gel and after electrophoreses the gel was blotted on a PVDF membrane. After staining the CVH29 and CVH50 bands were cut out from the blot and N-terminal sequencing was performed on both proteins. The N-terminal sequence of CVH50 is: SVLDFCVADPS-LPDGPAGYSCTEPSTVTSQDF. The N-terminal sequence of CVH29 is: SVLDFCVADPSLPDGPAGYSCKEPAKVTVDDFVFHGLGTA. A gene bank homology search (BLAST) showed high amino acid sequence homology (63%) with germin-like proteins isolated from *Arabidopsis* (Figure 12).

**Example 12:**

Identification signal sequence of CVH29

Because the germin-like protein CVH29 is excreted in  
5 heather nectar it was expected that part of the cDNA  
encodes a signal sequence. Based on the N-terminal amino  
acid sequence, degenerated primers were designed. The  
sequence of the forward primer prat 176 is: 5'-gayttyp-  
gygtngcngaycc-3' (y= c or t, n= c, t, a or g). The sequence  
10 of the reversed primer prat 177 is: ccrtgraanacraartcrtc  
(r= g or a). A PCR reaction performed on genomic DNA of  
heather yielded a 99 bp DNA fragment. The fragment was  
sequenced and two reversed, gene-specific 5' primers were  
designed to clone the 5' cDNA by "Marathon cDNA racing"  
15 using the kit and protocol of Clontech laboratories (proto-  
col PT1115-1, Clontech Palo Alto USA). The sequence of  
gene-specific primer prat 207 that was used is: 5'-  
ggtgacttttagagggtccttcgc-3', the sequence of gene-specific  
nested primer prat 206 is:  
20 5'-gctccttgccaggagtagcctgc-3' (Figure 13). RNA was isolated  
from open flowers of heather and mRNA was prepared using  
the Pharmacia quickprep micro mRNA kit. After cDNA synthe-  
sis and adapter ligation a PCR reaction was performed,  
using the adapter primer AP1 and the gene-specific primer  
25 prat 207. The PCR product was used for a second PCR, using  
adapter primer AP2 and the nested gene-specific primer prat  
206. A single fragment of around 300 nucleotides was  
obtained and cloned in a PMOSBlue T-vector. Four clones  
were sequenced. Figure 14 shows that three clones were  
30 identical and one clone had two different nucleotides in  
the untranslated 5' region. A putative signal sequence of  
17 amino acids was identified between the ATG start codon  
and the first codon of the mature protein CVH29 that was  
identical in all four clones. The nucleotide sequence of  
35 the putative signal sequence (SEQ ID NO:6) is:  
5'-atgtttcttccaattctcttcaccatttcctcctctctcctcccatgct-  
3'.

**Example 13:**

Construction of an expression cassette for excretion of proteins in nectar

- 5 To clone the *NEC1* promoter into a PMOSBlue vector a PCR reaction was carried out on pMA5-10 (example 5) using the forward primer prat 247 and the reversed primer prat 248 (Fig. 7). Prat 247 contains an extra *Pst*I restriction site. The *Nde*I restriction site of prat 248 coincides with the  
10 ATG translation start of *NEC1*. The nucleotide sequence of prat 247 is: 5'-ggctgcaggagtggttcttttgatagaatg-3', the nucleotide sequence of prat 248 is: 5'-cgccatattgttttttatggaagcccg-3'. Gene-specific regions are underlined. A 1,8 kb promoter fragment was obtained and  
15 cloned into a pMOSBlue vector, yielding the plasmid pNECP.

- A DNA molecule encoding the signal sequence CVSP as depicted in SEQ ID NO:6 was produced by synthesis and subsequent annealing of two oligo molecules prat 245 and prat 246. The  
20 sequence of prat 245 is: 5'tatgtttccttccaattcttttcactattttctcttcttttctcttctctcatgcttctgttcttgatttc/3, the sequence of prat 246 is: 5'gatccgaaatcaagaacagaaagcatgagaaagaaagaaagaaagagaaatagtgaaaaagaattggaaggaaca/3. The region encoding the signal sequence CVSP is underlined. To ensure correct  
25 cleavage of the signal peptide, the linkers were extended with the coding region for the first five amino acids of the mature germin-like protein (Fig. 13). The codon usage of the signal peptide sequence was optimised for Arabidopsis. By addition of a *Bam*HI restriction site at the 3' end,  
30 2 extra amino acids were linked in frame to the mature protein. The resulting DNA molecule is shown in Figure 15. The fragment was ligated into a *Nde*I/*Bam*HI cut PMOSBlue vector, yielding the plasmid pCVSP.
- 35 pNECP was digested with *Nde*I and *Pst*I to release the *NEC1* promoter fragment which was cloned into the *Pst*I/*Nde*I cut

- 29 -

pcVSP, yielding the plasmid pcV1. A schematic representation of pcV1 is given in Figure 16.

A 250 bp long fragment containing the NOS terminator sequence (NOST) was obtained by PCR, using the forward primer prat 251 and the reversed primer prat 252 on DNA of pRAP 33, which is a pUC 19 derived plasmid. Prat 251 adds a SacI and XhoI site, prat 252 adds a SmaI and EcoRI site. The sequence of prat 251 is: 5'-gggagctcgagtcggttcaaa-  
10 catttggcaataaaa-3'. The sequence of prat 252 is: 5'-cgaatt-  
cccgggagctctagtaacatagatgacac-3'. The NOST-specific regions are underlined. The PCR product was cloned into pCR-Script™ Amp SK(+) Cloning Kit (Catalog 21188-21190, Stratagene La Jolla USA), yielding the plasmid pCR-NOST. pCR-NOST was  
15 digested with SacI and EcoRI and the resulting fragment was cloned into the pUC 19 (ClonTech), derived plasmid pUCAP yielding the plasmid pcVNOS.

The plasmid pGUSN358 was purchased from Clontech (catalog 6030-1) containing the reporter gene GUS in pUC 119, modified to destroy the N-linked glycosylation site within the 1.814 Kb GUS coding sequence. A PCR reaction was carried out with gene-specific primers prat 249 and prat 250, yielding a fragment that contains the GUS gene coding  
25 region and a BamHI restriction site at the 5' end and a SacI restriction site at the 3' end. The sequence of prat 249 is: 5'-ccggatccatggttacctctgtagaaacc-3'. The sequence of prat 250 is: 5'-gggagctccaccgagctctgtag-3'. The GUS specific regions are underlined. Subsequently, the PCR fragment was  
30 digested with BamHI and SacI and ligated into the BamHI/SacI cut plasmid pcVNOS, yielding the plasmid pcV2. A schematic representation of pcV2 is given in Figure 17.

pcV1 is digested with PstI and BamHI and the resulting  
35 fragment is cloned into the PstI/BamHI cut plasmid pcV2, yielding the plasmid pcV3. A schematic representation of pcV3 is given in Figure 18. pcV3 is digested with AscI and

- 30 -

SmaI and the resulting fragment is cloned into a derivative of the binary plasmid pBIN, yielding the binary plasmid pBCV3. pBCV3 was transferred from *Escherichia coli* to the *Agrobacterium tumefaciens* strain LBA4404 and C58pMP90 by electroporation. The transformed *Agrobacterium* strain was used to transform *Arabidopsis* and *petunia*.

**Example 14:**

Protein production in nectar

Using the *GUS* reporter gene, *GUS* activity in nectar of transgenic plants was measured according to the method as described by Jefferson et al., (1987). Briefly, the assay was carried out by measuring the amount of methyl umbelliferone (MU) produced by *GUS* fluorometrically by emission of light of 455 nm. The absolute emission was corrected for artificial quenching using an internal standard of 1nM MU (Angenent et al., 1993).

**Example 15:**

Feeding experiments with honeybees

In September 1996 a beehive located outside was supplied with a 25% sucrose solution supplemented with 2% BSA (bovine serum albumin). After 3 weeks the bees had consumed 15 liters of the feeding solution and honey was harvested from the hive. Although the flowering season had mostly past, bees still foraged on flowers to collect nectar outside. Therefore, the honey produced during this period is derived from a mixture of the feeding solution and nectar from flowers. An SDS page protein gel was loaded with dialysed honey samples and sugar/BSA solutions. Figure 11 shows that the protein band of BSA was present in all the samples tested and no qualitative changes were observed in the honey samples compared to the sugar/BSA solutions. The BSA concentration in honey was 1.5 times higher than in the feeding samples, demonstrating that protein is concen-



trated in honey. Honeybees that foraged on the sugar/BSA solution did not show any aberrant behaviour and the colony developed normally.

5 **Example 16:**

Process of honey production from transgenic plants

Two hundred and fifty transgenic plants that each produce  
10 recombinant protein in nectar were grown in a greenhouse of  
25 square meters. The facilities were adjusted according to  
the safety rules according to European law, including  
safety measures to prevent in- or outflow of insects. A  
beehive adjusted for small populations, containing around  
15 200 worker honeybees and a queen, was placed in the green-  
house when the plants were flowering. When a queen is  
present, she will start laying eggs and larvae will come  
out. The presence of brood stimulates the bees to collect  
nectar and process it into honey. After 2-3 weeks bees  
20 processed the nectar into honey and stored in sealed cells  
of the honeycomb. Under the described conditions the amount  
of honey that can be harvested is 250-1000 grams.

**Example 17:**

25 Ablation of nectaries

By introducing the highly sensitive Rnase BARNASE in plant  
cells, under the control of a tissue-specific promoter,  
cell ablation can be achieved in very specific tissues or  
30 organs. Ablation of nectaries can be applied to decrease  
the attractiveness of plants for pest insects that forage  
on the nectar that is secreted by nectaries. In addition,  
plants without nectaries can be obtained that are more  
resistant to bacterial and fungal infections. An example is  
35 given for the ablation of nectary tissue by expressing  
bacterial BARNASE in nectaries, using the NEC1 promoter.

Plasmid DNA of pNEP1 (example 6) was digested with KpnI and NcoI to release the 1800 bp *NEC1* promoter fragment. The purified promoter fragment was ligated into a pWP90 derived vector, upstream of the BARNASE-BARSTAR bacterial operon construct (Hartley, 1988). The construct contains a 35SCaMV terminator of polyA signal cauliflower mosaic virus terminator sequence downstream of the BARNASE-BARSTAR operon. The resulting plasmid pWP126 was digested with KpnI/ XhoI to release the *NEC1*-promoter/BARNASE-BARSTAR/CamVpolyA fragment and this fragment was ligated into a pBIN-derived vector pBIN Plus. The recombinant vector was transferred via *Agrobacterium tumefaciens* (LBA4404) to petunia variety W115. Transgenic petunia plants were selected with flowers without nectaries or underdeveloped nectaries.

Many promoters are less specific than can be concluded based on promoter/GUS expression is concluded. Because the bacterial BARNASE is highly cytotoxic at very low concentrations it can be preferred to protect other plant tissues by expression of a ribonuclease inhibitor gene under the control of a weak, constitutive promoter (e.g. NOS promoter) or a tissue-specific promoter that is not active in the tissues where cell ablation is to be achieved (Mariani et al., 1992, Beals et al., 1997).

#### Example 18:

##### Ectopic nectary development

MADS box genes regulate floral meristem and floral organ identity. Ectopic expression of MADS box genes can change the developmental fate of floral organs or cells. Transgenic petunia plants ectopically expressing FBP11, an ovule-

- 33 -

specific MADS box gene, develop ovule-like structures on sepals and petals (Colombo et al., 1995). *FBP15* is a nectary-specific MADS box gene, involved in the molecular regulation of nectary development. In petunia nectaries develop at the base of the carpel. Ectopic expression of *FBP15* in petunia may result in the development of nectaries on other organs of the flower or on vegetative parts of the plant. An example is given of a gene construct that, when transformed to a plant, results in ectopic expression of *FBP15*.

*FBP15* was amplified using a 5' primer that hybridises with *FBP15* sequences just upstream of the ATG translation start site and a 3' primer that hybridises with *FBP15* sequences just downstream the translation stop site. The 5' primer contains a *NcoI* recognition site, the 3' primer contains a *BamHI* recognition site. After the sequence was confirmed, the amplified *FBP15* fragment was inserted as a *BamHI/NcoI* fragment into the binary vector pCPO31. This binary vector was derived from pPCV708, as described by Florack et al. (1994), and contains three expression cassettes with a multiple cloning site between the left and right T-DNA borders. The cDNA was cloned in sense orientation between a modified *CaMV* 35S promoter and the nopaline synthase terminator sequence. The chimerical gene construct was transferred via *Agrobacterium* GV3101 to petunia variety W115, using the transformation method as described in example 7. Transgenic petunia plants were selected that show ectopic nectary development.

#### Example 19:

Modification of sugar composition and nectar secretion

Although sugar content of nectar from different petunia W115 flowers shows some variation, the ratio between hexoses and sucrose is very stable. Down-regulation or up-regulation of genes involved in the establishment of the

ratio between hexoses and sucrose in nectar will therefore modify nectar composition. An example is given for antisense expression of a petunia-derived invertase gene.

5 PCR primers were designed that hybridise with the cDNA of an invertase gene cloned from *Solanum tuberosum*. The 5' primer 5'-AAGGACTTTAGAGAGACCCGACCACTGCTGG-3' and the 3' primer 5'-AAATGTCTTTGATGCATAATATTTCCCATATC-3' were used for a PCR reaction on genomic DNA of petunia to yield a  
10 fragment of around 420 bp. The fragment was sequenced and cloned into a pMOSBlue vector to used as a probe to screen a petunia nectary-specific cDNA library. Hybridizing phage plaques were purified and cDNAs were retrieved by in vivo excision as described in example 2. The expression of the  
15 cDNA's was determined by Northern blotting as described in example 3 and the sequence of a nectary-specific invertase was determined as described in example 2. The invertase gene was amplified using a 5' primer that hybridises with sequences just upstream of the ATG translation start site  
20 and a 3' primer that hybridises with sequences just downstream of the translation stop site. Extra restriction enzyme recognition sites were generated to allow cloning of the cDNA in sense (overexpression) or antisense direction into the binary vector pCPO31 as described in example 18.  
25 The chimerical gene constructs are transferred via *Agrobacterium* GV3101 to petunia variety W115, using the transformation method as described in example 7. Transgenic petunia plants were selected that exhibit modified sugar composition in nectar.

30

#### Example 20

Modification of plant development

35 A DNA which is the *NEC1* gene or a homologous gene is introduced into a plant cell, the said DNA being induced by promoter elements controlling the expression of the introduced DNA in such a way that transcription produces

sense RNA. Plants were regenerated from the transgenic cells as described in example 7. Plants that ectopically express the *NEC1* gene exhibited modified leaf morphology and modified sugar composition. Furthermore, plants that  
5 ectopically express the *NEC1* gene showed a delay in flowering time.

#### REFERENCES:

Angenent G.C., Franken J., Busscher M., Colombo L. and van  
Tunen A.J., 1993. Petal and stamen formation in petunia  
is regulated by the homeotic gene *fbp1*. Plant J. 4, 101-  
15 112.

Angenent G.C., Franken J., Busscher M., Weiss D. and van  
Tunen A.J., 1994. Co-suppression of the petunia homeotic  
gene *fbp2* affects the identity of the generative meri-  
20 stem. Plant J. 5, 33-44.

Baker H.G. and Baker I., 1982. Floral nectar constituents  
in relation to pollinator type. In: Handbook of experi-  
mental pollination biology (ED. by CE Jones and RJ  
25 Little), pp 117-141. Scientific and Academic Edition,  
Van Nostrand Reinhold, New York.

Beals T.P. and Goldberg R.B. (1997). A novel cell ablation  
strategy blocks tobacco anther dehiscence. The Plant  
30 Cell 9, 1527-1545.

Bevan M. (1984). Binary *Agrobacterium* vectors for plant  
transformation. Nucl. Acids Res. 12, 8711-8721

35 Butler C.G. (1962). The world of the honeybee. London:  
Collins.

- Canäs L.A., Busscher M., Angenent G.C., Beltran J-P and van Tunen A.J. (1994). Nuclear localisation of the petunia MADS box gene protein *FBP1*. *Plant J.* 6, 597-604.
- 5 Colombo L., Franken J., Koetje E., van Went J., Dons H.J.M., Angenent G.C. and van Tunen A.J. (1995). The petunia MADS Box gene *FBP11* determines ovule identity. *The Plant Cell* 7, 1859-1868.
- 10 Crailsheim K., Hrassnigg N., Lorenz W and Lass A. Protein consumption and distribution in a honeybee colony (*Apis mellifera carnica* Pollm). *Apidologie* 24 (5), 510-511.
- Custers J.B.M., Oldenhof, Schrauwen J.A.M., Cordewener J.H.G., Wullems G.J. and Lookeren Campagne M.M. (1997). Analysis of microspore-specific promoters in transgenic tobacco. *Plant molecular biology* 35, 689-699.
- 15 Davis A.R., Peterson R.L. and Shuel R.W. (1986). Anatomy and vasculature of the floral nectaries of *Brassica napus* (Brassicaceae). *Can. J. Bot.* vol. 64, 2508-2516.
- 20 Dumas B., Freyssinet G. and Pallett E. (1995). Tissue-specific expression of germin-like oxalate oxidase during development and fungal infection of barley seedlings. *Plant Physiol.* 107: 1091-1096.
- 25 Fahh A. (1979). Ultrastructure of nectaries in relation to nectar secretion. *Amer. J. Bot.* 66(8), 977-985.
- 30 Florack D.E.A, Dirkse W.G., Visser B., F. Heidekamp and Stiekema W.J. (1994). Expression of biologically active hordothionins in tobacco: Effects of pre- and pro-sequences at the amino and carboxyl termini of the hordothionin precursor on mature protein expression and sorting. *Plant Mol. Biol.* 24. 83-96.
- 35

- Hartley R.W. (1988). Barnase and Barstar: Expression of its cloned inhibitor permits expression of a cloed ribonuclease. J. Mol. Biol. 202, 913-915
- 5 Horsch R.B., Fry J.E., Hofman N.L., Eichholz D., Rogers S.G. and Fraley R.T. (1985). A simple and general method for transferring genes into plants. Science 227, 1229-1231.
- 10 Huang H., Tudor M., Su T., Hu Y. and Ma H. (1996). DNA binding properties of two Arabidopsis MADS domain proteins: Binding consensus and dimer formation. The Plant Cell 8, 81-94.
- 15 Jefferson R.A., Kavanagh T.A. and Bevan M. (1987). GUS fusion: J-glucuronidase as a sensitive and versatile gene fusion marker in higher plants. EMBO J. 6, 3901-3907.
- 20 Laemmli U.K. (1970). Cleavage of structural proteins during the assembly of the head bacteriophage T4. nature 227, 680-685.
- Lane B.G., Dunwell J.M., Ray J.A., Schmitt M.R. and Cuming A.C. (1993). Germin, a protein marker of early plant development, is an oxalate oxidase. The Journal of Biological Chemistry 268 (17), 12239-12242.
- 25
- Mariani C., Gossele V., De Beuckeleer M., De Block M., Goldberg R.B., De Greef W. and Leemans J. (1992). a chimaeric ribonuclease-inhibitor gene restores fertility to male sterile plants. Nature 357, 384-387.
- 30
- Martini M., Schmid A. and Hess D. (1990). Antibiotics, and amino acids in nectar of *Rhododendron* and *Piptanthus* species from Nepal. Bot. Acta 103, 343-348.
- 35

Mizukami Y., Huang H., Tudor M. and Ma H. (1996). Functional domains of the floral regulator AGAMOUS: Characterisation of the DNA binding domain and analysis of dominant negative mutations. The Plant Cell 8, 831-845.

5

Tsuchimoto S., van der Krol A.R. and Chua N.-H, 1993. Ectopic expression of pMADS3 in transgenic petunia phenocopies the petunia *blind* mutant. Plant Cell 5, 843-853.

10

Verwoerd T.C., Dekker, B.M.M. and Hoekema A. (1989). A small-scale procedure for the rapid isolation of plant RNAs. Nucl. Acids Res. 17, 2362.

15

Zer H. and Fahn A. (1992). Floral nectaries of *Rosmarinus officinalis* L. Structure, Ultrastructure and Nectar Secretion. Annals of Botany 70, 391-397.





SEQ ID No: 2 amino acid sequence of FBP15

```

Met Gly Arg Gly Lys Ile Glu Ile Lys Arg Ile Glu Asn Thr Thr Asn
 1           5           10           15
Arg Gln Val Thr Phe Cys Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala
           20           25           30
Tyr Glu Leu Ser Val Leu Cys Asp Ala Glu Val Ala Leu Ile Val Phe
           35           40           45
Ser Ser Arg Gly Arg Leu Tyr Glu Tyr Ala Asn Asn Ser Val Lys Ala
           50           55           60
Thr Ile Asp Arg Tyr Lys Lys Ala Ser Ser Asp Ser Ser Asn Thr Gly
           65           70           75           80
Ser Thr Ser Glu Ala Asn Thr Gln Phe Tyr Gln Gln Glu Ala Ala Lys
           85           90           95
Leu Arg Val Gln Ile Gly Asn Leu Gln Asn Ser Asn Arg Asn Met Leu
           100          105          110
Gly Glu Ser Leu Ser Ser Leu Thr Ala Lys Asp Leu Lys Gly Leu Glu
           115          120          125
Thr Lys Leu Glu Lys Gly Ile Ser Arg Ile Arg Ser Lys Lys Asn Glu
           130          135          140
Leu Leu Phe Ala Glu Ile Glu Tyr Met Arg Lys Arg Glu Ile Asp Leu
           145          150          155          160
His Asn Asn Asn Gln Met Leu Arg Ala Lys Ile Ala Glu Ser Glu Arg
           165          170          175
Asn Val Asn Met Met Gly Gly Glu Phe Glu Leu Met Gln Ser His Pro
           180          185          190
Tyr Asp Pro Arg Asp Phe Phe Gln Val Asn Gly Leu Gln His Asn His
           195          200          205
Gln Tyr Pro Arg Gln Asp Asn Met Ala Leu Gln Leu Val
           210          215          220

```

WO 00/04176

PCT/NL99/00453

- 41 -

SEQ ID NO:3 amino acid sequence CVSP

5 MFLPILFTISLLFSSSHA

## SEQ ID NO:4 Nucleotide sequence NEC1

5 1 TCGAGCGGCC GCCCGGGCAG GTATTCAACA AGAGTATTCA CCAC TTGAAC  
51 TCAAAAGGGG CTTCACTAAA AAAAAATCAT GGC GCAATTA CGTGCTGATG  
10 101 ACTTGCTTTT CATATTTGGC CTTCTTGGA ATATTGTATC ATTCATGGTC  
151 TTCCTAGCAC CCGTGCCAAC ATTTTACAAA ATATATAAAA GGAATCATC  
201 AGAAGGATAT CAAGCAATAC CATATATGGT AGCACTGTTC AGCGCCGGAC  
15 251 TATTGCTATA TTATGCTTAT CTCAGGAAGA ATGCTTATCT TATCGTCAGC  
301 ATTAATGGCT TTGGATGTGC CATTGAATTA ACATATATCT CTCGTGTTCT  
351 CTTTTACGCG CCCAGAAAGT CTAAGATTTT CACAGGGTGG CTGATGCTCT  
20 401 TAGAATTGGG AGCCCTAGGA ATGGTGATGC CAATTACTTA TTTATTAGCA  
451 GAAGGCTCAC ATAGAGTGAT GATAGTGGGA TGGATTGTG CAGCTATCAA  
25 501 TGTGCTGTC TTTGCTGCTC CTTTAAGCAT CATGAGGCAA GTAATAAAAA  
551 CAAAGAGTGT AGAGTTCATG CCCTTCACTT TATCTTTGTT CCTCACTCTC  
601 TGTGCCACTA TGTGGTTTTT CTATGGGTTT TTCAAGAAGG ACITTTTACAT  
30 651 TCGTTTCCA AATATACTGG GCTTTCTATT CGGAATCGTT CAAATGCTAT  
701 TATATTTTGT TTACAAGGAT TCAAAGAGAA TAGATGATGA AAAATCTGAT  
35 751 CCTGTTCGAG AAGCTACAAA ATCAAAAGAA GGTGTAGAAA TCATTATCAA  
801 CATTGAAGAT GATAATTCTG ATAACGCATT GCAGTCCATG GAGAAGGATT  
851 TTTCCAGACT GCGGACATCA AAATAAGCAA GAAGATGATC AAAAAATGAC  
40 901 AAAGCTAAGG AGTTTGAAGT AAGGCAAGGA ACTTGACACT GAATATCTAA  
951 GCTAATTAGC AAGACTTTAG CAGCTTGTA TATTAGTGT TTGTGAGGTG  
45 1001 TTACCTTATA ATTAGCTTGT AGCATAGCCT TCCCAC TAAT AATCTGCTT  
1051 AGCGAATCTT ATATATGGGA AATACTTACA CTAGTAGTGA TCTTCTATAT  
1101 ACATGTTTGG CACTTGACTA TACATAGAAA AATTAACAAG CATTTCTCAC  
50 1151 CTCAATTGTG CACTTACTTA TAAGTAGCTG AATAATATAA TGCAATTTTC  
1201 ACCCC

55

60

SEQ ID NO:5 Nucleotide sequence *FBP15*

1 TCTGAATACAAGCTGTGTGTGTAGAGAGATTTCTATAAAGACAGCAAACAT  
5 51 CCCCCTCTTTTGTCTGTCTTTTAAAAGTCCCTTCTTCAACCAGCTCTTTT  
101 CCTCATCAGGTAAGTTGCAAAATAAAGGGGATGTTCCAGAATCAAGAAGA  
15 151 GAAGATGTCAGACTCGCCTCAGAGGAAGATGGGAAGAGGAAGATTGAGA  
201 TTAAGAGGATTGAAAATACAACAATCGTCAAGTCACTTTCTGTAAGAGA  
251 AGAAATGGGTGCTTAAAAAAGCTTATGAACTTTCTGTCTTTGTGATGC  
15 301 TGAAGTTGCTCTCATCGTTTTCTCAAGCCGTGGCCGCTCTATGAATATG  
351 CTAACAACAGTGTGAAGGCAACAATTGATAGATATAAGAAAGCATCCTCA  
401 GATTCCTCCAACACTGGATCTACTTCTGAAGCTAACACTCAGTTTATCA  
20 451 ACAAGAAGCTGCCAACTCCGAGTTCAGATTGGTAACTTACAGAACTCAA  
501 ACAGGAACATGCTAGGCGAGTCTCTAAGTTCTCTGACTGCAAAAGATCTG  
25 551 AAAGGCCTGAGACCAAACCTTGAGAAAGGAATTAGTAGAATTAGGTCCAA  
601 AAAGAATGAACCTCTGTTTGTCTGAGATTGAGTATATGCAAAAAGGGAAA  
651 TTGATTGCAACAACAATCAGATGCTTCGGGCAAAGATAGCTGAGAGT  
30 701 GAAAGAAATGTGAACATGATGGGAGGAGAATTTGAGCTGATGCAATCTCA  
751 TCCGTACGATCCAAGAGACTTCTTCCAAGTGAACGGCTTACAGCATAATC  
35 801 ATCAATATCCACGCCAAGACAACATGGCTCTTCAATTAGTATAAGTTTAT  
851 AATAAAATGCATGGTTTGAAGCACTCTGATTGTGGTGGATTGGATTATG  
40 901 TATAAGGGAGTGCAGGCCATTTGCCAATTATTGAAAGGTACTCAAACAGG  
951 AAGTTGAAGAAGTTCATCATCTCTCTCATCTATATGTCTTAAACAAAAGTC  
1001 TTAGCTTATGGACTCTAAACAAGACTTAAATTTAACATATAAATATAAT  
45 1051 TGTGTAATGCTGTGTGATTGTATGGTATGTATCCAAAAACATTATAACC  
1101 TATCTTTTCTTCAAATTATGTCTCCTTGATACAACTACTAACATATT  
50 1151 TTCTTAT



SEQ ID NO:7 Nucleotide sequence *NEC1* promoter

1 CCTAGGAGAAATCAAGCCTACTCTTAAGATGGATGACTCACTTGCCCCGA  
5 51 TGGTAAGGTGAAGGATCTGTTGATTAGAGTTGGGAAGTTCATGTTCTCTG  
101 CTGATTTTATTATTCTAGACTATGAAGAGGACCAAGAAGCTCCAATAATT  
15 151 TTGGGAAGAGCATTCTTAATCACATCGATGGCAATTATTGACATGGAACT  
20 201 TGGGGAGATGACTGTGAGAGCGCATGGAGAAAAGGTTACTTTCAAGGTTT  
251 ATAATAAAAAGGATCATATGGCTAAGTTTGAAGAGTGTCTTTGATAGAA  
15 301 TGTGTCAGACGAGAACATGAAAGTAAACCGAAAGAGTGTTTGAGCGGAA  
351 TGTAGAACAAGTGACACCGGCACAATAATTGACAAGTTGAAGGAAAATT  
401 CACCTAAAGGAAGGAAGAAGACAAAAGTTCGTCGTAACAAGAGGAGACGT  
20 451 AAATGCTGGAAGTGAGCTTAAAGGTGTTGTCGTACTACGACGTTAACTAA  
501 GCGCCTTGTGCGGAGGCAACCCCTAGCTTTGTATGTAAATGTAAAAGTAAA  
25 551 AAATATATATATAGAAAAAGGAAAATACAAAAAGAGTCGTGCCGCGACGT  
601 TAAATCAAGCGCTTGTGGAAGGCAACCCCAATTTTTATTGTTTATTAGTTGT  
30 651 TTTACTTATTTAGTATTACGTAGTTTCTTGTTGTTTTGTAGGGCTCGGG  
701 ACTTTCGGAAGGTGAGGTAATTTCAAGGCATCGCGGTGTGTATTGCAGCG  
751 AGGTAAGTGTAAGAGTTGAGTTGGAAGCGTTTGGCCAAGTGTTGCAACCGT  
35 801 GAGAGGCTTTCAACCTGTTGCGACACGTGAAAAATTAAGAGCCAGATCTG  
851 CTACATTAGCACTGAAGCATCGCTTGGCCAATAGCTTGGAAATGGAAGCAA  
901 GAATTCAAACCAAAATCAGAAACGCCACAAGAGATGTGTCGCACACTGCA  
40 951 AAGCTTTGTGCAAACTAGTGAACGCAGAAATAGAAATGTACAGCCCCATG  
1001 CGTCGCTTGGCTTATGGCAGGCAGCAAAAATTCAGCAGCAAAACAGAAAC  
45 1051 GCTGCGAGAAACGCGTCGCATACGCCATAGCTTTGTGTCAAACAGAACGT  
1101 CCAGAAATTGAAAAGCTATAAGCCTGCGTCGCTTGCTCATGGCGTGCAG  
50 1151 ACTAGAAAAGCTCTAGCAGATGCGTCGCGTATTGTATAGCTTGGTGTGAA  
1201 ACAGAAAGTTTCGAAACTTGGAACGATAACCCAGCGTCGCTCTTCAAC  
1251 CGCCTCCAGGTAAGTTCAAGATTCTTACGGGTGACCCATTAAACCATTG  
55 1301 ATCGGCTGATTATAAACAATAAAACATCACCTTCAACTATCACATGATTT  
1351 CATAAGTTTGACCTAGGATATTTATATATATATATATATATACACAC  
1401 ACACACCATTTCAGCGATCTTACCTCATTTTTATTCAAACCATTTTTCT

WO 00/04176

PCT/NL99/00453

- 46

1451 GCTTCAAAAGTTTAAATTATTAATATGATAAGTCATCCATAGTCAAACAA  
1501 GATTTTCTATACTATTTTGTCCCTTGTAAATTTTAAAAAAAAAATGAGCGA  
5 1551 TGGTAAGATAAACATTGTTTGCAAGTGTACAATTTTAGTATATGCAAACC  
1601 AACGCTTCTTCTTCCAACATCACCTAAAACTACATCATTATGGCGGGC  
10 1651 GGACTAGACGTAGCCAAATATAAAAAACGCAATGGCCATTGAGTTCATGTC  
1701 ATTTTATATCCTTCATCCAATAATATTACTCAAATTTGATGTACAGTTT  
1751 GGTCTCTGATGTGCACCTTTACTATACGTAATACGGAATTTACATTATAAT  
15 1801 TAAAGAGAACTGTTCCACTAAATTTTAATGATTAAATTAATTTAACTCGG  
1851 TTACTTGTATTATTATTATTGCTGTATTTGTTTGTCAATTTGAATTTGGCA  
20 1901 CCGCAGATTTTGTATGCAATTAACCCCTCATATATCTTTGGCCAAATAA  
1951 AGAAAAAGTCTGCATATTTCTTGCCAAACATTTATCATACTTTACCGAAT  
2001 TCTTGTTTTTTGTTTCTCTGTTGTTGTTCTCCACTATAAATAACATTTGC  
25 2051 AGTGAGTAAAGTTTCTTCAGGTCTCTTTTGTAGATTCAACAAGAGTATTC  
2101 AGCACTTGAACTCAAAGGGGCTTCACTAAAAAATCATG



WO 00/04176

PCT/NL99/00453

- 47 -

SEQ ID NO:8 Nucleotide sequence *FBP15* promoter

27-10-2000

NL 009900453

EPO-DG 1

27. 10. 2000

## CLAIMS

(59)

1. An isolated DNA sequence from the promoter region upstream of a nectary-specific expressed sequence, which nectary-specific expressed sequence encodes a protein comprising the amino acid sequence given in SEQ ID NO:1, or a protein that has at least 60% homology to the amino acid sequence given in SEQ ID NO:1.
2. An isolated DNA sequence according to claim 1, wherein the nectary-specific expressed sequence has:
  - a) a nucleotide sequence given in SEQ ID NO:4, or
  - b) a nucleotide sequence which hybridises with (a) or with a fragment of (a) under the following conditions: pre-hybridisation for 1h at about 65 °C in a solution of Church and Gilbert, comprising 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS, followed by hybridisation in the same solution for 18h at about 65 °C, followed by washing three times in 0.1 x SSC, 0.1% SDS at about 65 °C for 30 min., or
  - c) a nucleotide sequence that has at least 85% homology to the nucleotide sequence of a).
3. An isolated DNA sequence according to claim 1 or 2, obtained from a plant of *Petunia hybrida*, the sequence consisting essentially of the sequence given in SEQ ID NO:7, or a functional fragment thereof having promoter activity.
4. An isolated DNA sequence encoding a protein comprising the amino acid sequence given in SEQ ID NO:1, or a protein having at least 60% homology with the amino acid sequence given in SEQ ID NO:1, which protein, when ectopically expressed, plays a role in sugar metabolism, the expression of the DNA sequence being predominantly confined to the nectaries of a plant.
5. An isolated DNA sequence according to claim 4 having:
  - a) a nucleotide sequence given in SEQ ID NO:4, or

AMENDED SHEET

27-10-2000

NL 009900453

- b) a nucleotide sequence that hybridises with the nucleotide sequence of (a) or with a fragment of (a) under the hybridisation conditions as defined in claim 2, or
  - c) a nucleotide sequence that has at least 85% homology to the nucleotide sequence of a).
6. An isolated DNA sequence that results from the sequence shown in SEQ ID NO:4 by insertion, deletion or substitution of one or more nucleotides, including naturally occurring variations or variations introduced by targeted mutagenesis or recombination, wherein the DNA sequence encodes a protein exhibiting the same function as the protein according to claim 4.
7. An isolated DNA sequence according to claim 4 having a nucleotide sequence given in SEQ ID NO:4, said sequence being produced by current DNA synthesis techniques.
8. An isolated DNA sequence comprising the coding region for a signal peptide, wherein the information contained in the DNA sequence permits, upon translational fusion with a DNA sequence encoding a protein that is expressed in nectaries, targeting of the protein to nectar.
9. An isolated DNA sequence according to claim 8, having:
- a) a nucleotide sequence given in SEQ ID NO:6 obtained from a plant of *Calluna vulgaris*, or
  - b) a nucleotide sequence that hybridises with the nucleotide sequence given in a), under the hybridisation conditions as defined in claim 2, or
  - c) a nucleotide sequence that has at least 95% homology to the nucleotide sequence of a).
10. A recombinant double-stranded DNA molecule comprising an expression cassette comprising the following constituents:
- i) a promoter functional in plants,
  - ii) a DNA sequence coding for a protein as defined in any of

AMENDED SHEET

27-10-2000

NL 009900453

- claims 4 to 7 which is fused to the promoter sequence in sense or antisense orientation, and optionally
- iii) a signal sequence functional in plants for the transcription determination and polyadenylation of an RNA molecule.
11. A recombinant double-stranded DNA molecule comprising an expression cassette comprising the following constituents:
- i) a promoter functional in nectaries of plants,
  - ii) a DNA sequence coding for a protein which is fused to the promoter sequence in sense or antisense orientation, and optionally
  - iii) a signal sequence functional in plants for the transcription termination and polyadenylation of an RNA molecule.
12. A recombinant double-stranded DNA molecule comprising an expression cassette comprising the following constituents:
- i) a promoter functional in nectaries of plants,
  - ii) a DNA sequence encoding a protein which is fused to the promoter,
  - iii) a DNA sequence encoding a signal peptide that targets the recombinant protein to nectar, which is translationally fused to the DNA sequence encoding the recombinant protein, and optionally
  - iv) a signal sequence functional in plants for the transcription termination and polyadenylation of an RNA molecule.
13. A recombinant double-stranded DNA molecule according to claim 11 or 12 wherein the promoter is as defined in any of claims 1-3.
14. A recombinant double-stranded DNA molecule according to claim 12 or 13 wherein the DNA sequence encoding a signal peptide is as defined in claim 8 or 9.
15. A process for producing a transgenic plant exhibiting excretion of a recombinant protein in its nectar, comprising:
- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in any of claims 12 to 14, wherein the recombinant protein is excreted in nectar,
  - ii) regenerating plants from the transgenic cell, and

AMENDED SHEET

27-10-2000

NL 009900453

- iii) selecting transgenic plants.
16. A process for producing a transgenic plant exhibiting a modified nectar composition, comprising:
- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in any of claims 11 to 14, wherein the recombinant protein interferes with metabolic pathways in the nectaries,
  - ii) regenerating plants from the transgenic cell, and
  - iii) selecting transgenic plants.
17. A process for producing a transgenic plant exhibiting a modified nectar secretion, comprising:
- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in any of claims 11 to 14, wherein the recombinant protein interferes with sink strength of nectaries,
  - ii) regenerating plants from the transgenic cell, and
  - iii) selecting transgenic plants.
18. A process for producing a transgenic plant exhibiting a modified nectary development, comprising:
- i) introducing in a plant cell a recombinant double-stranded DNA-molecule as defined in claims 11 or 14, wherein the recombinant protein interferes with the development of nectaries,
  - ii) regenerating plants from the transgenic cell, and
  - iii) selecting transgenic plants.
19. A process for producing honey from modified nectar of transgenic plants, comprising:
- i) producing a transgenic plant by introducing in a plant cell a recombinant double-stranded DNA molecule as defined in any of claims 11 to 14, regenerating plants from the transgenic cell, and selecting modified plants exhibiting the excretion of nectar with a modified composition,
  - ii) allowing insects, preferably bees, to collect nectar from the transgenic plants and to process the nectar into honey.
20. A process for producing a recombinant gene product from honey, comprising:
- i) producing a transgenic plant by introducing in a plant cell

AMENDED SHEET

27-10-2000

NL 009900453

- a recombinant double-stranded DNA molecule as defined in any of claims 12 to 14, regenerating plants from the transgenic cell, and selecting modified plants exhibiting excretion of the recombinant gene product in nectar,
- ii) allowing insects, preferably bees, to collect nectar from the transgenic plants and to process the nectar into honey, and
  - iii) isolating and purifying the gene product from the honey.
21. A process for producing a metabolite from honey, comprising:
- i) producing a plant that excretes this metabolite in nectar and which plant has been produced by current breeding and selection methods,
  - ii) allowing insects, preferably bees, to collect nectar from the selected plants and to process the nectar into honey, and
  - iii) isolating and purifying the metabolite from the honey.
22. Micro organisms containing DNA sequences according to one or more of claims 1 to 9.
23. Micro organisms containing recombinant DNA molecules according to any of claims 10 to 14.
24. A plant cell or plant cell culture transformed with one or more DNA sequences according to claims 1 to 9.
25. A plant cell or plant cell culture transformed with recombinant DNA molecules according to any of 10 to 14.
26. A plant consisting essentially of the plant cells of claims 24 or 25.
27. A transgenic plant obtained by the process of any of claims 15 to 18.
28. Seeds, tissue culture, plant parts or progeny plants derived from a transgenic plant according to claim 27.
29. Honey obtained from nectar from transgenic plants, which nectar has a modified composition.

AMENDED SHEET

27-10-2000

NL 009900453

30. Honey obtained from nectar from transgenic plants, which nectar comprises a recombinant gene product.


AMENDED SHEET

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: <b>C12N 15/82, 5/10, C07K 14/415, A01H 5/00</b>		(11) International Publication Number: <b>WO 00/04176</b>
(23) International Application Number: <b>PCT/NL99/00453</b>		(43) International Publication Date: <b>27 January 2000 (37.01.00)</b>
(22) International Filing Date: <b>15 July 1999 (15.07.99)</b>		(74) Agent: <b>DE HOOP, Eric; Octrooibureau Vriesendorp &amp; Gade, P.O. Box 266, NL-2501 AW The Hague (NL).</b>
(30) Priority Date: <b>98202375.6 16 July 1998 (16.07.98) EP</b> <b>98204215.2 14 December 1998 (14.12.98) EP</b>		(81) Designated States: <b>AE, AT, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EF, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, OM, KE, LS, MW, SD, SI, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>
(73) Applicant (for all designated States except US): <b>STICHTING CENTRUM VOOR PLANTENVERDELINGS-EN REPRODUKTIIONDERZOEK (CPRO-DLO) (NL/NL); Droevedalssteeg 1, NL-6708 PB Wageningen (NL).</b>		
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>CREEMERS, Jantina (NL/NL); Stichting Centrum voor Plantenverdelings-en Reproductieonderzoek (CPRO-DLO), Droevedalssteeg 1, NL-6708 PB Wageningen (NL). ANGENENT, Uerit, Cornelis (NL/NL); Stichting Centrum voor Plantenverdelings-en Reproductieonderzoek (CPRO-DLO), Droevedalssteeg 1, NL-6708 PB Wageningen (NL). KATER, Martin, Maria (NL/NL); Stichting Centrum voor Plantenverdelings-en Reproductieonderzoek (CPRO-DLO), Droevedalssteeg 1, NL-6708 Wageningen (NL).</b>		
Published With international search report		

(54) Title: **PROCESS TO COLLECT METABOLITES FROM MODIFIED NECTAR BY INSECTS**

## (57) Abstract

The invention relates to a recombinant double stranded DNA molecule comprising an expression cassette comprising the following constituents: i) a promoter functional in nectaries of plants, ii) a DNA sequence encoding a protein which is fused to the promoter, iii) a DNA sequence encoding a signal peptide that targets the recombinant protein to nectar, which is translationally fused to the DNA sequence encoding the recombinant protein, and optionally iv) a signal sequence functional in plants for the transcription termination and sequence encoding the recombinant protein, and optionally v) a signal sequence functional in plants for the transcription termination and sequence encoding the recombinant protein. The invention further relates to a process for producing a recombinant gene product from honey, comprising: i) producing a transgenic plant by introducing in a plant cell a recombinant double-stranded DNA molecule, regenerating plants from the transgenic cell, and selecting modified plants exhibiting excretion of the recombinant gene product in nectar, ii) allowing insects, preferably bees, to collect nectar from the transgenic plants and to process the nectar into honey, and iii) isolating and purifying the gene product from the honey.






FIG.1

1 TGATCCTGTT CGAGAAGCTA CAAAATCAAA AGAAGGTGTA GAAATCATTA  
51 TCAACATTGA AGATGATAAT TCTGATAACG CATTGCAGTC CATGGAGAAG prat 119 ←  
101 GATTTTTCCA GACTGCGGAC ATCAAAATAA GCAAGAAGAT GATCAAAAAA  
151 TGACAAAGCT AAGGAGTTTG AAGTAAGGCA AGGAACTTGA CACTGAAATAT  
201 CTAAGCTAAT TAGCAAGACT TTAGCAGCTT GTAATATTTA GTGTTTGTGA  
251 GGTGTTACCT TATAATTAGC TTGTAGCATA GCCTTCCCAC TAATAATTCT prat 122 ←  
301 GCTTAGCGAA TCTTATATAT GGGAAATACT TACACTAGTA TGCATCTTCT  
351 ATATACATGT TTGGCACTTG ACTATACATA GAAAAATTAA CAAGCATTTT  
401 TCACCTCAAT TTGTCACTTA CTTATAAGTA GCTGAATAAT ATAATGCAAT  
451 TTTCACCCC

FIG. 2

1 TCGAGCGGCC GCCCGGGCAG GTATTCAACA AGAGTATTCA CCACTTGAAC  
51 TCAAAAGGGG CTTCACTAAA AAAAAATCAT GGCGCAATTA CGTGTGATG prat 129 →  
101 ACTTGTCTTT CATATTTGGC CTTCTTGGTA ATATTGTATC ATTCATGGTC  
151 TTCCTAGCAC CCGTGCCAAC ATTTTACAAA ATATATAAAA GGAAATCATC  
201 AGAAGGATAT CAAGCAATAC CATATATGGT AGCACTGTTC AGCGCCGGAC  
251 TATTGCTATA TTATGCTTAT CTCAGGAAGA ATGCCTATCT TATCGTCAGC  
301 ATTAATGGCT TTGGATGTGC CATTGAATTA ACATATATCT CTCTGTTTCT  
351 CTTTTACGCG CCCAGAAAGT CTAAGATTTT CACAGGGTGG CTGATGCTCT  
401 TAGAATTGGG AGCCCTAGGA ATGGTGATGC CAATTACTTA TTTATTAGCA  
451 GAAGGCTCAC ATAGAGTGAT GATAGTGGGA TGGATTTGTG CAGCTATCAA  
501 TGTTGCTGTC TTGCTGCTC CTTTAAGCAT CATGAGGCAA GTAATAAAAA  
551 CAAAGAGTGT AGAGTTCATG CCCTTCACCT TATCTTTGTT CCTCACTCTC  
601 TGTGCCACTA TGTGGTTTTT CTATGGGTTT TTCAAGAAGG ACTTTTACAT  
651 TGC GTTTCCA AATATACTGG GCTTTCTATT CGGAATCGTT CAAATGCTAT  
701 TATATTTTGT TTACAAGGAT TCAAAGAGAA TAGATGATGA AAAATCTGAT  
751 CCTGTTTCGAG AAGCTACAAA ATCAAAAGAA GGTGTAGAAA TCATTATCAA  
801 CATTGAAGAT GATAATTCTG ATAACGCATT GCAGTCCATG GAGAAGG

FIG.3

1 TCGAGCGGCC GCCCGGGCAG GTATTCAACA AGAGTATTCA CCACTTGAAC  
51 TCAAAAGGGG CTTCACTAAA AAAAAATCAT GCGCAATTA CGTGTGTATG  
101 ACTTGCTCTT CATATTGGC CTCTCTGGTA ATATTGTATC ATTCATGGTC  
151 TTCCTAGCAC CCGTGCCAAC ATTTTACAAA ATATATAAAA GGAATTCATC  
201 AGAAGGATAT CAAGCAATAC CATATATGGT AGCACTGTTC AGCGCCGGAC  
251 TATTGCTATA TTATGCTTAT CTCAGGAAGA ATGCCTATCT TATCGTCAGC  
301 ATTAATGGCT TTGGATGTGC CATTGAATTA ACATATATCT CTCTGTTTCT  
351 CTTTTACGCG CCCAGAAAGT CTAAGATTTT CACAGGGTGG CTGATGCTCT  
401 TAGAATTGGG AGCCCTAGGA ATGGTGATGC CAATTACTTA TTTATTAGCA  
451 GAAGGCTCAC ATAGAGTGAT GATAGTGGGA TGGATTTGTG CAGCTATCAA  
501 TGTGTGCTGC TTTGCTGCTC CTTTAAGCAT CATGAGGCAA GTAATAAAAA  
551 CAAAGAGTGT AGAGTTCATG CCCTTCACCT TATCTTTGTT CCTCACTCTC  
601 TGTGCCACTA TGTGGTTTTT CTATGGGTTT TTCAAGAAGG ACTTTTACAT  
651 TGC GTTTCCA AATATACTGG GCTTTCTATT CGGAATCGTT CAAATGCTAT  
701 TATATTTTGT TTACAAGGAT TCAAAGAGAA TAGATGATGA AAAATCTGAT  
751 CCTGTTTCGAG AAGCTACAAA ATCAAAAGAA GGTGTAGAAA TCATTATCAA  
801 CATTGAAGAT GATAATTCTG ATAACGCATT GCAGTCCATG GAGAAGGATT  
851 TTTCCAGACT GCGGACATCA AAATAAGCAA GAAGATGATC AAAAAATGAC  
901 AAAGCTAAGG AGTTTGAAGT AAGGCAAGGA ACTTGACACT GAATATCTAA  
951 GCTAATTAGC AAGACTTTAG CAGCTTGTA TATTTAGTGT TTGTGAGGTG  
1001 TTACCTTATA ATTAGCTTGT AGCATAGCCT TCCCACATAAT AATTCTGCTT  
1051 AGCGAATCTT ATATATGGGA AATACTTACA CTAGTATGCA TCTTCTATAT  
1101 ACATGTTTGG CACTTGACTA TACATAGAAA AATTAACAAG CATTTCACAC  
1151 CTCAATTGTG CACTTACTTA TAAGTAGCTG AATAATATAA TGCAATTTTC  
1201 ACCCC

FIG. 4




FIG.5





FIG. 6

09/743885

WO 00/04176

PCT/NL99/00453

7/20

1 CCTAGGAGAAATCAAGCCTACTCTTAAGATGGATGACTCACTTGCCCCGA  
51 TGGTAAGGTGAAGGATCTGTTGATTAGAGTTGGGAAGTTTCATGTTCTCTG  
101 CTGATTTTATTA TTCTAGACTATGAAGAGGACCAAGAAGCTCCAATAATT  
151 TTGGGAAGAGCATCTCTTAATCACATCGATGGCAATTATTGACATGGAAC T  
201 TGGGGAGATGACTGTGAGAGCGCATGGAGAAAAGGTTACTTTCAAGGTTT  
251 ATAATAAAAAGGATCATATGGCTAAGTTTGAAGAGTGTTCTTTGATAGAA  
301 TGTGTCAGACGAGAACATGAAAGTAAACCGAAAGAGGTGTTTGAGCGGAA  
351 TGTAACAAGTGACCACGGCACAATAATTGACAAGTTGAAGGAAAATT  
401 CACCTAAAGGAAGGAAGAAGACAAAAGTTTCGTCGTAACAAGAGGAGACGT  
451 AAATGCTGGAAGTGAGCTTAAAGGTGTTGTCGTACTACGACGTTAACTAA  
501 GCGCCTTGTCGGGAGGCAACCCCTAGCTTGTATGTAAATGTAAAAGTAA  
551 AAATATATATATAGAAAAAGGAAAATACAAAAAGAGTCGTGCCGCGACGT  
601 TAAATCAAGCGCTTGTGGAAGGCAACCCAAATTTTATTGTTTTAGTTGT  
651 TTTACTTATTTAGTATTACGTAGTTTCTTGTTGTTTTGTAGGGCTCGGG  
701 ACTTTCGGAAGGTGAGGTAATTTCAAGGCATCGCGTGTGTATTGCACGC  
751 AGGTAAGTGTAAGAGTTGAGTTGGAAGCGTTTGCCCAAGTGTGCACCGT  
801 GAGAGGCTTTCAACCTGTTGCGACACGTGAAAAATTAAGAGCCAGATCTG  
851 CTACATTAGCACTGAAGCATCGCTTGGCCAATAGCTTGGAAATGGAAGCAA  
901 GAATTCAAACCAAAATCAGAAACGCCACAAGAGATGTGTCGCACACTGCA  
951 AAGCTTTGTGCAAACTAGTGAACGCAGAAATAGAAATGTACAGCCCATG  
1001 CGTCGCTTGGCTTATGGCAGGCAGCAAAAATTCAGCAGCAAAACAGAAAC  
1051 GCTGCGAGAAACGCGTCGCATACGCCATAGCTTTGTGTCAAACAGAACGT  
1101 CCAGAAATTGAAAAGCTATAAGCCTGCGTCGCTTGGCTCATGGCGTGCAG  
1151 ACTAGAAAAGCTCTAGCAGATGCGTCGCGTATTGTATAGCTTGGTGTGAA  
1201 ACAGAAAGTTTCGAAACTTGGAAGACGATAACCCAGCGTCGCTCTCTCAAC  
1251 CGCGTCCAGGTAAGTTCAAGATTCTTACGGGTTGACCCATTAAACCATTG  
1301 ATCGGCTGATTATAAACAATAAACATCACCTTCAACTATCACATGATTT  
1351 CATAAGTTTGACCTAGGATATTTTATATATATATATATATATACACAC

FIG.7

WO 00/04176

PCT/NL99/00453

8/20

1401 ACACACCATTTCCAGCGATCTTACCTCATTTTTATTCAAACCATTTTTCT  
1451 GCTTCAAAAGTTTAAATTATTAATATGATAAGTCATCCATAGTCAAACAA  
1501 GATTTTCTATACTATTTTGTCCCTTGTAATTTTAAAAAATAATGAGCGA  
1551 TGGTAAGATAAACATTGTTTGCAGGTGACAATTTTAGTATATGCAAACC  
1601 AACGCTTCTTCTTCCAACTATCACCTAAAACTACATCATTTATGGCGGGC  
1651 GGACTAGACGTAGCCAAATATAAAAACGCAATGGCCATTGAGTTCATGTC  
1701 ATTTTATATCCTTCATCCAATAATATTACTCAAAATTGATGTACAGTTT  
1751 GGTCTCTGATGTGCACTTTACTATACGTAATACGGAATTTACATTATAAT  
1801 TAAAGAGAACTGTTCCACTAAATTTAATGATTTAATTAATTTAACTCGG  
1851 TTACTTGTATTATTATTATTTGCTGTATTTGTTTGTCTATTGAATTTGGCA  
1901 CCGCAGATTTTGTATGCAATTAACCTCATATATCTTTTGGCCAAATAA  
1951 AGAAAAAGCTGTCATATTTCTTGCCAAACATTTATCATACTTTACCGAAT  
2001 TCTTGTTTTTTGTTTTCTCTGTTGTTGTTCTCCACTATAAATAACATTGC  
2051 AGTGAGTAAAGTTTCTTCAGGTCTCTTTTGTAGATTCAACAAGAGTATTC  
2101 AGCACTTGAACCTAAAAGGGCTTCACTAAAAAAATCATG

FIG.7(CONTIN.)



9/20

## PBNEPI




FIG. 8

10/20




FIG. 9

## SDS page of honey and nectar




FIG.10

1 2 3 4 5 6 7 8 9



A

1 2 3 4 5 6 7 8 9 M



B

FIG. 11

09/743885

===17-APR-1998=====PC/GENE===

\*\*\*\*\*  
 \* ALIGNMENT OF TWO PROTEIN SEQUENCES. \*  
 \*\*\*\*\*

The two sequences to be aligned are:

PCVH29.

Total number of residues: 60.

GER1.

Total number of residues: 211.

Comparison matrix : Structure-genetic matrix.

Open gap cost : 7

Unit gap cost : 1

The character to show that two aligned residues are identical is '|'.

```
PCVH29  - MKMFLPILFTISLLFSSSHASVLDFCVADPSLPDGPAGYSCKEPAKVTVD -50
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GER1    - MKMRIQIIFILSLFSSISFASVQDFCVADPKGPQNPSGYSCKNPDQVTEN -50
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
PCVH29  - DVFVHGLGTA -60
          ||| ||| ||| |||
GER1    - DPAFSGLGKAGNTSNVIKAAVTPAFAPAFAGLNGLDVSLARLDLAGGGVI -100
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GER1    - PLHTHPGASEVLVVIQGTICAGFISSANKVYLKTLRSGDSMVFPQGLLHF -150
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GER1    - QLNSGKGPAFAFVAFGSSSPGLQILPFALFANDLPSELVEATTFLSDEEV -200
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GER1    - KKLKGVLGGTN -211
```


Identity : 36 ( 60%)

Number of gaps inserted in PCVH29: 0

Number of gaps inserted in GER1: 0

===17-APR-1998=====PC/GENE===

FIG.12



A

B

FIG.13

MAP5H6	CGCCGGGCTGGTAAACAAGTAGTGTGTATCTACTCATTTGTTATTTCCCTTAA	50
MAP5H8	CGCCGGGCTGGTAAACAAGTAGTGTGTATCTACTCATTTGTTATTTCCCTTAA	50
MAP5R6	CGCCGGGCTGGTAAACAAGTAGTGTGTATCTACTCATTTGTTATTTCCCTTAA	50
MAP5H8	CGCCGGGCTGGTAAACAAGTAGTGTGTATCTACTCATTTGTTATTTCCCTTAA	50
	*****	
MAP5H6	AAAGCACTGTCAAATTCGACCAACGAGTATATAGTATCATTTCC	100
MAP5H8	AAAGCACTGTCAAATTCGACCAACGAGTATATAGTATCATTTCC	100
MAP5R6	AAAGCACTGTCAAATTCGACCAACGAGTATATAGTATCATTTCC	100
MAP5H8	AA-GCACTGTCAAATTCGACCAACGAGTATATAGTATCATTTCC	99
	** *****	
MAP5H6	CCCTATGGACACGCACTCTAGAGGGCAATCAGACACACCAACCAT	150
MAP5H8	CCCTATGGACACGCACTCTAGAGGGCAATCAGACACACCAACCAT	150
MAP5R6	CCCTATGGACACGCACTCTAGAGGGCAATCAGACACACCAACCAT	150
MAP5H8	CCCTATAAACCCGCACTCTAGAGGGCAATCAGACACACCAACCAT	149
	*****	
MAP5H6	TGCACCTGTGAGATGTTCTTCCAAATTCCTTCACCAITTCCTCTCT	200
MAP5H8	TGCACCTGTGAGATGTTCTTCCAATTCCTTCACCAITTCCTCTCT	200
MAP5R6	TGCACCTGTGAGATGTTCTTCCAATTCCTTCACCAITTCCTCTCT	200
MAP5H8	TGCACCTATGAGATGTTCTTCCAATTCCTTCACCAITTCCTCTCT	199
	*****	
	signal sequence ←-----→ mature protein	
MAP5H6	TCCTCTCTCCATGCTTCAGGTGTGGACTTCGCGTAGCAGCCCATCC	250
MAP5H8	TCCTCTCTCCATGCTTCAGGTGTGGACTTCGCGTAGCAGCCCATCC	250
MAP5R6	TCCTCTCTCCATGCTTCAGGTGTGGACTTCGCGTAGCAGCCCATCC	250
MAP5H8	TCCTCTCTCCATGCTTCAGGTGTGGACTTCGCGTAGCAGCCCATCC	249
	*****	

FIG. 14

tatgttccttccaattcttttcactatttctcttcttcttcttcttctcattgcttctgttcttgatttcg  
acaagggaaggttaagaaagtgataaagagaagaaagagaagagatccgagacaagaactaaagcctag

FIG.15






FIG.16

18/ 20




FIG.17




FIG. 18

20/20

1 TCTGAATACAAGCTGTGTGTGTAGAGAGATTTTCATAAAGACAGCAAACAT  
 51 CCCTTCTTTTTTGTCTGTGTTTTAAAAGTTCCTTCTTCAACCAGCTCTTTT  
 101 CCTCATCAGGGTAAGTTGCAAATAAAGGGGATGTTCAGAATCAAGAAGA  
 151 GAAGATGTCAGACTCGCCTCAGAGGAATGCGGAAGAGAAAGATTGAGA  
 201 TTAAGAGGATTGAAAAACAAACAATCGTCAAGTCACCTTCTGTAAAGAGA  
 251 AGAAATGGTTGCTTAAAAAAGCTTATGAACTTCTGTCTTTGTGATGC  
 301 TGAAGTTGCTCTCATCGTTTCTCAAGCCGTGGCCGCTCTATGAATATG  
 351 CTAACACAGTGTGAAGGCAACAATTGATAGATATAAGAAAGCATCCTCA  
 401 GATTCCCTCCAACACTGGATCTACTTCTGAAGCTAACACTCAGTTTATCA  
 451 ACAAGAAGCTGCCAAACTCCGAGTTCAGATTGGTAACTTACAGAACTCAA  
 501 ACAGGAACATGCTAGGCGAGTCTCTAAGTTCTCTGACTGCAAAAGATCTG  
 551 AAAGCGCTGGAGACCAAACTTGAGAAAGGAATTAGTAGAATTAGGTCCAA  
 601 AAAGAAATGAACTCCTGTTTGCTGAGATTGAGTATATGCCAAAAAGGAAA  
 651 TTGATTGTCACAACAACAATCAGATGCTTCGGGCAAAGATAGCTGAGAGT  
 701 GAAAGAAATGTGAACATGATGGGAGGAGAAATTGAGCTGATGCAATCTCA  
 751 TCCGTACGATCCAAGAGACTTCTTCCAAGTGAACGGCTTACAGCATAATC  
 801 ATCAATATCCACGCCAAGACAACATGGCTCTTCAATTAGTATAGGTTTAT  
 851 AATAAAATGCATGGTTGAAGCACTCTGATTGTGGTGAATTGGATTATG  
 901 TATAAGGGAGTGCAGGCCATTGCCAATTATTGAAAGGTACTCAACACAGG  
 951 AAGTTGAAGAAGTTTCATCTCTCATCTATATGTCCTTAACAAAAGTC  
 1001 TTAGCTTATGGACTCTAAAACAAAGACTTAATTTAACATATAAATATAAT  
 1051 TGTGTAATGCTGTTGTATGTATGTTATGTTATCCAAAAACATTAATAACC  
 1101 TATCTTTTTCTTCAAATTATGTCTCCTTTGATACAACTACTAACATATT  
 1151 TTCTTAT

MADS-box

K-box

FIG.19

Practitioner's Docket No. \_\_\_\_\_

PATENT

Optional Customer No. Bar Code

\*00140\*

00140

PATENT TRADEMARK OFFICE

**COMBINED DECLARATION AND POWER OF ATTORNEY**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,  
CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is of the following type:

*(check one applicable item below)*

- ☐ original.  
☐ design.

*NOTE: With the exception of a supplemental oath or declaration submitted in a reissue, a supplemental oath or declaration is not treated as an amendment under 37 CFR 1.312 (Amendments after allowance) M P E.P. Section 714 16, 7<sup>th</sup> Ed*

- ☐ supplemental.

*NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items*

- ☒ national stage of PCT.

*NOTE: If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P.*

*NOTE: See 37 C.F.R. Section 1.63(d) (continued prosecution application) for use of a prior nonprovisional application declaration in the continuation or divisional application being filed on behalf of the same or fewer of the inventors named in the prior application*

- ☐ divisional.  
☐ continuation.

*NOTE: Where an application discloses and claims subject matter not disclosed in the prior application, or a continuation or divisional application names an inventor not named in the prior application, a continuation-in-part application must be filed under 37 C.F.R. Section 1.53(b) (application filing requirements-nonprovisional application).*

- ☐ continuation-in-part (C-I-P).

**INVENTORSHIP IDENTIFICATION**

**WARNING:** *If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.*

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

PROCESS TO COLLECT METABOLITES FROM MODIFIED NECTAR BY INSECTS

**SPECIFICATION IDENTIFICATION**

The specification of which:

(complete (a), (b), or (c))

(a) ☐ is attached hereto.

**NOTE:** *"The following combinations of information supplied in an oath or declaration filed on the application filing date with a specification are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 C.F.R. Section 1.63.*

*"(1) name of inventor(s), and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration on filing;*

*"(2) name of inventor(s), and attorney docket number which was on the specification as filed; or*

*"(3) name of inventor(s), and title which was on the specification as filed "*

*Notice of July 13, 1995 (1177 O.G. 60)*

(b) ☐ was filed on \_\_\_\_\_, ☐ as Application No. \_\_\_\_\_  
☐ and was amended on \_\_\_\_\_ (if applicable).

**NOTE:** *Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 C.F.R. Section 1.67.*

**NOTE:** *"The following combinations of information supplied in an oath or declaration filed after the filing date are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 C.F.R. Section 1.63:*

*(A) application number (consisting of the series code and the serial number, e.g., 08/123,456),*

*(B) serial number and filing date,*

*(C) attorney docket number which was on the specification as filed,*

*(D) title which was on the specification as filed and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration; or*

*(E) title which was on the specification as filed and accompanied by a cover letter accurately identifying the application for which it was intended by either the application number (consisting of the series code and the serial number, e.g., 08/123,456), or serial number and filing date. Absent any statement(s) to the contrary, it will be presumed that the application filed in the PTO is the application which the inventor(s) executed by signing the oath or declaration.*

*M.P.E.P. Section 601.01(a), 7th ed*

- (c) ☒ [ X ] was described and claimed in PCT International Application No. PCT/NL99/00453 filed on 15 July 1999 and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

# **SUPPLEMENTAL DECLARATION (37 C.F.R. Section 1.67(b))**

*(complete the following where a supplemental declaration is being submitted)*

- ☐ [ ] I hereby declare that the subject matter of the

☐ [ ] attached amendment

☐ [ ] amendment filed on \_\_\_\_\_.

was part of my/our invention and was invented before the filing date of the original application, above identified, for such invention.

# **ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56,

*(also check the following items, if desired)*

- ☐ [ ] and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and

- ☐ [ ] in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 C.F.R. Section 1.98.

# **PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))**

**NOTE.** "The claim to priority need be in no special form and may be made by the attorney or agent if the foreign application is referred to in the oath or declaration as required by Section 1.63. The claim for priority and the certified copy of the foreign application specified in 35 U.S.C. Section 119(b) must be filed in the case of an interference (Section 1.630), when necessary to overcome the date of a reference relied upon by the examiner, when specifically required by the examiner, and in all other situations, before the patent is granted. If the claim for priority or the certified copy of the foreign application is filed after the date the issue fee is paid, it must be accompanied by a petition requesting entry and by the fee set forth in Section 1.17(i). If the certified copy is not in the English language, a translation need not be filed except in the case of interference, or when necessary to overcome the date of a reference relied upon by the examiner, or when specifically required by the examiner, in which event an English language translation must be filed together with a statement that the translation of the certified copy is accurate." 37 C.F.R. Section 1.55(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

*(complete (d) or (e))*

- (d) ☐ no such applications have been filed.  
 (e) ☒ such applications have been filed as follows.

*NOTE: Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim*

**PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS  
 (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION  
 AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. SECTION 119(a)-(d)**

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 USC 119
Europe	98202375.6	16 July 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Europe	98204215.2	14 December 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)  
 (35 U.S.C. Section 119(e))**

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

**PROVISIONAL APPLICATION NUMBER**

/ \_\_\_\_\_  
 / \_\_\_\_\_  
 / \_\_\_\_\_

**FILING DATE**

\_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)  
 UNDER 35 U.S.C. SECTION 120**

- ☐ The claim for the benefit of any such applications are set forth in the attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN-PART (C-I-P) APPLICATION.



**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

*NOTE: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. Section 120*

**POWER OF ATTORNEY**

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

*(list name and registration number)*

JOSEPH H. HANDELMAN, 26179

RICHARD P. BERG, 28145

JOHN RICHARDS, 31053

JULIAN H. COHEN, 20302

RICHARD J. STREIT, 25765

WILLIAM R. EVANS 25858

PETER D. GALLOWAY, 27885

JANET I. CORD, 33778

IAN C. BAILLIE, 24090

CLIFFORD J. MASS, 30086

THOMAS F. PETERSON, 24790

CYNTHIA R. MILLER, 34678

*(Check the following item, if applicable)*

- ☐ I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.
- ☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named practitioner(s) to accept and follow instructions from my representative(s).

*NOTE: "Special care should be taken in continuation or divisional applications to ensure that any change of correspondence address in a prior application is reflected in the continuation or divisional application. For example, where a copy of the oath or declaration from the prior application is submitted for a continuation or divisional application filed under 37 CFR 1.53(b) and the copy of the oath or declaration from the prior application designates an old correspondence address, the Office may not recognize, in the continuation or divisional application, the change of correspondence address made during the prosecution of the prior application. Applicant is required to identify the change of correspondence address in the continuation or divisional application to ensure that communications from the Office are mailed to the current correspondence address. 37 CFR 1.63(d)(4) " Section 601.03, M.P.E.P., 7th Ed*

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:  
(Name and telephone number)

**Ladas & Parry**  
**26 West 61<sup>st</sup> Street**  
**New York, N.Y. 10023**

(complete the following if applicable)

Since this filing is a ☐ continuation ☐ divisional there is attached hereto a Change of Correspondence Address so that there will be no question as to where the PTO should direct all correspondence.

#### DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

## SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other document.

NOTE: Each inventor must be identified by full name, including the family name, and at least one given name without abbreviation together with any other given name or initial, and by his/her residence, post office address and country of citizenship. 37 C.F.R. Section 1.63(a)(3).

NOTE: Inventors may execute separate declarations/oaths provided each declaration/oath sets forth all the inventors. Section 1.63(a)(3) requires that a declaration/oath, inter alia, identify each inventor and prohibits the execution of separate declarations/oaths which each sets forth only the name of the executing inventor. 62 Fed. Reg. 53,131, 53,142, October 10, 1997.

## Full name of sole or first inventor

Jantina

CREEMERS

(Given Name)

(Middle Initial or Name)

Family (Or Last Name)

Inventor's signature

Date JAN 29 2001

Country of Citizenship Netherlands

Residence c/o Stichting Centrum voor Plantenveredelings- en Reproductieonderzoek (CPRO-DLO), Droevendaalsesteeg 1, 6708 PB WAGENINGEN, The Netherlands

Post Office Address same as above

\*\*\*\*\*

## Full name of second joint inventor, if any

Gerrit

Cornelis

ANGENENT

(Given Name)

(Middle Initial or Name)

Family (Or Last Name)

Inventor's signature

Date JAN 29 2001

Country of Citizenship Netherlands

Residence c/o Stichting Centrum voor Plantenveredelings- en Reproductieonderzoek (CPRO-DLO), Droevendaalsesteeg 1, 6708 PB WAGENINGEN, The Netherlands

Post Office Address same as above

\*\*\*\*\*

## Full name of third joint inventor, if any

Martin

Maria

KATER

(Given Name)

(Middle Initial or Name)

Family (Or Last Name)

Inventor's signature

Date JAN 25 2001

Country of Citizenship Netherlands

Residence c/o Stichting Centrum voor Plantenveredelings- en Reproductieonderzoek (CPRO-DLO), Droevendaalsesteeg 1, 6708 PB WAGENINGEN, The Netherlands

Post Office Address same as above

(check proper box(es) for any of the following added page(s)  
that form a part of this declaration)

- ☐ **Signature** for fourth and subsequent joint inventors. *Number of pages added* \_\_\_\_\_

\* \* \*

- ☐ **Signature** by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. *Number of pages added* \_\_\_\_\_

\* \* \*

- ☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 C.F.R. Section 1.47. *Number of pages added* \_\_\_\_\_

\* \* \*

- ☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 C.F.R. Section 1.47)

\* \* \*

- ☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added \_\_\_\_\_

\* \* \*

- ☐ Authorization of practitioner(s) to accept and follow instructions from representative.

(If no further pages form a part of this Declaration,  
then end this Declaration with this page and check the following item)

☒ This declaration ends with this page.

## SEQUENCE LISTING

<110> CREEMERS, Jantina  
 ANGENENT, Gerrit  
 KATER, Martin

<120> Process to collect metabolites from modified nectar by  
 insects

<130> U-13212-4

<140> 09/743885

<141> 2001-01-16

<160> 29

<170> PatentIn Ver. 2.1

<210> 1

<211> 265

<212> PRT

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland

<220>

<223> NEC1 amino acid sequence

<400> 1

Met Ala Gln Leu Arg Ala Asp Asp Leu Ser Phe Ile Phe Gly Leu Leu  
 1 5 10 15

Gly Asn Ile Val Ser Phe Met Val Phe Leu Ala Pro Val Pro Thr Phe  
 20 25 30

Tyr Lys Ile Tyr Lys Arg Lys Ser Ser Glu Gly Tyr Gln Ala Ile Pro  
 35 40 45

Tyr Met Val Ala Leu Phe Ser Ala Gly Leu Leu Tyr Tyr Ala Tyr  
 50 55 60

Leu Arg Lys Asn Ala Tyr Leu Ile Val Ser Ile Asn Gly Phe Gly Cys  
 65 70 75 80

Ala Ile Glu Leu Thr Tyr Ile Ser Leu Phe Leu Phe Tyr Ala Pro Arg  
 85 90 95

Lys Ser Lys Ile Phe Thr Gly Trp Leu Met Leu Leu Glu Leu Gly Ala  
 100 105 110

Leu Gly Met Val Met Pro Ile Thr Tyr Leu Leu Ala Glu Gly Ser His  
 115 120 125

Arg Val Met Ile Val Gly Trp Ile Cys Ala Ala Ile Asn Val Ala Val  
 130 135 140  
 Phe Ala Ala Pro Leu Ser Ile Met Arg Gln Val Ile Lys Thr Lys Ser  
 145 150 155 160  
 Val Glu Phe Met Pro Phe Thr Leu Ser Leu Phe Leu Thr Leu Cys Ala  
 165 170 175  
 Thr Met Trp Phe Phe Tyr Gly Phe Phe Lys Lys Asp Phe Tyr Ile Ala  
 180 185 190  
 Phe Pro Asn Ile Leu Gly Phe Leu Phe Gly Ile Val Gln Met Leu Leu  
 195 200 205  
 Tyr Phe Val Tyr Lys Asp Ser Lys Arg Ile Asp Asp Glu Lys Ser Asp  
 210 215 220  
 Pro Val Arg Glu Ala Thr Lys Ser Lys Glu Gly Val Glu Ile Ile Ile  
 225 230 235 240  
 Asn Ile Glu Asp Asp Asn Ser Asp Asn Ala Leu Gln Ser Met Glu Lys  
 245 250 255  
 Asp Phe Ser Arg Leu Arg Thr Ser Lys  
 260 265

<210> 2

<211> 221

<212> PRT

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland, secretory cell

<220>

<223> FBP15 amino acid sequence

<400> 2

Met Gly Arg Gly Lys Ile Glu Ile Lys Arg Ile Glu Asn Thr Thr Asn  
 1 5 10 15  
 Arg Gln Val Thr Phe Cys Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala  
 20 25 30  
 Tyr Glu Leu Ser Val Leu Cys Asp Ala Glu Val Ala Leu Ile Val Phe  
 35 40 45  
 Ser Ser Arg Gly Arg Leu Tyr Glu Tyr Ala Asn Asn Ser Val Lys Ala  
 50 55 60  
 Thr Ile Asp Arg Tyr Lys Lys Ala Ser Ser Asp Ser Ser Asn Thr Gly  
 65 70 75 80

Ser Thr Ser Glu Ala Asn Thr Gln Phe Tyr Gln Gln Glu Ala Ala Lys  
85 90 95  
Leu Arg Val Gln Ile Gly Asn Leu Gln Asn Ser Asn Arg Asn Met Leu  
100 105 110  
Gly Glu Ser Leu Ser Ser Leu Thr Ala Lys Asp Leu Lys Gly Leu Glu  
115 120 125  
Thr Lys Leu Glu Lys Gly Ile Ser Arg Ile Arg Ser Lys Lys Asn Glu  
130 135 140  
Leu Leu Phe Ala Glu Ile Glu Tyr Met Arg Lys Arg Glu Ile Asp Leu  
145 150 155 160  
His Asn Asn Asn Gln Met Leu Arg Ala Lys Ile Ala Glu Ser Glu Arg  
165 170 175  
Asn Val Asn Met Met Gly Gly Glu Phe Glu Leu Met Gln Ser His Pro  
180 185 190  
Tyr Asp Pro Arg Asp Phe Phe Gln Val Asn Gly Leu Gln His Asn His  
195 200 205  
Gln Tyr Pro Arg Gln Asp Asn Met Ala Leu Gln Leu Val  
210 215 220

<210> 3

<211> 18

<212> PRT

<213> Calluna vulgaris

<220>

<223> tissue type: flower

<220>

<223> Calluna vulgaris signal peptide

<400> 3

Met Phe Leu Pro Ile Leu Phe Thr Ile Ser Leu Leu Phe Ser Ser Ser  
1 5 10 15

His Ala

<210> 4

<211> 1205

<212> DNA

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland

<220>

<223> NEC1

<400> 4

```
tgcagcggcc gccggggcag gtattcaaca agagtattca ccacttgaac tcaaaagggg 60
cttcaactaaa aaaaaatcat ggcgcaatta cgtgctgatg acttgtcttt catatttggc 120
cttctctggta atattgtatc attcatggtc ttcttagcac ccgtgccaac attttacaaa 180
atatataaaa ggaatatcatc agaaggatat caagcaatcac catatatggt agcattggtc 240
agcgcgggac tattgctata ttatgcttat cttaggaaga atgcttatct tatcgtcagc 300
attaatggct ttggatgtgc cattgaatta acatatatct ctctgtttct cttttacggc 360
cccagaaagt ctaagatttt cacaggggtg ctgatgctct tagaattggg agccctagga 420
atgggtgatgc caattactta ttattatgca gaaggctcac atagagtgat gatagtggga 480
tggattttgt cagctatcaa tgttgcgtgc ttgtcgtctc ctttaagcat catgaggcaa 540
tgaataaaaa caaagagtgt agagtccatg cccttcactt tatctttgtt cctcactctc 600
tgtgccacta tgtgggtttt ctatgggttt ttcaagaagg actttttacat tgcgtttcca 660
aatatactgg gctttctatt cggaatcggt caaatgctat tatattttgt ttacaaggat 720
tcaaaagaaa tagatgatga aaaatctgat cctgttcgag aagctacaaa atcaaaagaa 780
ggtgtagaaa tcattatcaa cattgaagat gataattctg ataacgcat gcagtcacatg 840
gagaaggatt ttccagact gcggacatca aaataagcaa gaagatgatc aaaaaatgac 900
aaagctaaag agtttgaagt aaggcaagga acttgacact gaatatctaa gctaatttagc 960
aagactttag cagctgttaa tatttagtgt ttgtgagggt ttaccttata attagcttgt 1020
agcatagctt tcccactaat aattctgctt agcgaatctt atatatggga aatactttaca 1080
ctagtatgca tcttctatat acatgttttg cacttgacta tacatagaaa aattaacaag 1140
catttctcac ctcaatttgt cacttactta taagttagctg aataataata tgcaattttc 1200
acccc 1205
```

<210> 5

<211> 1157

<212> DNA

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland

<220>

<223> cDNA library of nectaries from Petunia hybrida flowers

<220>

<223> FBP15

<400> 5

```
tctgaataca agctgtgtgt gtagagagat ttcataaaga cagcaaacat ccctctcttt 60
tgttctgttt taaaagtctc ctctctcaac cagctctttt cctcatcagg gtaagttgca 120
aataaaagggg atgttccaga atcaagaaga gaagatgtca gactcgctc agaggaagat 180
gggaagagga aagatttgaga ttaagaggat tgaaaataca acaaatcgtc aagtcacttt 240
ctgtaagaga agaaatgggt tgcttaaaaa agcttatgaa ctttctgttc ttgttgatgc 300
tgaagttgct ctcactgctt tctcaagcgg tggcgcgctc tatgaatatg ctaaccaacag 360
tgtgaaggca acaattgata gatataagaa agcatcctca gattctctca acactggatc 420
tacttctgaa gctaacactc agttttatca acaagaagct gccaaactcc gagttcagat 480
tggtaactta cagaactcaa acaggaacat gctaggcgag tctctaagtt ctctgactgc 540
aaaagatctg aaaggcctgg agacaaaact tgagaaagga attagtagaa ttaggttcaa 600
```



```

aaagaatgaa ctctctgttg ctgagattga gtatatgcga aaaagggaaa ttgatttgca 660
caacaacaat cagatgtctc gggcaaatga agctgagagt gaaagaatgt tgaacatgat 720
gggaggagaa tttagctgta tgcaatctca tccgtacgat ccaagagact tcttccaagt 780
gaacgggctta cagcataatc atcaatatcc acgccaagac aacatggctc ttcaattagt 840
ataagtttat aataaaatgc atggtttgaa gcactctgat tgtgtgtgat ttggattatg 900
tataaggag tgacggccat ttgccaatta ttgaaaggta ctcaaacagg aagttgaaga 960
agttctcatc ctctctcatc tatatgtctt aacaaaagtc ttacgtctatg gactctaaaa 1020
caaaagactta atttaacata taaataataa tgtgtaatgc tgtgtattg tatggtatgt 1080
atccaaaaac attaataacc tatctttttc ttcaaatat gtctcctttg atacaaacta 1140
ctaacatatt ttcttat
1157

```

```

<210> 6
<211> 54
<212> DNA
<213> Calluna vulgaris

```

```

<220>
<221> sig_peptide
<222> (1)..(54)

```

```

<400> 6
atgtttcttc caattctctt caccatttcc ctctctttct cctctctcca tgct 54

```

```

<210> 7
<211> 2141
<212> DNA
<213> Petunia x hybrida

```

```

<220>
<223> strain: W115

```

```

<220>
<223> NEC1 promoter

```

```

<400> 7
cctaggagaa atcaagccta ctcttaagat ggatgaetca ctctgccga ttgtaagggtg 60
aaggatctgt tgattagagt tgggaagttc atgttctctg ctgattttat tattctagac 120
tatgaagagg accaagaagc tccaataatt ttgggaagag cattcttaat cacatcgatg 180
gcaattattg acatggaaact tggggagatg actgtgagag cgcattggaga aaaggttact 240
ttcaagggtt ataataaaaa ggatcatatg gctaaagttt aagagtggttc ttgatagaa 300
tgtgtcgagc gagaacatga aagtaaaccc aaagaggtgt ttgagcggaa tgtagaacaa 360
agtgaccacg gcacaataat tgacaagtgt aaggaataat cacctaaagg aaggaagaag 420
acaaaagtct cgtctaacaa gaggagacgt aaatgctgga agtgagctta aaggtgttgt 480
cgtactacga cgttaactaa ggcgctgtgc gggaggcaac cctagctttg tatgtaaatg 540
taaaagtaaa aaatatatat atagaaaaag gaaaatacaa aaagagtcgt gccgcgacgt 600
aaatcaacgc gcttgtttgga aggcaaccca atttttatgt ttttagttgt ttacttatt 660
tagtattacg tagttttctg ttgtttttgt agggctcggg actttccgaa ggtgaggtaa 720
tttcaaggca tgcggtgttg tattgcagcg aggttaagtgt aagagttgag ttggaagcgt 780
ttggccaagt tgcgcacgtg gagaggtctt caacctgttg cgacacgtga aaaattaaaga 840
gccagattctg ctacattagc actgaagcat cgtctggcca atagcttggga atggaagcaa 900
gaattcaaac caaaatcaga aacgccacaa gagatgtgtc gcacactgca aagcttttgt 960
caaaactagt aacgcagaaa tagaaatgct acagcccatg cgtcgtttg cttatggcag 1020
cgcgcagaaa ttcagcagca aaacagaaac gctgcgagaa acgcgtgcga tacgccatag 1080
cttaggtbca aacagacgt ccagaaattg aaaagctata agcctgcgtc gcttggctaa 1140
tggcgtgcag actagaaaag ctctagcaga tgcgtcgcgt attgtatagc ttggtgtgaa 1200
acagaaaggt cgaaacttgg aaaaacgataa cccagcgtcg cctcttcaac cgcgtccagg 1260

```

```

taagttcaag attcttaagg gttgacccat taacccattg atcggtgat tataaacaat 1320
aaaacatcac ctccaactat cacatgattt cataagtttg acctaggata ttttatatat 1380
atatatatat atatacacac acacaccatt tccagcgatc ttacctcatt tttattcaaa 1440
ccattttctc gcttcaaaaag tttaaattat taatatgata agtcacccat agtcaaacaa 1500
gattttctat actattttgt cccttgtaat tttaaaaaaa aaatgagcga tggtaagata 1560
aacattgttt gcaagtgtac aatttttagta tatgcaaaac aacgcttctt ctccaacta 1620
tcacctaaaa ctacatcatt tatggcgggc ggactagacg tagccaaaaa taaaaacgca 1680
atgggccattc agttcatgtc atttttatat ccttcaccca ataattacc tcaaaattga 1740
tgtcacagttt ggtctctgat gtgcacttta ctatacgtaa tacggaattt acattataat 1800
taaagagaaac tgttcocacta aattttaatg atttaattaa ttttaactcg ttacttgtat 1860
tattattatt gctgtatttg ttgtcattt gaatttgca ccgcagattt ttgtatgcaa 1920
ttaaccctca tatatctttt ggccaaataa agaaaaagtc tgcattttc ttgccaaaac 1980
tttateatc tttaccgaat tcttgttttt tgttctctg ttgtgttct ccactataaa 2040
taacatttgc agtgagtaaa gtttcttcag gtctctttt tagattcaac aagagtattc 2100
agcacttgaa ctcaaaaggc gcttcactaa aaaaaatcat g 2141

```

```

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer prat
122

```

```

<400> 8
gtgggaagc tatgctacaa gc 22

```

```

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer prat
119

```

```

<400> 9
ccttctccat ggactgcaat gcg 23

```

```

<210> 10
<211> 29
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer prat
129

```

```

<400> 10
gggatccatg gcgcaattac gtgctgatg 29

```

```

<210> 11
<211> 24

```

<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer prat  
 148  
  
 <400> 11  
 ccaagaaggc caaatatgaa agac 24  
  
 <210> 12  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer prat  
 149  
  
 <400> 12  
 aagtcatcag cacgtaattg cgcc 24  
  
 <210> 13  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer prat  
 169  
  
 <400> 13  
 cgctgcagcg ccatgggttt ttttagtgaa gcccc 35  
  
 <210> 14  
 <211> 32  
 <212> PRT  
 <213> Calluna vulgaris  
  
 <220>  
 <223> CVH 50 N-terminal sequence  
  
 <400> 14  
 Ser Val Leu Asp Phe Cys Val Ala Asp Pro Ser Leu Pro Asp Gly Pro  
 1 5 10 15  
 Ala Gly Tyr Ser Cys Thr Glu Pro Ser Thr Val Thr Ser Gln Asp Phe  
 20 25 30  
  
 <210> 15

<211> 40  
 <212> PRT  
 <213> *Calluna vulgaris*

<220>  
 <223> CVH 29 N-terminal sequence

<400> 15  
 Ser Val Leu Asp Phe Cys Val Ala Asp Pro Ser Leu Pro Asp Gly Pro  
   1                  5                  10                  15  
 Ala Gly Tyr Ser Cys Lys Glu Pro Ala Lys Val Thr Val Asp Asp Phe  
                   20                  25                  30  
 Val Phe His Gly Leu Gly Thr Ala  
           35                  40

<210> 16  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
           176

<400> 16  
 gayttytgyg tngcngaycc 20

<210> 17  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
           177

<400> 17  
 certgraana craartctc 20

<210> 18  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
           207

<400> 18  
 ggtgacttta gagggctcct tgc 23

<210> 19  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 206

<400> 19  
 gctccttgca ggagtagcct gc 22

<210> 20  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 247

<400> 20  
 ggctgcagga gtgttctttg atagaatg 28

<210> 21  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 248

<400> 21  
 cgccatatgt ttttttatgg aagcccc 27

<210> 22  
 <211> 70  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer prat  
 245

<400> 22  
 tatgttccct ccaattcttt tcaactatttc tcttcttttc tcttcttttc atgtttctgt 60  
 tcttgatttc 70

<210> 23  
 <211> 73  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
246

<400> 23

gatccgaaat caagaacaga agcatgagaa gaagagaaaa gaagagaaat agtgaaaaga 60  
attggaagga aca 73

<210> 24

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
251

<400> 24

gggagctcga gtcgttcaaa catttggaac taaag 35

<210> 25

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
252

<400> 25

cgaattcccg ggatctagta acatagatga cac 33

<210> 26

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
249

<400> 26

ccggatccat gttacgtcct gtagaaacc 29

<210> 27

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer prat  
250

<400> 27

gggagctccc accgaggctg tag

23

<210> 28

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 28

aaggacttta gagagaccg accactgctg g

31

<210> 29

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 29

aaatgtttt gatgcataat atttcccata atc

33

WO 00/04176

09/743885  
10 Rec'd PCT/EP 16 JAN 2001  
PCT/NL99/00453

SEQUENCE LISTING

<110> CPRO-DLO

<120> Process to collect metabolites from modified nectar by  
insects

<130> 159782

<140> pct/nl99/00453

<141> 1999-07-15

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 265

<212> PRT

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland

<220>

<223> NECl amino acid sequence

<400> 1

Met Ala Gln Leu Arg Ala Asp Asp Leu Ser Phe Ile Phe Gly Leu Leu  
1 5 10 15

Gly Asn Ile Val Ser Phe Met Val Phe Leu Ala Pro Val Pro Thr Phe  
20 25 30

Tyr Lys Ile Tyr Lys Arg Lys Ser Ser Glu Gly Tyr Gln Ala Ile Pro  
35 40 45

Tyr Met Val Ala Leu Phe Ser Ala Gly Leu Leu Tyr Tyr Ala Tyr  
50 55 60

Leu Arg Lys Asn Ala Tyr Leu Ile Val Ser Ile Asn Gly Phe Gly Cys  
65 70 75 80

Ala Ile Glu Leu Thr Tyr Ile Ser Leu Phe Leu Phe Tyr Ala Pro Arg  
85 90 95



WO 00/04176

PCT/NL99/00453

Lys Ser Lys Ile Phe Thr Gly Trp Leu Met Leu Leu Glu Leu Gly Ala  
 100 105 110

Leu Gly Met Val Met Pro Ile Thr Tyr Leu Leu Ala Glu Gly Ser His  
 115 120 125

Arg Val Met Ile Val Gly Trp Ile Cys Ala Ala Ile Asn Val Ala Val  
 130 135 140

Phe Ala Ala Pro Leu Ser Ile Met Arg Gln Val Ile Lys Thr Lys Ser  
 145 150 155 160

Val Glu Phe Met Pro Phe Thr Leu Ser Leu Phe Leu Thr Leu Cys Ala  
 165 170 175

Thr Met Trp Phe Phe Tyr Gly Phe Phe Lys Lys Asp Phe Tyr Ile Ala  
 180 185 190

Phe Pro Asn Ile Leu Gly Phe Leu Phe Gly Ile Val Gln Met Leu Leu  
 195 200 205

Tyr Phe Val Tyr Lys Asp Ser Lys Arg Ile Asp Asp Glu Lys Ser Asp  
 210 215 220

Pro Val Arg Glu Ala Thr Lys Ser Lys Glu Gly Val Glu Ile Ile Ile  
 225 230 235 240

Asn Ile Glu Asp Asp Asn Ser Asp Asn Ala Leu Gln Ser Met Glu Lys  
 245 250 255

Asp Phe Ser Arg Leu Arg Thr Ser Lys  
 260 265

<210> 2

<211> 221

<212> PRT

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland, secretory cell

<220>

&lt;223&gt; FBP15 amino acid sequence

&lt;400&gt; 2

```

Met Gly Arg Gly Lys Ile Glu Ile Lys Arg Ile Glu Asn Thr Thr Asn
  1           5           10           15

Arg Gln Val Thr Phe Cys Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala
          20           25           30

Tyr Glu Leu Ser Val Leu Cys Asp Ala Glu Val Ala Leu Ile Val Phe
      35           40           45

Ser Ser Arg Gly Arg Leu Tyr Glu Tyr Ala Asn Asn Ser Val Lys Ala
      50           55           60

Thr Ile Asp Arg Tyr Lys Lys Ala Ser Ser Asp Ser Ser Asn Thr Gly
      65           70           75           80

Ser Thr Ser Glu Ala Asn Thr Gln Phe Tyr Gln Gln Glu Ala Ala Lys
          85           90           95

Leu Arg Val Gln Ile Gly Asn Leu Gln Asn Ser Asn Arg Asn Met Leu
      100           105           110

Gly Glu Ser Leu Ser Ser Leu Thr Ala Lys Asp Leu Lys Gly Leu Glu
      115           120           125

Thr Lys Leu Glu Lys Gly Ile Ser Arg Ile Arg Ser Lys Lys Asn Glu
      130           135           140

Leu Leu Phe Ala Glu Ile Glu Tyr Met Arg Lys Arg Glu Ile Asp Leu
      145           150           155           160

His Asn Asn Asn Gln Met Leu Arg Ala Lys Ile Ala Glu Ser Glu Arg
          165           170           175

Asn Val Asn Met Met Gly Gly Glu Phe Glu Leu Met Gln Ser His Pro
      180           185           190

Tyr Asp Pro Arg Asp Phe Phe Gln Val Asn Gly Leu Gln His Asn His
      195           200           205

Gln Tyr Pro Arg Gln Asp Asn Met Ala Leu Gln Leu Val
      210           215           220

```

&lt;210&gt; 3

WO 00/04176

PCT/NL99/00453

<211> 18

<212> PRT

<213> *Calluna vulgaris*

<220>

<223> tissue type: flower

<220>

<223> *Calluna vulgaris* signal peptide

<400> 3

Met Phe Leu Pro Ile Leu Phe Thr Ile Ser Leu Leu Phe Ser Ser Ser  
1 5 10 15

His Ala

<210> 4

<211> 1205

<212> DNA

<213> *Petunia x hybrida*

<220>

<221> CDS

<222> (79)..(873)

<220>

<223> strain: W115

<220>

<223> tissue type: nectar gland

<220>

<223> NEC1

<400> 4

tgcgagcggcc gcccgggcag gtattcaaca agagtattca ccaattgaac tcaaaagggg 60

cttcaactaaa aaaaaatc atg gcg caa tta cgt gct gat gac ttg tct ttc 111  
Met Ala Gln Leu Arg Ala Asp Asp Leu Ser Phe  
1 5 10

ata ttt ggc ctt ctt ggt aat att gta tca ttc atg gtc ttc cta gca 159  
Ile Phe Gly Leu Leu Gly Asn Ile Val Ser Phe Met Val Phe Leu Ala  
15 20 25

WO 00/04176

PCT/NL99/00453

ccc gtg cca aca ttt tac aaa ata tat aaa agg aaa tca tca gaa gga	207
Pro Val Pro Thr Phe Tyr Lys Ile Tyr Lys Arg Lys Ser Ser Glu Gly	
30 35 40	
tat caa gca ata cca tat atg gta gca ctg ttc agc gcc gga cta ttg	255
Tyr Gln Ala Ile Pro Tyr Met Val Ala Leu Phe Ser Ala Gly Leu Leu	
45 50 55	
cta tat tat gct tat ctc agg aag aat gcc tat ctt atc gtc agc att	303
Leu Tyr Tyr Ala Tyr Leu Arg Lys Asn Ala Tyr Leu Ile Val Ser Ile	
60 65 70 75	
aat ggc ttt gga tgt gcc att gaa tta aca tat atc tct ctg ttt ctc	351
Asn Gly Phe Gly Cys Ala Ile Glu Leu Thr Tyr Ile Ser Leu Phe Leu	
80 85 90	
ttt tac gcg ccc aga aag tct aag att ttc aca ggg tgg ctg atg ctc	399
Phe Tyr Ala Pro Arg Lys Ser Lys Ile Phe Thr Gly Trp Leu Met Leu	
95 100 105	
tta gaa ttg gga gcc cta gga atg gtg atg cca att act tat tta tta	447
Leu Glu Leu Gly Ala Leu Gly Met Val Met Pro Ile Thr Tyr Leu Leu	
110 115 120	
gca gaa ggc tca cat aga gtg atg ata gtg gga tgg att tgt gca gct	495
Ala Glu Gly Ser His Arg Val Met Ile Val Gly Trp Ile Cys Ala Ala	
125 130 135	
atc aat gtt gct gtc ttt gct gct cct tta agc atc atg agg caa gta	543
Ile Asn Val Ala Val Phe Ala Ala Pro Leu Ser Ile Met Arg Gln Val	
140 145 150 155	
ata aaa aca aag agt gta gag ttc atg ccc ttc act tta tct ttg ttc	591
Ile Lys Thr Lys Ser Val Glu Phe Met Pro Phe Thr Leu Ser Leu Phe	
160 165 170	
ctc act ctc tgt gcc act atg tgg ttt ttc tat ggg ttt ttc aag aag	639
Leu Thr Leu Cys Ala Thr Met Trp Phe Phe Tyr Gly Phe Phe Lys Lys	
175 180 185	
gac ttt tac att gcg ttt cca aat ata ctg ggc ttt cta ttc gga atc	687
Asp Phe Tyr Ile Ala Phe Pro Asn Ile Leu Gly Phe Leu Phe Gly Ile	
190 195 200	
gtt caa atg cta tta tat ttt gtt tac aag gat tca aag aga ata gat	735
Val Gln Met Leu Leu Tyr Phe Val Tyr Lys Asp Ser Lys Arg Ile Asp	
205 210 215	

gat gaa aaa tct gat cct gtt cga gaa gct aca aaa tca aaa gaa ggt 783  
 Asp Glu Lys Ser Asp Pro Val Arg Glu Ala Thr Lys Ser Lys Glu Gly  
 220 225 230 235

gta gaa atc att atc aac att gaa gat gat aat tct gat aac gca ttg 831  
 Val Glu Ile Ile Ile Asn Ile Glu Asp Asp Asn Ser Asp Asn Ala Leu  
 240 245 250

cag tcc atg gag aag gat ttt tcc aga ctg cgg aca tca aaa 873  
 Gln Ser Met Glu Lys Asp Phe Ser Arg Leu Arg Thr Ser Lys  
 255 260 265

taagcaagaa gatgatcaaa aaatgacaaa gctaaggagt ttgaagtaag gcaaggaact 933  
 tgacactgaa tatctaagct aattagcaag acttttagcag ctgttaatat ttagtgttg 993  
 tgagggtgta ccttataatt agcttgtagc atagccttcc cactaataat tctgcttagc 1053  
 gaatcttata tatgggaaat acttacacta gtatgcatct tctatataca tgtttggcac 1113  
 ttgactatac atagaaaaat taacaagcat ttctcacctc aattttgcac ttacttataa 1173  
 gtagctgaat aatataatgc aattttcacc cc 1205

<210> 5  
 <211> 265  
 <212> PRT  
 <213> Petunia x hybrida  
 <223> NEC1

<400> 5  
 Met Ala Gln Leu Arg Ala Asp Asp Leu Ser Phe Ile Phe Gly Leu Leu  
 1 5 10 15  
 Gly Asn Ile Val Ser Phe Met Val Phe Leu Ala Pro Val Pro Thr Phe  
 20 25 30  
 Tyr Lys Ile Tyr Lys Arg Lys Ser Ser Glu Gly Tyr Gln Ala Ile Pro  
 35 40 45  
 Tyr Met Val Ala Leu Phe Ser Ala Gly Leu Leu Leu Tyr Tyr Ala Tyr  
 50 55 60  
 Leu Arg Lys Asn Ala Tyr Leu Ile Val Ser Ile Asn Gly Phe Gly Cys  
 65 70 75 80  
 Ala Ile Glu Leu Thr Tyr Ile Ser Leu Phe Leu Phe Tyr Ala Pro Arg

	85	90	95
Lys Ser Lys Ile Phe Thr Gly Trp Leu Met Leu Leu Glu Leu Gly Ala	100	105	110
Leu Gly Met Val Met Pro Ile Thr Tyr Leu Leu Ala Glu Gly Ser His	115	120	125
Arg Val Met Ile Val Gly Trp Ile Cys Ala Ala Ile Asn Val Ala Val	130	135	140
Phe Ala Ala Pro Leu Ser Ile Met Arg Gln Val Ile Lys Thr Lys Ser	145	150	155
Val Glu Phe Met Pro Phe Thr Leu Ser Leu Phe Leu Thr Leu Cys Ala	165	170	175
Thr Met Trp Phe Phe Tyr Gly Phe Phe Lys Lys Asp Phe Tyr Ile Ala	180	185	190
Phe Pro Asn Ile Leu Gly Phe Leu Phe Gly Ile Val Gln Met Leu Leu	195	200	205
Tyr Phe Val Tyr Lys Asp Ser Lys Arg Ile Asp Asp Glu Lys Ser Asp	210	215	220
Pro Val Arg Glu Ala Thr Lys Ser Lys Glu Gly Val Glu Ile Ile Ile	225	230	235
Asn Ile Glu Asp Asp Asn Ser Asp Asn Ala Leu Gln Ser Met Glu Lys	245	250	255
Asp Phe Ser Arg Leu Arg Thr Ser Lys	260	265	

&lt;210&gt; 6

&lt;211&gt; 1157

&lt;212&gt; DNA

&lt;213&gt; Petunia x hybrida

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (179)..(841)

&lt;220&gt;

&lt;223&gt; strain: W115







```

Arg Gln Val Thr Phe Cys Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala
      20                      25                      30

Tyr Glu Leu Ser Val Leu Cys Asp Ala Glu Val Ala Leu Ile Val Phe
      35                      40                      45

Ser Ser Arg Gly Arg Leu Tyr Glu Tyr Ala Asn Asn Ser Val Lys Ala
      50                      55                      60

Thr Ile Asp Arg Tyr Lys Lys Ala Ser Ser Asp Ser Ser Asn Thr Gly
      65                      70                      75                      80

Ser Thr Ser Glu Ala Asn Thr Gln Phe Tyr Gln Gln Glu Ala Ala Lys
      85                      90                      95

Leu Arg Val Gln Ile Gly Asn Leu Gln Asn Ser Asn Arg Asn Met Leu
      100                     105                     110

Gly Glu Ser Leu Ser Ser Leu Thr Ala Lys Asp Leu Lys Gly Leu Glu
      115                     120                     125

Thr Lys Leu Glu Lys Gly Ile Ser Arg Ile Arg Ser Lys Lys Asn Glu
      130                     135                     140

Leu Leu Phe Ala Glu Ile Glu Tyr Met Arg Lys Arg Glu Ile Asp Leu
      145                     150                     155                     160

His Asn Asn Asn Gln Met Leu Arg Ala Lys Ile Ala Glu Ser Glu Arg
      165                     170                     175

Asn Val Asn Met Met Gly Gly Glu Phe Glu Leu Met Gln Ser His Pro
      180                     185                     190

Tyr Asp Pro Arg Asp Phe Phe Gln Val Asn Gly Leu Gln His Asn His
      195                     200                     205

Gln Tyr Pro Arg Gln Asp Asn Met Ala Leu Gln Leu Val
      210                     215                     220

```

&lt;210&gt; 8

&lt;211&gt; 54

&lt;212&gt; DNA

&lt;213&gt; Calluna vulgaris

&lt;220&gt;

WO 00/04176

PCT/NL99/00453

<221> CDS

<222> (1)..(54)

<220>

<221> sig\_peptide

<222> (1)..(54)

<400> 8

atg ttt ctt cca att ctc ttc acc att tcc ctc ctc ttc tcc tcc tcc 48

Met Phe Leu Pro Ile Leu Phe Thr Ile Ser Leu Leu Phe Ser Ser

1

5

10

15

cat gct

54

His Ala

<210> 9

<211> 18

<212> PRT

<213> Calluna vulgaris

<400> 9

Met Phe Leu Pro Ile Leu Phe Thr Ile Ser Leu Leu Phe Ser Ser Ser

1

5

10

15

His Ala

<210> 10

<211> 2141

<212> DNA

<213> Petunia x hybrida

<220>

<223> strain: W115

<220>

<223> NEC1 promoter

<400> 10

cctaggagaa atcaagccta ctcttaagat ggatgactca ctgccccga tggtaagggtg 60  
aaggatctgt tgattagagt tgggaagttc atgttctctg ctgattttat tattctagac 120  
tatgaagagg accaagaagc tccaataatt ttgggaagag cattcttaat cacatcgatg 180  
gcaattattg acatggaact tggggagatg actgtgagag cgcattggaga aaagggttact 240  
ttcaagggtt ataataaaaa ggatcatatg gctaagtttg aagagtgttc ttgatagaa 300  
tgtgtcagac gagaacatga aagtaaacccg aaagaggtgt ttgagcggaa tgtagaacaa 360

